id	sid	tid	token	lemma	pos
ajst-32484	1	1	111	111	NUM
ajst-32484	1	2	research	research	NOUN
ajst-32484	1	3	progress	progress	NOUN
ajst-32484	1	4	on	on	ADP
ajst-32484	1	5	resistance	resistance	NOUN
ajst-32484	1	6	mechanisms	mechanism	NOUN
ajst-32484	1	7	and	and	CCONJ
ajst-32484	1	8	postresistance	postresistance	NOUN
ajst-32484	1	9	treatment	treatment	NOUN
ajst-32484	1	10	of	of	ADP
ajst-32484	1	11	targeted	target	VERB
ajst-32484	1	12	therapy	therapy	NOUN
ajst-32484	1	13	in	in	ADP
ajst-32484	1	14	non	non	ADJ
ajst-32484	1	15	-	-	ADJ
ajst-32484	1	16	small	small	ADJ
ajst-32484	1	17	cell	cell	NOUN
ajst-32484	1	18	lung	lung	NOUN
ajst-32484	1	19	cancer	cancer	NOUN
ajst-32484	1	20	ziyuan	ziyuan	PROPN
ajst-32484	1	21	gao	gao	PROPN
ajst-32484	1	22	1	1	NUM
ajst-32484	1	23	,	,	PUNCT
ajst-32484	1	24	†	†	NOUN
ajst-32484	1	25	,	,	PUNCT
ajst-32484	1	26	*	*	PROPN
ajst-32484	1	27	,	,	PUNCT
ajst-32484	1	28	yuzhu	yuzhu	PROPN
ajst-32484	1	29	chen	chen	PROPN
ajst-32484	1	30	2	2	NUM
ajst-32484	1	31	,	,	PUNCT
ajst-32484	1	32	†	†	PROPN
ajst-32484	1	33	1	1	NUM
ajst-32484	1	34	school	school	NOUN
ajst-32484	1	35	of	of	ADP
ajst-32484	1	36	medicine	medicine	NOUN
ajst-32484	1	37	,	,	PUNCT
ajst-32484	1	38	xi'an	xi'an	PROPN
ajst-32484	1	39	jiaotong	jiaotong	PROPN
ajst-32484	1	40	university	university	PROPN
ajst-32484	1	41	,	,	PUNCT
ajst-32484	1	42	xi’an	xi’an	PROPN
ajst-32484	1	43	shaanxi	shaanxi	PROPN
ajst-32484	1	44	,	,	PUNCT
ajst-32484	1	45	710049	710049	NUM
ajst-32484	1	46	,	,	PUNCT
ajst-32484	1	47	china	china	PROPN
ajst-32484	1	48	2	2	NUM
ajst-32484	1	49	department	department	NOUN
ajst-32484	1	50	of	of	ADP
ajst-32484	1	51	oncology	oncology	NOUN
ajst-32484	1	52	,	,	PUNCT
ajst-32484	1	53	beijing	beijing	PROPN
ajst-32484	1	54	chest	chest	PROPN
ajst-32484	1	55	hospital	hospital	NOUN
ajst-32484	1	56	,	,	PUNCT
ajst-32484	1	57	capital	capital	PROPN
ajst-32484	1	58	medical	medical	PROPN
ajst-32484	1	59	university	university	PROPN
ajst-32484	1	60	,	,	PUNCT
ajst-32484	1	61	beijing	beijing	NOUN
ajst-32484	1	62	tuberculosis	tuberculosis	NOUN
ajst-32484	1	63	and	and	CCONJ
ajst-32484	1	64	thoracic	thoracic	NOUN
ajst-32484	1	65	tumor	tumor	PROPN
ajst-32484	1	66	research	research	PROPN
ajst-32484	1	67	institute	institute	PROPN
ajst-32484	1	68	,	,	PUNCT
ajst-32484	1	69	beijing	beijing	PROPN
ajst-32484	1	70	101149	101149	NUM
ajst-32484	1	71	,	,	PUNCT
ajst-32484	1	72	china	china	PROPN
ajst-32484	1	73	*	*	PUNCT
ajst-32484	1	74	corresponding	correspond	VERB
ajst-32484	1	75	author	author	NOUN
ajst-32484	1	76	:	:	PUNCT
ajst-32484	1	77	ziyuan	ziyuan	PROPN
ajst-32484	1	78	gao	gao	PROPN
ajst-32484	1	79	(	(	PUNCT
ajst-32484	1	80	email	email	NOUN
ajst-32484	1	81	:	:	PUNCT
ajst-32484	1	82	gzy042813@163.com	gzy042813@163.com	X
ajst-32484	1	83	)	)	PUNCT
ajst-32484	1	84	†	†	NOUN
ajst-32484	1	85	two	two	NUM
ajst-32484	1	86	authors	author	NOUN
ajst-32484	1	87	have	have	AUX
ajst-32484	1	88	made	make	VERB
ajst-32484	1	89	equal	equal	ADJ
ajst-32484	1	90	contributions	contribution	NOUN
ajst-32484	1	91	to	to	ADP
ajst-32484	1	92	this	this	DET
ajst-32484	1	93	article	article	NOUN
ajst-32484	1	94	abstract	abstract	NOUN
ajst-32484	1	95	.	.	PUNCT
ajst-32484	2	1	non	non	ADJ
ajst-32484	2	2	-	-	ADJ
ajst-32484	2	3	small	small	ADJ
ajst-32484	2	4	cell	cell	NOUN
ajst-32484	2	5	lung	lung	NOUN
ajst-32484	2	6	cancer	cancer	NOUN
ajst-32484	2	7	(	(	PUNCT
ajst-32484	2	8	nsclc	nsclc	NOUN
ajst-32484	2	9	)	)	PUNCT
ajst-32484	2	10	is	be	AUX
ajst-32484	2	11	the	the	DET
ajst-32484	2	12	most	most	ADV
ajst-32484	2	13	common	common	ADJ
ajst-32484	2	14	cause	cause	NOUN
ajst-32484	2	15	of	of	ADP
ajst-32484	2	16	cancer	cancer	NOUN
ajst-32484	2	17	-	-	PUNCT
ajst-32484	2	18	related	relate	VERB
ajst-32484	2	19	mortality	mortality	NOUN
ajst-32484	2	20	worldwide	worldwide	ADV
ajst-32484	2	21	,	,	PUNCT
ajst-32484	2	22	and	and	CCONJ
ajst-32484	2	23	about	about	ADV
ajst-32484	2	24	60	60	NUM
ajst-32484	2	25	%	%	NOUN
ajst-32484	2	26	of	of	ADP
ajst-32484	2	27	the	the	DET
ajst-32484	2	28	advanced	advanced	ADJ
ajst-32484	2	29	cancer	cancer	NOUN
ajst-32484	2	30	stage	stage	NOUN
ajst-32484	2	31	patients	patient	NOUN
ajst-32484	2	32	carry	carry	VERB
ajst-32484	2	33	particular	particular	ADJ
ajst-32484	2	34	molecular	molecular	ADJ
ajst-32484	2	35	mutations	mutation	NOUN
ajst-32484	2	36	that	that	PRON
ajst-32484	2	37	model	model	VERB
ajst-32484	2	38	potential	potential	ADJ
ajst-32484	2	39	targets	target	NOUN
ajst-32484	2	40	in	in	ADP
ajst-32484	2	41	terms	term	NOUN
ajst-32484	2	42	of	of	ADP
ajst-32484	2	43	targeted	target	VERB
ajst-32484	2	44	therapy	therapy	NOUN
ajst-32484	2	45	.	.	PUNCT
ajst-32484	3	1	gene	gene	NOUN
ajst-32484	3	2	mutations	mutation	NOUN
ajst-32484	3	3	such	such	ADJ
ajst-32484	3	4	as	as	ADP
ajst-32484	3	5	egfr	egfr	NOUN
ajst-32484	3	6	,	,	PUNCT
ajst-32484	3	7	met	meet	VERB
ajst-32484	3	8	,	,	PUNCT
ajst-32484	3	9	and	and	CCONJ
ajst-32484	3	10	alk	alk	VERB
ajst-32484	3	11	are	be	AUX
ajst-32484	3	12	key	key	ADJ
ajst-32484	3	13	drivers	driver	NOUN
ajst-32484	3	14	of	of	ADP
ajst-32484	3	15	nsclc	nsclc	NOUN
ajst-32484	3	16	.	.	PUNCT
ajst-32484	4	1	targeted	target	VERB
ajst-32484	4	2	drugs	drug	NOUN
ajst-32484	4	3	against	against	ADP
ajst-32484	4	4	these	these	DET
ajst-32484	4	5	mutations	mutation	NOUN
ajst-32484	4	6	,	,	PUNCT
ajst-32484	4	7	including	include	VERB
ajst-32484	4	8	egfrtkis	egfrtki	NOUN
ajst-32484	4	9	,	,	PUNCT
ajst-32484	4	10	met	meet	VERB
ajst-32484	4	11	-	-	PUNCT
ajst-32484	4	12	tkis	tkis	NOUN
ajst-32484	4	13	,	,	PUNCT
ajst-32484	4	14	and	and	CCONJ
ajst-32484	4	15	alk	alk	PROPN
ajst-32484	4	16	-	-	PUNCT
ajst-32484	4	17	tkis	tkis	NOUN
ajst-32484	4	18	,	,	PUNCT
ajst-32484	4	19	have	have	AUX
ajst-32484	4	20	significantly	significantly	ADV
ajst-32484	4	21	improved	improve	VERB
ajst-32484	4	22	patient	patient	ADJ
ajst-32484	4	23	prognosis	prognosis	NOUN
ajst-32484	4	24	.	.	PUNCT
ajst-32484	5	1	however	however	ADV
ajst-32484	5	2	,	,	PUNCT
ajst-32484	5	3	acquired	acquire	VERB
ajst-32484	5	4	resistance	resistance	NOUN
ajst-32484	5	5	remains	remain	VERB
ajst-32484	5	6	a	a	DET
ajst-32484	5	7	significant	significant	ADJ
ajst-32484	5	8	challenge	challenge	NOUN
ajst-32484	5	9	,	,	PUNCT
ajst-32484	5	10	with	with	ADP
ajst-32484	5	11	mechanisms	mechanism	NOUN
ajst-32484	5	12	involving	involve	VERB
ajst-32484	5	13	secondary	secondary	ADJ
ajst-32484	5	14	target	target	NOUN
ajst-32484	5	15	mutations	mutation	NOUN
ajst-32484	5	16	,	,	PUNCT
ajst-32484	5	17	bypass	bypass	NOUN
ajst-32484	5	18	activation	activation	NOUN
ajst-32484	5	19	,	,	PUNCT
ajst-32484	5	20	and	and	CCONJ
ajst-32484	5	21	phenotypic	phenotypic	ADJ
ajst-32484	5	22	transformation	transformation	NOUN
ajst-32484	5	23	.	.	PUNCT
ajst-32484	6	1	this	this	DET
ajst-32484	6	2	review	review	NOUN
ajst-32484	6	3	summarizes	summarize	VERB
ajst-32484	6	4	the	the	DET
ajst-32484	6	5	resistance	resistance	NOUN
ajst-32484	6	6	mechanisms	mechanism	NOUN
ajst-32484	6	7	of	of	ADP
ajst-32484	6	8	targeted	target	VERB
ajst-32484	6	9	therapy	therapy	NOUN
ajst-32484	6	10	in	in	ADP
ajst-32484	6	11	nsclc	nsclc	NOUN
ajst-32484	6	12	and	and	CCONJ
ajst-32484	6	13	corresponding	corresponding	ADJ
ajst-32484	6	14	therapeutic	therapeutic	ADJ
ajst-32484	6	15	strategies	strategy	NOUN
ajst-32484	6	16	,	,	PUNCT
ajst-32484	6	17	aiming	aim	VERB
ajst-32484	6	18	to	to	PART
ajst-32484	6	19	provide	provide	VERB
ajst-32484	6	20	new	new	ADJ
ajst-32484	6	21	insights	insight	NOUN
ajst-32484	6	22	for	for	ADP
ajst-32484	6	23	post	post	ADJ
ajst-32484	6	24	-	-	ADJ
ajst-32484	6	25	resistance	resistance	NOUN
ajst-32484	6	26	treatment	treatment	NOUN
ajst-32484	6	27	.	.	PUNCT
ajst-32484	7	1	keywords	keyword	NOUN
ajst-32484	7	2	:	:	PUNCT
ajst-32484	7	3	non	non	ADJ
ajst-32484	7	4	-	-	ADJ
ajst-32484	7	5	small	small	ADJ
ajst-32484	7	6	cell	cell	NOUN
ajst-32484	7	7	lung	lung	NOUN
ajst-32484	7	8	cancer	cancer	NOUN
ajst-32484	7	9	(	(	PUNCT
ajst-32484	7	10	nsclc	nsclc	NOUN
ajst-32484	7	11	)	)	PUNCT
ajst-32484	7	12	;	;	PUNCT
ajst-32484	7	13	targeted	target	VERB
ajst-32484	7	14	therapy	therapy	NOUN
ajst-32484	7	15	;	;	PUNCT
ajst-32484	7	16	egfr	egfr	PROPN
ajst-32484	7	17	-	-	PUNCT
ajst-32484	7	18	tkis	tkis	PROPN
ajst-32484	7	19	;	;	PUNCT
ajst-32484	7	20	acquired	acquire	VERB
ajst-32484	7	21	resistance	resistance	NOUN
ajst-32484	7	22	.	.	PUNCT
ajst-32484	8	1	1	1	X
ajst-32484	8	2	.	.	X
ajst-32484	8	3	introduction	introduction	NOUN
ajst-32484	8	4	lung	lung	NOUN
ajst-32484	8	5	cancer	cancer	NOUN
ajst-32484	8	6	is	be	AUX
ajst-32484	8	7	the	the	DET
ajst-32484	8	8	most	most	ADV
ajst-32484	8	9	frequent	frequent	ADJ
ajst-32484	8	10	cancer	cancer	NOUN
ajst-32484	8	11	-	-	PUNCT
ajst-32484	8	12	related	relate	VERB
ajst-32484	8	13	mortality	mortality	NOUN
ajst-32484	8	14	worldwide	worldwide	ADV
ajst-32484	8	15	,	,	PUNCT
ajst-32484	8	16	and	and	CCONJ
ajst-32484	8	17	non	non	ADJ
ajst-32484	8	18	-	-	ADJ
ajst-32484	8	19	small	small	ADJ
ajst-32484	8	20	cell	cell	NOUN
ajst-32484	8	21	lung	lung	NOUN
ajst-32484	8	22	cancer	cancer	NOUN
ajst-32484	8	23	(	(	PUNCT
ajst-32484	8	24	nsclc	nsclc	NOUN
ajst-32484	8	25	)	)	PUNCT
ajst-32484	8	26	represents	represent	VERB
ajst-32484	8	27	80%85	80%85	NUM
ajst-32484	8	28	of	of	ADP
ajst-32484	8	29	the	the	DET
ajst-32484	8	30	cases	case	NOUN
ajst-32484	8	31	[	[	X
ajst-32484	8	32	1	1	NUM
ajst-32484	8	33	]	]	PUNCT
ajst-32484	8	34	.	.	PUNCT
ajst-32484	9	1	molecular	molecular	ADJ
ajst-32484	9	2	advances	advance	NOUN
ajst-32484	9	3	have	have	AUX
ajst-32484	9	4	driven	drive	VERB
ajst-32484	9	5	targeted	target	VERB
ajst-32484	9	6	therapy	therapy	NOUN
ajst-32484	9	7	forward	forward	ADV
ajst-32484	9	8	;	;	PUNCT
ajst-32484	9	9	around	around	ADV
ajst-32484	9	10	60	60	NUM
ajst-32484	9	11	%	%	NOUN
ajst-32484	9	12	of	of	ADP
ajst-32484	9	13	advanced	advanced	ADJ
ajst-32484	9	14	nsclc	nsclc	NOUN
ajst-32484	9	15	patients	patient	NOUN
ajst-32484	9	16	carry	carry	VERB
ajst-32484	9	17	actionable	actionable	ADJ
ajst-32484	9	18	mutations	mutation	NOUN
ajst-32484	9	19	[	[	X
ajst-32484	9	20	2	2	NUM
ajst-32484	9	21	]	]	PUNCT
ajst-32484	9	22	.	.	PUNCT
ajst-32484	10	1	the	the	DET
ajst-32484	10	2	most	most	ADV
ajst-32484	10	3	prevalent	prevalent	ADJ
ajst-32484	10	4	,	,	PUNCT
ajst-32484	10	5	which	which	PRON
ajst-32484	10	6	occur	occur	VERB
ajst-32484	10	7	in	in	ADP
ajst-32484	10	8	50	50	NUM
ajst-32484	10	9	percent	percent	NOUN
ajst-32484	10	10	of	of	ADP
ajst-32484	10	11	asian	asian	ADJ
ajst-32484	10	12	and	and	CCONJ
ajst-32484	10	13	10	10	NUM
ajst-32484	10	14	percent	percent	NOUN
ajst-32484	10	15	to	to	ADP
ajst-32484	10	16	16.6	16.6	NUM
ajst-32484	10	17	percent	percent	NOUN
ajst-32484	10	18	of	of	ADP
ajst-32484	10	19	caucasian	caucasian	ADJ
ajst-32484	10	20	patients	patient	NOUN
ajst-32484	10	21	,	,	PUNCT
ajst-32484	10	22	are	be	AUX
ajst-32484	10	23	egfr	egfr	ADJ
ajst-32484	10	24	mutations	mutation	NOUN
ajst-32484	11	1	[	[	X
ajst-32484	11	2	3	3	NUM
ajst-32484	11	3	]	]	PUNCT
ajst-32484	11	4	.	.	PUNCT
ajst-32484	12	1	egfr	egfr	PROPN
ajst-32484	12	2	-	-	PUNCT
ajst-32484	12	3	tkis	tkis	PROPN
ajst-32484	12	4	have	have	AUX
ajst-32484	12	5	markedly	markedly	ADV
ajst-32484	12	6	improved	improve	VERB
ajst-32484	12	7	outcomes	outcome	NOUN
ajst-32484	12	8	,	,	PUNCT
ajst-32484	12	9	evolving	evolve	VERB
ajst-32484	12	10	through	through	ADP
ajst-32484	12	11	generations	generation	NOUN
ajst-32484	12	12	to	to	PART
ajst-32484	12	13	counter	counter	VERB
ajst-32484	12	14	resistance	resistance	NOUN
ajst-32484	12	15	—	—	PUNCT
ajst-32484	12	16	notably	notably	ADV
ajst-32484	12	17	the	the	DET
ajst-32484	12	18	t790	t790	NUM
ajst-32484	12	19	m	m	NOUN
ajst-32484	12	20	mutation	mutation	NOUN
ajst-32484	12	21	with	with	ADP
ajst-32484	12	22	third	third	ADJ
ajst-32484	12	23	-	-	PUNCT
ajst-32484	12	24	generation	generation	NOUN
ajst-32484	12	25	agents	agent	NOUN
ajst-32484	12	26	.	.	PUNCT
ajst-32484	13	1	however	however	ADV
ajst-32484	13	2	,	,	PUNCT
ajst-32484	13	3	acquired	acquire	VERB
ajst-32484	13	4	resistance	resistance	NOUN
ajst-32484	13	5	remains	remain	VERB
ajst-32484	13	6	a	a	DET
ajst-32484	13	7	major	major	ADJ
ajst-32484	13	8	clinical	clinical	ADJ
ajst-32484	13	9	challenge	challenge	NOUN
ajst-32484	13	10	.	.	PUNCT
ajst-32484	14	1	met	meet	VERB
ajst-32484	14	2	alterations	alteration	NOUN
ajst-32484	14	3	occur	occur	VERB
ajst-32484	14	4	in	in	ADP
ajst-32484	14	5	∼7	∼7	PROPN
ajst-32484	14	6	%	%	NOUN
ajst-32484	14	7	of	of	ADP
ajst-32484	14	8	nsclc	nsclc	NOUN
ajst-32484	14	9	cases	case	NOUN
ajst-32484	14	10	,	,	PUNCT
ajst-32484	14	11	with	with	ADP
ajst-32484	14	12	type	type	NOUN
ajst-32484	14	13	i	i	PRON
ajst-32484	14	14	met	meet	VERB
ajst-32484	14	15	-	-	PUNCT
ajst-32484	14	16	tkis	tkis	NOUN
ajst-32484	14	17	offering	offering	NOUN
ajst-32484	14	18	targeted	target	VERB
ajst-32484	14	19	inhibition	inhibition	NOUN
ajst-32484	14	20	[	[	X
ajst-32484	14	21	4	4	NUM
ajst-32484	14	22	]	]	PUNCT
ajst-32484	14	23	.	.	PUNCT
ajst-32484	15	1	alk	alk	VERB
ajst-32484	15	2	rearrangements	rearrangement	NOUN
ajst-32484	15	3	,	,	PUNCT
ajst-32484	15	4	more	more	ADV
ajst-32484	15	5	common	common	ADJ
ajst-32484	15	6	in	in	ADP
ajst-32484	15	7	young	young	ADJ
ajst-32484	15	8	non	non	NOUN
ajst-32484	15	9	-	-	NOUN
ajst-32484	15	10	smokers	smoker	NOUN
ajst-32484	15	11	,	,	PUNCT
ajst-32484	15	12	promote	promote	VERB
ajst-32484	15	13	tumorigenesis	tumorigenesis	NOUN
ajst-32484	15	14	via	via	ADP
ajst-32484	15	15	downstream	downstream	ADJ
ajst-32484	15	16	signaling	signal	VERB
ajst-32484	15	17	[	[	X
ajst-32484	15	18	5	5	NUM
ajst-32484	15	19	]	]	PUNCT
ajst-32484	15	20	.	.	PUNCT
ajst-32484	16	1	alk	alk	PROPN
ajst-32484	16	2	-	-	PUNCT
ajst-32484	16	3	tkis	tkis	PROPN
ajst-32484	16	4	have	have	AUX
ajst-32484	16	5	also	also	ADV
ajst-32484	16	6	advanced	advance	VERB
ajst-32484	16	7	generationally	generationally	ADV
ajst-32484	16	8	.	.	PUNCT
ajst-32484	17	1	despite	despite	SCONJ
ajst-32484	17	2	improved	improved	ADJ
ajst-32484	17	3	outcomes	outcome	NOUN
ajst-32484	17	4	,	,	PUNCT
ajst-32484	17	5	acquired	acquire	VERB
ajst-32484	17	6	resistance	resistance	NOUN
ajst-32484	17	7	—	—	PUNCT
ajst-32484	17	8	through	through	ADP
ajst-32484	17	9	secondary	secondary	ADJ
ajst-32484	17	10	mutations	mutation	NOUN
ajst-32484	17	11	,	,	PUNCT
ajst-32484	17	12	bypass	bypass	NOUN
ajst-32484	17	13	activation	activation	NOUN
ajst-32484	17	14	,	,	PUNCT
ajst-32484	17	15	or	or	CCONJ
ajst-32484	17	16	phenotypic	phenotypic	ADJ
ajst-32484	17	17	transformation	transformation	NOUN
ajst-32484	17	18	—	—	PUNCT
ajst-32484	17	19	limits	limit	VERB
ajst-32484	17	20	long	long	ADJ
ajst-32484	17	21	-	-	PUNCT
ajst-32484	17	22	term	term	NOUN
ajst-32484	17	23	efficacy	efficacy	NOUN
ajst-32484	17	24	.	.	PUNCT
ajst-32484	18	1	these	these	DET
ajst-32484	18	2	mechanisms	mechanism	NOUN
ajst-32484	18	3	are	be	AUX
ajst-32484	18	4	important	important	ADJ
ajst-32484	18	5	to	to	PART
ajst-32484	18	6	understand	understand	VERB
ajst-32484	18	7	and	and	CCONJ
ajst-32484	18	8	come	come	VERB
ajst-32484	18	9	up	up	ADP
ajst-32484	18	10	with	with	ADP
ajst-32484	18	11	post	post	NOUN
ajst-32484	18	12	-	-	NOUN
ajst-32484	18	13	resistance	resistance	NOUN
ajst-32484	18	14	.	.	PUNCT
ajst-32484	19	1	this	this	DET
ajst-32484	19	2	review	review	NOUN
ajst-32484	19	3	is	be	AUX
ajst-32484	19	4	a	a	DET
ajst-32484	19	5	summary	summary	NOUN
ajst-32484	19	6	of	of	ADP
ajst-32484	19	7	resistance	resistance	NOUN
ajst-32484	19	8	in	in	ADP
ajst-32484	19	9	nsclc	nsclc	NOUN
ajst-32484	19	10	targeted	target	VERB
ajst-32484	19	11	therapy	therapy	NOUN
ajst-32484	19	12	and	and	CCONJ
ajst-32484	19	13	responsive	responsive	ADJ
ajst-32484	19	14	therapies	therapy	NOUN
ajst-32484	19	15	.	.	PUNCT
ajst-32484	20	1	2	2	X
ajst-32484	20	2	.	.	X
ajst-32484	20	3	resistance	resistance	NOUN
ajst-32484	20	4	mechanisms	mechanism	VERB
ajst-32484	20	5	2.1	2.1	NUM
ajst-32484	20	6	resistance	resistance	NOUN
ajst-32484	20	7	mechanisms	mechanism	NOUN
ajst-32484	20	8	to	to	ADP
ajst-32484	20	9	egfr	egfr	ADJ
ajst-32484	20	10	-	-	PUNCT
ajst-32484	20	11	tkis	tkis	NOUN
ajst-32484	20	12	resistance	resistance	NOUN
ajst-32484	20	13	to	to	ADP
ajst-32484	20	14	egfr	egfr	NOUN
ajst-32484	20	15	-	-	PUNCT
ajst-32484	20	16	tkis	tkis	NOUN
ajst-32484	20	17	is	be	AUX
ajst-32484	20	18	classified	classify	VERB
ajst-32484	20	19	as	as	ADP
ajst-32484	20	20	primary	primary	ADJ
ajst-32484	20	21	or	or	CCONJ
ajst-32484	20	22	acquired	acquire	VERB
ajst-32484	20	23	.	.	PUNCT
ajst-32484	21	1	acquired	acquire	VERB
ajst-32484	21	2	resistance	resistance	NOUN
ajst-32484	21	3	further	far	ADV
ajst-32484	21	4	divides	divide	VERB
ajst-32484	21	5	into	into	ADP
ajst-32484	21	6	egfr	egfr	NOUN
ajst-32484	21	7	-	-	PUNCT
ajst-32484	21	8	dependent	dependent	ADJ
ajst-32484	21	9	and	and	CCONJ
ajst-32484	21	10	independent	independent	ADJ
ajst-32484	21	11	mechanisms	mechanism	NOUN
ajst-32484	21	12	.	.	PUNCT
ajst-32484	22	1	egfr	egfr	ADJ
ajst-32484	22	2	-	-	PUNCT
ajst-32484	22	3	dependent	dependent	ADJ
ajst-32484	22	4	resistance	resistance	NOUN
ajst-32484	22	5	primarily	primarily	ADV
ajst-32484	22	6	involves	involve	VERB
ajst-32484	22	7	secondary	secondary	ADJ
ajst-32484	22	8	mutations	mutation	NOUN
ajst-32484	22	9	reducing	reduce	VERB
ajst-32484	22	10	drug	drug	NOUN
ajst-32484	22	11	binding	bind	VERB
ajst-32484	22	12	affinity	affinity	NOUN
ajst-32484	22	13	,	,	PUNCT
ajst-32484	22	14	notably	notably	ADV
ajst-32484	22	15	t790	t790	NUM
ajst-32484	22	16	m	m	VERB
ajst-32484	22	17	conferring	confer	VERB
ajst-32484	22	18	resistance	resistance	NOUN
ajst-32484	22	19	to	to	ADP
ajst-32484	22	20	first	first	ADJ
ajst-32484	22	21	and	and	CCONJ
ajst-32484	22	22	second	second	ADJ
ajst-32484	22	23	-	-	PUNCT
ajst-32484	22	24	generation	generation	NOUN
ajst-32484	22	25	tkis	tkis	NOUN
ajst-32484	23	1	[	[	X
ajst-32484	23	2	6	6	NUM
ajst-32484	23	3	]	]	PUNCT
ajst-32484	23	4	,	,	PUNCT
ajst-32484	23	5	and	and	CCONJ
ajst-32484	23	6	c797s	c797s	PROPN
ajst-32484	23	7	driving	drive	VERB
ajst-32484	23	8	resistance	resistance	NOUN
ajst-32484	23	9	to	to	ADP
ajst-32484	23	10	third	third	ADJ
ajst-32484	23	11	-	-	PUNCT
ajst-32484	23	12	generation	generation	NOUN
ajst-32484	23	13	agents	agent	NOUN
ajst-32484	23	14	like	like	ADP
ajst-32484	23	15	osimertinib	osimertinib	NOUN
ajst-32484	23	16	[	[	X
ajst-32484	23	17	7	7	NUM
ajst-32484	23	18	]	]	PUNCT
ajst-32484	23	19	.	.	PUNCT
ajst-32484	24	1	egfr	egfr	ADJ
ajst-32484	24	2	-	-	PUNCT
ajst-32484	24	3	independent	independent	ADJ
ajst-32484	24	4	resistance	resistance	NOUN
ajst-32484	24	5	commonly	commonly	ADV
ajst-32484	24	6	arises	arise	VERB
ajst-32484	24	7	through	through	ADP
ajst-32484	24	8	bypass	bypass	NOUN
ajst-32484	24	9	activation	activation	NOUN
ajst-32484	24	10	,	,	PUNCT
ajst-32484	24	11	such	such	ADJ
ajst-32484	24	12	as	as	ADP
ajst-32484	24	13	met	meet	VERB
ajst-32484	24	14	amplification	amplification	NOUN
ajst-32484	24	15	(	(	PUNCT
ajst-32484	24	16	5%–10	5%–10	NUM
ajst-32484	24	17	%	%	NOUN
ajst-32484	24	18	of	of	ADP
ajst-32484	24	19	cases	case	NOUN
ajst-32484	24	20	)	)	PUNCT
ajst-32484	24	21	activating	activate	VERB
ajst-32484	24	22	pi3k	pi3k	PROPN
ajst-32484	24	23	-	-	PUNCT
ajst-32484	24	24	akt	akt	NOUN
ajst-32484	24	25	via	via	ADP
ajst-32484	24	26	her3	her3	ADJ
ajst-32484	24	27	dimerization	dimerization	NOUN
ajst-32484	24	28	[	[	X
ajst-32484	24	29	8	8	NUM
ajst-32484	24	30	-	-	SYM
ajst-32484	24	31	10	10	NUM
ajst-32484	24	32	]	]	PUNCT
ajst-32484	24	33	,	,	PUNCT
ajst-32484	24	34	or	or	CCONJ
ajst-32484	24	35	other	other	ADJ
ajst-32484	24	36	112	112	NUM
ajst-32484	24	37	mechanisms	mechanism	NOUN
ajst-32484	24	38	including	include	VERB
ajst-32484	24	39	her2	her2	PROPN
ajst-32484	24	40	amplification	amplification	NOUN
ajst-32484	24	41	,	,	PUNCT
ajst-32484	24	42	ras	ras	NOUN
ajst-32484	24	43	-	-	ADJ
ajst-32484	24	44	mapk	mapk	NOUN
ajst-32484	24	45	pathway	pathway	NOUN
ajst-32484	24	46	activation	activation	NOUN
ajst-32484	24	47	,	,	PUNCT
ajst-32484	24	48	and	and	CCONJ
ajst-32484	24	49	oncogenic	oncogenic	ADJ
ajst-32484	24	50	fusions	fusion	NOUN
ajst-32484	24	51	.	.	PUNCT
ajst-32484	25	1	histological	histological	ADJ
ajst-32484	25	2	transformation	transformation	NOUN
ajst-32484	25	3	,	,	PUNCT
ajst-32484	25	4	e.g.	e.g.	ADV
ajst-32484	25	5	,	,	PUNCT
ajst-32484	25	6	to	to	ADP
ajst-32484	25	7	sclc	sclc	PROPN
ajst-32484	25	8	,	,	PUNCT
ajst-32484	25	9	occurs	occur	VERB
ajst-32484	25	10	in	in	ADP
ajst-32484	25	11	5%–10	5%–10	NUM
ajst-32484	25	12	%	%	NOUN
ajst-32484	25	13	of	of	ADP
ajst-32484	25	14	patients	patient	NOUN
ajst-32484	25	15	,	,	PUNCT
ajst-32484	25	16	often	often	ADV
ajst-32484	25	17	with	with	ADP
ajst-32484	25	18	rb1	rb1	PROPN
ajst-32484	25	19	/	/	SYM
ajst-32484	25	20	tp53	tp53	PROPN
ajst-32484	25	21	loss	loss	NOUN
ajst-32484	25	22	[	[	X
ajst-32484	25	23	8	8	NUM
ajst-32484	25	24	-	-	SYM
ajst-32484	25	25	11	11	NUM
ajst-32484	25	26	]	]	PUNCT
ajst-32484	25	27	.	.	PUNCT
ajst-32484	26	1	2.2	2.2	NUM
ajst-32484	26	2	resistance	resistance	NOUN
ajst-32484	26	3	mechanisms	mechanism	NOUN
ajst-32484	26	4	to	to	ADP
ajst-32484	26	5	other	other	ADJ
ajst-32484	26	6	targeted	target	VERB
ajst-32484	26	7	drugs	drug	NOUN
ajst-32484	26	8	for	for	ADP
ajst-32484	26	9	met	meet	VERB
ajst-32484	26	10	-	-	PUNCT
ajst-32484	26	11	tkis	tkis	NOUN
ajst-32484	26	12	,	,	PUNCT
ajst-32484	26	13	resistance	resistance	NOUN
ajst-32484	26	14	involves	involve	VERB
ajst-32484	26	15	met	meet	VERB
ajst-32484	26	16	-	-	PUNCT
ajst-32484	26	17	dependent	dependent	ADJ
ajst-32484	26	18	mutations	mutation	NOUN
ajst-32484	26	19	(	(	PUNCT
ajst-32484	26	20	e.g.	e.g.	ADV
ajst-32484	26	21	,	,	PUNCT
ajst-32484	26	22	d1228	d1228	VERB
ajst-32484	26	23	,	,	PUNCT
ajst-32484	26	24	y1230	y1230	ADJ
ajst-32484	26	25	)	)	PUNCT
ajst-32484	26	26	or	or	CCONJ
ajst-32484	26	27	amplification	amplification	NOUN
ajst-32484	26	28	,	,	PUNCT
ajst-32484	26	29	and	and	CCONJ
ajst-32484	26	30	met	meet	VERB
ajst-32484	26	31	-	-	PUNCT
ajst-32484	26	32	independent	independent	ADJ
ajst-32484	26	33	mechanisms	mechanism	NOUN
ajst-32484	26	34	like	like	ADP
ajst-32484	26	35	ras	ras	NOUN
ajst-32484	26	36	/	/	SYM
ajst-32484	26	37	mapk	mapk	NOUN
ajst-32484	26	38	or	or	CCONJ
ajst-32484	26	39	pi3k	pi3k	PROPN
ajst-32484	26	40	/	/	SYM
ajst-32484	26	41	akt	akt	PROPN
ajst-32484	26	42	activation	activation	NOUN
ajst-32484	26	43	or	or	CCONJ
ajst-32484	26	44	egfr	egfr	X
ajst-32484	26	45	/	/	SYM
ajst-32484	26	46	her2	her2	PROPN
ajst-32484	26	47	bypass	bypass	NOUN
ajst-32484	26	48	[	[	X
ajst-32484	26	49	12	12	NUM
ajst-32484	26	50	,	,	PUNCT
ajst-32484	26	51	13	13	NUM
ajst-32484	26	52	]	]	PUNCT
ajst-32484	26	53	.	.	PUNCT
ajst-32484	27	1	alk	alk	PROPN
ajst-32484	27	2	-	-	PUNCT
ajst-32484	27	3	tki	tki	NOUN
ajst-32484	27	4	resistance	resistance	NOUN
ajst-32484	27	5	includes	include	VERB
ajst-32484	27	6	alk	alk	NOUN
ajst-32484	27	7	-	-	PUNCT
ajst-32484	27	8	dependent	dependent	ADJ
ajst-32484	27	9	compound	compound	NOUN
ajst-32484	27	10	mutations	mutation	NOUN
ajst-32484	27	11	(	(	PUNCT
ajst-32484	27	12	e.g.	e.g.	ADV
ajst-32484	27	13	,	,	PUNCT
ajst-32484	27	14	g1202r+l1196	g1202r+l1196	NOUN
ajst-32484	27	15	m	m	NOUN
ajst-32484	27	16	)	)	PUNCT
ajst-32484	27	17	and	and	CCONJ
ajst-32484	27	18	alk	alk	NOUN
ajst-32484	27	19	-	-	PUNCT
ajst-32484	27	20	independent	independent	ADJ
ajst-32484	27	21	bypass	bypass	NOUN
ajst-32484	27	22	activation	activation	NOUN
ajst-32484	27	23	;	;	PUNCT
ajst-32484	27	24	the	the	DET
ajst-32484	27	25	2024	2024	NUM
ajst-32484	27	26	asco	asco	ADJ
ajst-32484	27	27	crown	crown	NOUN
ajst-32484	27	28	study	study	NOUN
ajst-32484	27	29	reported	report	VERB
ajst-32484	27	30	lorlatinib	lorlatinib	NOUN
ajst-32484	27	31	resistance	resistance	NOUN
ajst-32484	27	32	primarily	primarily	ADV
ajst-32484	27	33	involving	involve	VERB
ajst-32484	27	34	mapk	mapk	NOUN
ajst-32484	27	35	/	/	SYM
ajst-32484	27	36	pi3k	pi3k	PROPN
ajst-32484	27	37	/	/	SYM
ajst-32484	27	38	rtk	rtk	PROPN
ajst-32484	27	39	pathway	pathway	NOUN
ajst-32484	27	40	alterations	alteration	NOUN
ajst-32484	27	41	and	and	CCONJ
ajst-32484	27	42	cell	cell	NOUN
ajst-32484	27	43	cycle	cycle	NOUN
ajst-32484	27	44	abnormalities	abnormality	NOUN
ajst-32484	27	45	[	[	X
ajst-32484	27	46	14	14	NUM
ajst-32484	27	47	]	]	PUNCT
ajst-32484	27	48	.	.	PUNCT
ajst-32484	28	1	figure	figure	NOUN
ajst-32484	28	2	1	1	NUM
ajst-32484	28	3	.	.	PUNCT
ajst-32484	28	4	illustrates	illustrate	VERB
ajst-32484	28	5	the	the	DET
ajst-32484	28	6	acquired	acquire	VERB
ajst-32484	28	7	resistance	resistance	NOUN
ajst-32484	28	8	mechanisms	mechanism	NOUN
ajst-32484	28	9	to	to	ADP
ajst-32484	28	10	egfr	egfr	NOUN
ajst-32484	28	11	-	-	PUNCT
ajst-32484	28	12	tkis	tkis	NOUN
ajst-32484	28	13	,	,	PUNCT
ajst-32484	28	14	categorized	categorize	VERB
ajst-32484	28	15	into	into	ADP
ajst-32484	28	16	egfr	egfr	NOUN
ajst-32484	28	17	-	-	PUNCT
ajst-32484	28	18	dependent	dependent	ADJ
ajst-32484	28	19	and	and	CCONJ
ajst-32484	28	20	independent	independent	ADJ
ajst-32484	28	21	.	.	PUNCT
ajst-32484	29	1	mutations	mutation	NOUN
ajst-32484	29	2	(	(	PUNCT
ajst-32484	29	3	e.g.	e.g.	ADV
ajst-32484	29	4	,	,	PUNCT
ajst-32484	29	5	t790	t790	NUM
ajst-32484	29	6	m	m	NOUN
ajst-32484	29	7	,	,	PUNCT
ajst-32484	29	8	c797s	c797s	PROPN
ajst-32484	29	9	)	)	PUNCT
ajst-32484	29	10	are	be	AUX
ajst-32484	29	11	part	part	NOUN
ajst-32484	29	12	of	of	ADP
ajst-32484	29	13	the	the	DET
ajst-32484	29	14	egfrdependent	egfrdependent	ADJ
ajst-32484	29	15	mechanisms	mechanism	NOUN
ajst-32484	29	16	,	,	PUNCT
ajst-32484	29	17	which	which	PRON
ajst-32484	29	18	decrease	decrease	VERB
ajst-32484	29	19	drug	drug	NOUN
ajst-32484	29	20	binding	bind	VERB
ajst-32484	29	21	.	.	PUNCT
ajst-32484	30	1	egfr	egfr	ADJ
ajst-32484	30	2	-	-	PUNCT
ajst-32484	30	3	independent	independent	ADJ
ajst-32484	30	4	pathways	pathway	NOUN
ajst-32484	30	5	include	include	VERB
ajst-32484	30	6	bypass	bypass	NOUN
ajst-32484	30	7	resistance	resistance	NOUN
ajst-32484	30	8	(	(	PUNCT
ajst-32484	30	9	ex	ex	NOUN
ajst-32484	30	10	,	,	PUNCT
ajst-32484	30	11	met	meet	VERB
ajst-32484	30	12	amplification	amplification	NOUN
ajst-32484	30	13	,	,	PUNCT
ajst-32484	30	14	her2	her2	VERB
ajst-32484	30	15	amplification	amplification	NOUN
ajst-32484	30	16	,	,	PUNCT
ajst-32484	30	17	alk	alk	VERB
ajst-32484	30	18	fusion	fusion	NOUN
ajst-32484	30	19	)	)	PUNCT
ajst-32484	30	20	and	and	CCONJ
ajst-32484	30	21	aberrant	aberrant	ADJ
ajst-32484	30	22	downstream	downstream	ADJ
ajst-32484	30	23	signalling	signal	VERB
ajst-32484	30	24	(	(	PUNCT
ajst-32484	30	25	ex	ex	NOUN
ajst-32484	30	26	,	,	PUNCT
ajst-32484	30	27	pi3k	pi3k	PROPN
ajst-32484	30	28	/	/	SYM
ajst-32484	30	29	akt	akt	PROPN
ajst-32484	30	30	/	/	SYM
ajst-32484	30	31	mtor	mtor	PROPN
ajst-32484	30	32	,	,	PUNCT
ajst-32484	30	33	ras	ras	PROPN
ajst-32484	30	34	/	/	SYM
ajst-32484	30	35	raf	raf	PROPN
ajst-32484	30	36	/	/	SYM
ajst-32484	30	37	mek	mek	PROPN
ajst-32484	30	38	/	/	SYM
ajst-32484	30	39	erk	erk	PROPN
ajst-32484	30	40	)	)	PUNCT
ajst-32484	30	41	,	,	PUNCT
ajst-32484	30	42	which	which	PRON
ajst-32484	30	43	facilitates	facilitate	VERB
ajst-32484	30	44	the	the	DET
ajst-32484	30	45	survival	survival	NOUN
ajst-32484	30	46	of	of	ADP
ajst-32484	30	47	cancer	cancer	NOUN
ajst-32484	30	48	cells	cell	NOUN
ajst-32484	30	49	,	,	PUNCT
ajst-32484	30	50	their	their	PRON
ajst-32484	30	51	growth	growth	NOUN
ajst-32484	30	52	,	,	PUNCT
ajst-32484	30	53	and	and	CCONJ
ajst-32484	30	54	anti	anti	ADJ
ajst-32484	30	55	-	-	ADJ
ajst-32484	30	56	apoptosis	apoptosis	ADJ
ajst-32484	30	57	.	.	PUNCT
ajst-32484	31	1	it	it	PRON
ajst-32484	31	2	is	be	AUX
ajst-32484	31	3	also	also	ADV
ajst-32484	31	4	important	important	ADJ
ajst-32484	31	5	that	that	SCONJ
ajst-32484	31	6	there	there	PRON
ajst-32484	31	7	should	should	AUX
ajst-32484	31	8	be	be	AUX
ajst-32484	31	9	a	a	DET
ajst-32484	31	10	histological	histological	ADJ
ajst-32484	31	11	change	change	NOUN
ajst-32484	31	12	(	(	PUNCT
ajst-32484	31	13	e.g.	e.g.	ADV
ajst-32484	31	14	,	,	PUNCT
ajst-32484	31	15	nsclc	nsclc	NOUN
ajst-32484	31	16	to	to	ADP
ajst-32484	31	17	sclc	sclc	PROPN
ajst-32484	31	18	/	/	SYM
ajst-32484	31	19	scc	scc	PROPN
ajst-32484	31	20	)	)	PUNCT
ajst-32484	31	21	.	.	PUNCT
ajst-32484	32	1	3	3	X
ajst-32484	32	2	.	.	X
ajst-32484	32	3	post	post	ADJ
ajst-32484	32	4	-	-	ADJ
ajst-32484	32	5	resistance	resistance	ADJ
ajst-32484	32	6	treatment	treatment	NOUN
ajst-32484	32	7	3.1	3.1	NUM
ajst-32484	32	8	treatment	treatment	NOUN
ajst-32484	32	9	after	after	ADP
ajst-32484	32	10	egfr	egfr	ADJ
ajst-32484	32	11	-	-	PUNCT
ajst-32484	32	12	tki	tki	NOUN
ajst-32484	32	13	resistance	resistance	NOUN
ajst-32484	32	14	egfr	egfr	NOUN
ajst-32484	32	15	-	-	PUNCT
ajst-32484	32	16	tkis	tkis	NOUN
ajst-32484	32	17	are	be	AUX
ajst-32484	32	18	currently	currently	ADV
ajst-32484	32	19	used	use	VERB
ajst-32484	32	20	as	as	ADP
ajst-32484	32	21	first	first	ADJ
ajst-32484	32	22	-	-	PUNCT
ajst-32484	32	23	line	line	NOUN
ajst-32484	32	24	therapy	therapy	NOUN
ajst-32484	32	25	of	of	ADP
ajst-32484	32	26	advanced	advanced	ADJ
ajst-32484	32	27	msg	msg	NOUN
ajst-32484	32	28	of	of	ADP
ajst-32484	32	29	the	the	DET
ajst-32484	32	30	lung	lung	NOUN
ajst-32484	32	31	(	(	PUNCT
ajst-32484	32	32	ets	ets	PROPN
ajst-32484	32	33	)	)	PUNCT
ajst-32484	32	34	,	,	PUNCT
ajst-32484	32	35	which	which	PRON
ajst-32484	32	36	is	be	AUX
ajst-32484	32	37	positive	positive	ADJ
ajst-32484	32	38	on	on	ADP
ajst-32484	32	39	tested	test	VERB
ajst-32484	32	40	for	for	ADP
ajst-32484	32	41	epidermal	epidermal	ADJ
ajst-32484	32	42	growth	growth	NOUN
ajst-32484	32	43	factor	factor	NOUN
ajst-32484	32	44	receptor	receptor	NOUN
ajst-32484	32	45	(	(	PUNCT
ajst-32484	32	46	egfr	egfr	NOUN
ajst-32484	32	47	)	)	PUNCT
ajst-32484	32	48	.	.	PUNCT
ajst-32484	33	1	the	the	DET
ajst-32484	33	2	progression	progression	NOUN
ajst-32484	33	3	that	that	PRON
ajst-32484	33	4	occurs	occur	VERB
ajst-32484	33	5	after	after	SCONJ
ajst-32484	33	6	the	the	DET
ajst-32484	33	7	resistance	resistance	NOUN
ajst-32484	33	8	can	can	AUX
ajst-32484	33	9	be	be	AUX
ajst-32484	33	10	categorised	categorise	VERB
ajst-32484	33	11	into	into	ADP
ajst-32484	33	12	oligoprogression	oligoprogression	NOUN
ajst-32484	33	13	,	,	PUNCT
ajst-32484	33	14	intracranial	intracranial	ADJ
ajst-32484	33	15	progression	progression	NOUN
ajst-32484	33	16	,	,	PUNCT
ajst-32484	33	17	and	and	CCONJ
ajst-32484	33	18	extensive	extensive	ADJ
ajst-32484	33	19	progression	progression	NOUN
ajst-32484	33	20	.	.	PUNCT
ajst-32484	34	1	the	the	DET
ajst-32484	34	2	first	first	ADJ
ajst-32484	34	3	asia	asia	PROPN
ajst-32484	34	4	-	-	PUNCT
ajst-32484	34	5	pacific	pacific	PROPN
ajst-32484	34	6	consensus	consensus	NOUN
ajst-32484	34	7	,	,	PUNCT
ajst-32484	34	8	based	base	VERB
ajst-32484	34	9	on	on	ADP
ajst-32484	34	10	the	the	DET
ajst-32484	34	11	third	third	ADJ
ajst-32484	34	12	-	-	PUNCT
ajst-32484	34	13	generation	generation	NOUN
ajst-32484	34	14	resistance	resistance	NOUN
ajst-32484	34	15	of	of	ADP
ajst-32484	34	16	the	the	DET
ajst-32484	34	17	two	two	NUM
ajst-32484	34	18	types	type	NOUN
ajst-32484	34	19	of	of	ADP
ajst-32484	34	20	origin	origin	NOUN
ajst-32484	34	21	medicine	medicine	NOUN
ajst-32484	34	22	,	,	PUNCT
ajst-32484	34	23	of	of	ADP
ajst-32484	34	24	the	the	DET
ajst-32484	34	25	use	use	NOUN
ajst-32484	34	26	of	of	ADP
ajst-32484	34	27	drugs	drug	NOUN
ajst-32484	34	28	targeted	target	VERB
ajst-32484	34	29	at	at	ADP
ajst-32484	34	30	a	a	DET
ajst-32484	34	31	gene	gene	NOUN
ajst-32484	34	32	controller	controller	NOUN
ajst-32484	34	33	(	(	PUNCT
ajst-32484	34	34	egfr	egfr	NOUN
ajst-32484	34	35	-	-	PUNCT
ajst-32484	34	36	tki	tki	NOUN
ajst-32484	34	37	)	)	PUNCT
ajst-32484	34	38	,	,	PUNCT
ajst-32484	34	39	recommendation	recommendation	NOUN
ajst-32484	34	40	by	by	ADP
ajst-32484	34	41	the	the	DET
ajst-32484	34	42	guidelines	guideline	NOUN
ajst-32484	34	43	of	of	ADP
ajst-32484	34	44	china	china	PROPN
ajst-32484	34	45	in	in	ADP
ajst-32484	34	46	the	the	DET
ajst-32484	34	47	medical	medical	ADJ
ajst-32484	34	48	sciences	sciences	PROPN
ajst-32484	34	49	(	(	PUNCT
ajst-32484	34	50	csco	csco	PROPN
ajst-32484	34	51	)	)	PUNCT
ajst-32484	34	52	recommends	recommend	VERB
ajst-32484	34	53	customized	customize	VERB
ajst-32484	34	54	mode	mode	NOUN
ajst-32484	34	55	of	of	ADP
ajst-32484	34	56	the	the	DET
ajst-32484	34	57	method	method	NOUN
ajst-32484	34	58	.	.	PUNCT
ajst-32484	35	1	113	113	NUM
ajst-32484	35	2	3.1.1	3.1.1	NUM
ajst-32484	35	3	strategies	strategy	NOUN
ajst-32484	35	4	for	for	ADP
ajst-32484	35	5	oligoprogression	oligoprogression	NOUN
ajst-32484	35	6	and	and	CCONJ
ajst-32484	35	7	intracranial	intracranial	ADJ
ajst-32484	35	8	progression	progression	NOUN
ajst-32484	35	9	for	for	ADP
ajst-32484	35	10	oligoprogression	oligoprogression	NOUN
ajst-32484	35	11	,	,	PUNCT
ajst-32484	35	12	local	local	ADJ
ajst-32484	35	13	therapies	therapy	NOUN
ajst-32484	35	14	(	(	PUNCT
ajst-32484	35	15	e.g.	e.g.	ADV
ajst-32484	35	16	,	,	PUNCT
ajst-32484	35	17	radiotherapy	radiotherapy	NOUN
ajst-32484	35	18	,	,	PUNCT
ajst-32484	35	19	surgery	surgery	NOUN
ajst-32484	35	20	,	,	PUNCT
ajst-32484	35	21	radiofrequency	radiofrequency	NOUN
ajst-32484	35	22	ablation	ablation	NOUN
ajst-32484	35	23	)	)	PUNCT
ajst-32484	35	24	combined	combine	VERB
ajst-32484	35	25	with	with	ADP
ajst-32484	35	26	continued	continue	VERB
ajst-32484	35	27	egfr	egfr	ADJ
ajst-32484	35	28	-	-	PUNCT
ajst-32484	35	29	tkis	tkis	NOUN
ajst-32484	35	30	are	be	AUX
ajst-32484	35	31	recommended	recommend	VERB
ajst-32484	35	32	,	,	PUNCT
ajst-32484	35	33	with	with	ADP
ajst-32484	35	34	studies	study	NOUN
ajst-32484	35	35	showing	show	VERB
ajst-32484	35	36	improved	improve	VERB
ajst-32484	35	37	pfs	pf	NOUN
ajst-32484	35	38	and	and	CCONJ
ajst-32484	35	39	os	os	NOUN
ajst-32484	35	40	compared	compare	VERB
ajst-32484	35	41	to	to	ADP
ajst-32484	35	42	egfr	egfr	NOUN
ajst-32484	35	43	-	-	PUNCT
ajst-32484	35	44	tkis	tkis	NOUN
ajst-32484	35	45	alone	alone	ADV
ajst-32484	35	46	.	.	PUNCT
ajst-32484	36	1	for	for	ADP
ajst-32484	36	2	intracranial	intracranial	ADJ
ajst-32484	36	3	progression	progression	NOUN
ajst-32484	36	4	,	,	PUNCT
ajst-32484	36	5	treatment	treatment	NOUN
ajst-32484	36	6	(	(	PUNCT
ajst-32484	36	7	surgery	surgery	NOUN
ajst-32484	36	8	or	or	CCONJ
ajst-32484	36	9	systemic	systemic	ADJ
ajst-32484	36	10	therapy	therapy	NOUN
ajst-32484	36	11	)	)	PUNCT
ajst-32484	36	12	is	be	AUX
ajst-32484	36	13	guided	guide	VERB
ajst-32484	36	14	by	by	ADP
ajst-32484	36	15	the	the	DET
ajst-32484	36	16	number	number	NOUN
ajst-32484	36	17	and	and	CCONJ
ajst-32484	36	18	size	size	NOUN
ajst-32484	36	19	of	of	ADP
ajst-32484	36	20	brain	brain	NOUN
ajst-32484	36	21	metastases	metastasis	NOUN
ajst-32484	36	22	.	.	PUNCT
ajst-32484	37	1	3.1.2	3.1.2	NUM
ajst-32484	37	2	strategies	strategy	NOUN
ajst-32484	37	3	for	for	ADP
ajst-32484	37	4	extensive	extensive	ADJ
ajst-32484	37	5	progression	progression	NOUN
ajst-32484	37	6	biopsies	biopsy	NOUN
ajst-32484	37	7	after	after	SCONJ
ajst-32484	37	8	third	third	ADJ
ajst-32484	37	9	-	-	PUNCT
ajst-32484	37	10	generation	generation	NOUN
ajst-32484	37	11	egfr	egfr	ADJ
ajst-32484	37	12	-	-	PUNCT
ajst-32484	37	13	tki	tki	NOUN
ajst-32484	37	14	resistance	resistance	NOUN
ajst-32484	37	15	identify	identify	VERB
ajst-32484	37	16	mechanisms	mechanism	NOUN
ajst-32484	37	17	in	in	ADP
ajst-32484	37	18	some	some	DET
ajst-32484	37	19	patients	patient	NOUN
ajst-32484	37	20	,	,	PUNCT
ajst-32484	37	21	but	but	CCONJ
ajst-32484	37	22	30%-50	30%-50	NUM
ajst-32484	37	23	%	%	NOUN
ajst-32484	37	24	remain	remain	VERB
ajst-32484	37	25	unclear	unclear	ADJ
ajst-32484	37	26	.	.	PUNCT
ajst-32484	38	1	3.1.2.1	3.1.2.1	NUM
ajst-32484	38	2	treatment	treatment	NOUN
ajst-32484	38	3	for	for	ADP
ajst-32484	38	4	defined	define	VERB
ajst-32484	38	5	resistance	resistance	NOUN
ajst-32484	38	6	mechanisms	mechanism	NOUN
ajst-32484	38	7	for	for	ADP
ajst-32484	38	8	defined	define	VERB
ajst-32484	38	9	resistance	resistance	NOUN
ajst-32484	38	10	mechanisms	mechanism	NOUN
ajst-32484	38	11	,	,	PUNCT
ajst-32484	38	12	treatment	treatment	NOUN
ajst-32484	38	13	strategies	strategy	NOUN
ajst-32484	38	14	are	be	AUX
ajst-32484	38	15	highly	highly	ADV
ajst-32484	38	16	targeted	target	VERB
ajst-32484	38	17	.	.	PUNCT
ajst-32484	39	1	fourth	fourth	ADJ
ajst-32484	39	2	-	-	PUNCT
ajst-32484	39	3	generation	generation	NOUN
ajst-32484	39	4	egfr	egfr	NOUN
ajst-32484	39	5	-	-	PUNCT
ajst-32484	39	6	tkis	tkis	NOUN
ajst-32484	39	7	,	,	PUNCT
ajst-32484	39	8	including	include	VERB
ajst-32484	39	9	bdtx-1535	bdtx-1535	NOUN
ajst-32484	39	10	,	,	PUNCT
ajst-32484	39	11	are	be	AUX
ajst-32484	39	12	active	active	ADJ
ajst-32484	39	13	in	in	ADP
ajst-32484	39	14	egfr	egfr	ADJ
ajst-32484	39	15	-	-	PUNCT
ajst-32484	39	16	dependent	dependent	ADJ
ajst-32484	39	17	resistance	resistance	NOUN
ajst-32484	39	18	,	,	PUNCT
ajst-32484	39	19	which	which	PRON
ajst-32484	39	20	includes	include	VERB
ajst-32484	39	21	the	the	DET
ajst-32484	39	22	c797s	c797s	PROPN
ajst-32484	39	23	mutation	mutation	NOUN
ajst-32484	39	24	,	,	PUNCT
ajst-32484	39	25	where	where	SCONJ
ajst-32484	39	26	the	the	DET
ajst-32484	39	27	phase	phase	NOUN
ajst-32484	39	28	ii	ii	NOUN
ajst-32484	39	29	trial	trial	NOUN
ajst-32484	39	30	(	(	PUNCT
ajst-32484	39	31	nct05256290	nct05256290	VERB
ajst-32484	39	32	)	)	PUNCT
ajst-32484	39	33	recorded	record	VERB
ajst-32484	39	34	a	a	DET
ajst-32484	39	35	response	response	NOUN
ajst-32484	39	36	rate	rate	NOUN
ajst-32484	39	37	(	(	PUNCT
ajst-32484	39	38	orr	orr	PROPN
ajst-32484	39	39	)	)	PUNCT
ajst-32484	39	40	of	of	ADP
ajst-32484	39	41	42	42	NUM
ajst-32484	39	42	%	%	NOUN
ajst-32484	39	43	[	[	X
ajst-32484	39	44	15	15	NUM
ajst-32484	39	45	]	]	PUNCT
ajst-32484	39	46	.	.	PUNCT
ajst-32484	40	1	the	the	DET
ajst-32484	40	2	conventional	conventional	ADJ
ajst-32484	40	3	treatment	treatment	NOUN
ajst-32484	40	4	is	be	AUX
ajst-32484	40	5	platinum	platinum	NOUN
ajst-32484	40	6	chemotherapy	chemotherapy	NOUN
ajst-32484	40	7	.	.	PUNCT
ajst-32484	41	1	for	for	ADP
ajst-32484	41	2	egfr	egfr	ADJ
ajst-32484	41	3	-	-	PUNCT
ajst-32484	41	4	independent	independent	ADJ
ajst-32484	41	5	resistance	resistance	NOUN
ajst-32484	41	6	,	,	PUNCT
ajst-32484	41	7	combination	combination	NOUN
ajst-32484	41	8	therapies	therapy	NOUN
ajst-32484	41	9	are	be	AUX
ajst-32484	41	10	selected	select	VERB
ajst-32484	41	11	based	base	VERB
ajst-32484	41	12	on	on	ADP
ajst-32484	41	13	the	the	DET
ajst-32484	41	14	specific	specific	ADJ
ajst-32484	41	15	mechanism	mechanism	NOUN
ajst-32484	41	16	:	:	PUNCT
ajst-32484	41	17	osimertinib	osimertinib	NOUN
ajst-32484	41	18	combined	combine	VERB
ajst-32484	41	19	with	with	ADP
ajst-32484	41	20	met	meet	VERB
ajst-32484	41	21	-	-	PUNCT
ajst-32484	41	22	tkis	tkis	NOUN
ajst-32484	41	23	is	be	AUX
ajst-32484	41	24	recommended	recommend	VERB
ajst-32484	41	25	for	for	ADP
ajst-32484	41	26	met	meet	VERB
ajst-32484	41	27	amplification	amplification	NOUN
ajst-32484	41	28	[	[	X
ajst-32484	41	29	16	16	NUM
ajst-32484	41	30	,	,	PUNCT
ajst-32484	41	31	17	17	NUM
ajst-32484	41	32	]	]	PUNCT
ajst-32484	41	33	;	;	PUNCT
ajst-32484	41	34	trastuzumab	trastuzumab	NOUN
ajst-32484	41	35	deruxtecan	deruxtecan	NOUN
ajst-32484	41	36	(	(	PUNCT
ajst-32484	41	37	t	t	PROPN
ajst-32484	41	38	-	-	PUNCT
ajst-32484	41	39	dxd	dxd	NOUN
ajst-32484	41	40	)	)	PUNCT
ajst-32484	41	41	has	have	AUX
ajst-32484	41	42	shown	show	VERB
ajst-32484	41	43	significant	significant	ADJ
ajst-32484	41	44	activity	activity	NOUN
ajst-32484	41	45	against	against	ADP
ajst-32484	41	46	her2	her2	PROPN
ajst-32484	41	47	amplification	amplification	NOUN
ajst-32484	41	48	,	,	PUNCT
ajst-32484	41	49	as	as	SCONJ
ajst-32484	41	50	evidenced	evidence	VERB
ajst-32484	41	51	in	in	ADP
ajst-32484	41	52	the	the	DET
ajst-32484	41	53	destiny	destiny	NOUN
ajst-32484	41	54	-	-	PUNCT
ajst-32484	41	55	lung02	lung02	VERB
ajst-32484	41	56	trial	trial	NOUN
ajst-32484	42	1	[	[	X
ajst-32484	42	2	18	18	NUM
ajst-32484	42	3	]	]	X
ajst-32484	42	4	;	;	PUNCT
ajst-32484	42	5	dabrafenib	dabrafenib	NOUN
ajst-32484	42	6	plus	plus	CCONJ
ajst-32484	42	7	trametinib	trametinib	NOUN
ajst-32484	42	8	is	be	AUX
ajst-32484	42	9	an	an	DET
ajst-32484	42	10	established	establish	VERB
ajst-32484	42	11	strategy	strategy	NOUN
ajst-32484	42	12	for	for	ADP
ajst-32484	42	13	braf	braf	NOUN
ajst-32484	42	14	v600e	v600e	NOUN
ajst-32484	42	15	mutations	mutation	NOUN
ajst-32484	42	16	,	,	PUNCT
ajst-32484	42	17	with	with	ADP
ajst-32484	42	18	five	five	NUM
ajst-32484	42	19	-	-	PUNCT
ajst-32484	42	20	year	year	NOUN
ajst-32484	42	21	follow	follow	NOUN
ajst-32484	42	22	-	-	PUNCT
ajst-32484	42	23	up	up	ADP
ajst-32484	42	24	data	datum	NOUN
ajst-32484	42	25	showing	show	VERB
ajst-32484	42	26	5	5	NUM
ajst-32484	42	27	-	-	PUNCT
ajst-32484	42	28	year	year	NOUN
ajst-32484	42	29	os	os	NOUN
ajst-32484	42	30	rates	rate	NOUN
ajst-32484	42	31	of	of	ADP
ajst-32484	42	32	19	19	NUM
ajst-32484	42	33	%	%	NOUN
ajst-32484	42	34	in	in	ADP
ajst-32484	42	35	pretreated	pretreate	VERB
ajst-32484	42	36	and	and	CCONJ
ajst-32484	42	37	22	22	NUM
ajst-32484	42	38	%	%	NOUN
ajst-32484	42	39	in	in	ADP
ajst-32484	42	40	untreated	untreated	ADJ
ajst-32484	42	41	patients	patient	NOUN
ajst-32484	42	42	[	[	X
ajst-32484	42	43	19	19	NUM
ajst-32484	42	44	,	,	PUNCT
ajst-32484	42	45	20	20	NUM
ajst-32484	42	46	]	]	PUNCT
ajst-32484	42	47	.	.	PUNCT
ajst-32484	43	1	combinations	combination	NOUN
ajst-32484	43	2	targeting	target	VERB
ajst-32484	43	3	downstream	downstream	ADJ
ajst-32484	43	4	pathways	pathway	NOUN
ajst-32484	43	5	are	be	AUX
ajst-32484	43	6	under	under	ADP
ajst-32484	43	7	active	active	ADJ
ajst-32484	43	8	investigation	investigation	NOUN
ajst-32484	43	9	.	.	PUNCT
ajst-32484	44	1	3.1.2.2	3.1.2.2	NUM
ajst-32484	44	2	treatment	treatment	NOUN
ajst-32484	44	3	for	for	ADP
ajst-32484	44	4	undefined	undefined	ADJ
ajst-32484	44	5	resistance	resistance	NOUN
ajst-32484	44	6	mechanisms	mechanism	VERB
ajst-32484	44	7	another	another	DET
ajst-32484	44	8	future	future	ADJ
ajst-32484	44	9	strategy	strategy	NOUN
ajst-32484	44	10	with	with	ADP
ajst-32484	44	11	respect	respect	NOUN
ajst-32484	44	12	to	to	ADP
ajst-32484	44	13	patients	patient	NOUN
ajst-32484	44	14	of	of	ADP
ajst-32484	44	15	unspecified	unspecified	ADJ
ajst-32484	44	16	resistance	resistance	NOUN
ajst-32484	44	17	mechanisms	mechanism	NOUN
ajst-32484	44	18	is	be	AUX
ajst-32484	44	19	antibodydrug	antibodydrug	ADV
ajst-32484	44	20	conjugates	conjugate	NOUN
ajst-32484	44	21	(	(	PUNCT
ajst-32484	44	22	adcs	adcs	ADJ
ajst-32484	44	23	)	)	PUNCT
ajst-32484	44	24	.	.	PUNCT
ajst-32484	45	1	in	in	ADP
ajst-32484	45	2	a	a	DET
ajst-32484	45	3	phase	phase	NOUN
ajst-32484	45	4	ii	ii	NOUN
ajst-32484	45	5	trial	trial	NOUN
ajst-32484	45	6	(	(	PUNCT
ajst-32484	45	7	herthena	herthena	NOUN
ajst-32484	45	8	-	-	PUNCT
ajst-32484	45	9	lung01	lung01	PROPN
ajst-32484	45	10	)	)	PUNCT
ajst-32484	45	11	,	,	PUNCT
ajst-32484	45	12	her23	her23	PROPN
ajst-32484	45	13	-	-	PUNCT
ajst-32484	45	14	dxd	dxd	PROPN
ajst-32484	45	15	(	(	PUNCT
ajst-32484	45	16	patritumab	patritumab	NOUN
ajst-32484	45	17	deruxtecan	deruxtecan	ADJ
ajst-32484	45	18	)	)	PUNCT
ajst-32484	45	19	was	be	AUX
ajst-32484	45	20	discovered	discover	VERB
ajst-32484	45	21	to	to	PART
ajst-32484	45	22	have	have	VERB
ajst-32484	45	23	an	an	DET
ajst-32484	45	24	orr	orr	NOUN
ajst-32484	45	25	and	and	CCONJ
ajst-32484	45	26	a	a	DET
ajst-32484	45	27	median	median	ADJ
ajst-32484	45	28	progression	progression	NOUN
ajst-32484	45	29	-	-	PUNCT
ajst-32484	45	30	free	free	ADJ
ajst-32484	45	31	survival	survival	NOUN
ajst-32484	45	32	(	(	PUNCT
ajst-32484	45	33	mpfs	mpfs	PROPN
ajst-32484	45	34	)	)	PUNCT
ajst-32484	45	35	of	of	ADP
ajst-32484	45	36	29.8	29.8	NUM
ajst-32484	45	37	and	and	CCONJ
ajst-32484	45	38	5.5	5.5	NUM
ajst-32484	45	39	months	month	NOUN
ajst-32484	45	40	,	,	PUNCT
ajst-32484	45	41	respectively	respectively	ADV
ajst-32484	45	42	[	[	X
ajst-32484	45	43	21].adcs	21].adcs	NUM
ajst-32484	45	44	targeting	target	VERB
ajst-32484	45	45	trop2	trop2	ADV
ajst-32484	45	46	,	,	PUNCT
ajst-32484	45	47	including	include	VERB
ajst-32484	45	48	datopotamab	datopotamab	NOUN
ajst-32484	45	49	deruxtecan	deruxtecan	PROPN
ajst-32484	45	50	(	(	PUNCT
ajst-32484	45	51	datodxd	datodxd	ADJ
ajst-32484	45	52	)	)	PUNCT
ajst-32484	45	53	,	,	PUNCT
ajst-32484	45	54	have	have	AUX
ajst-32484	45	55	also	also	ADV
ajst-32484	45	56	shown	show	VERB
ajst-32484	45	57	clinical	clinical	ADJ
ajst-32484	45	58	response	response	NOUN
ajst-32484	45	59	in	in	ADP
ajst-32484	45	60	phase	phase	NOUN
ajst-32484	45	61	iii	iii	NUM
ajst-32484	45	62	trials	trial	NOUN
ajst-32484	45	63	.	.	PUNCT
ajst-32484	46	1	the	the	DET
ajst-32484	46	2	conventional	conventional	ADJ
ajst-32484	46	3	chemotherapy	chemotherapy	NOUN
ajst-32484	46	4	based	base	VERB
ajst-32484	46	5	on	on	ADP
ajst-32484	46	6	platinum	platinum	NOUN
ajst-32484	46	7	has	have	VERB
ajst-32484	46	8	its	its	PRON
ajst-32484	46	9	limitations	limitation	NOUN
ajst-32484	46	10	,	,	PUNCT
ajst-32484	46	11	but	but	CCONJ
ajst-32484	46	12	it	it	PRON
ajst-32484	46	13	is	be	AUX
ajst-32484	46	14	still	still	ADV
ajst-32484	46	15	at	at	ADP
ajst-32484	46	16	the	the	DET
ajst-32484	46	17	backbone	backbone	NOUN
ajst-32484	46	18	of	of	ADP
ajst-32484	46	19	treatment	treatment	NOUN
ajst-32484	46	20	.	.	PUNCT
ajst-32484	47	1	the	the	DET
ajst-32484	47	2	combination	combination	NOUN
ajst-32484	47	3	of	of	ADP
ajst-32484	47	4	lazertinib	lazertinib	NOUN
ajst-32484	47	5	,	,	PUNCT
ajst-32484	47	6	amivantamab	amivantamab	ADV
ajst-32484	47	7	,	,	PUNCT
ajst-32484	47	8	and	and	CCONJ
ajst-32484	47	9	chemotherapy	chemotherapy	NOUN
ajst-32484	47	10	showed	show	VERB
ajst-32484	47	11	potential	potential	NOUN
ajst-32484	47	12	in	in	ADP
ajst-32484	47	13	a	a	DET
ajst-32484	47	14	small	small	ADJ
ajst-32484	47	15	study	study	NOUN
ajst-32484	47	16	[	[	X
ajst-32484	47	17	22	22	NUM
ajst-32484	47	18	]	]	PUNCT
ajst-32484	47	19	,	,	PUNCT
ajst-32484	47	20	while	while	SCONJ
ajst-32484	47	21	immunotherapy	immunotherapy	NOUN
ajst-32484	47	22	combined	combine	VERB
ajst-32484	47	23	with	with	ADP
ajst-32484	47	24	egfr	egfr	ADJ
ajst-32484	47	25	-	-	PUNCT
ajst-32484	47	26	tkis	tkis	NOUN
ajst-32484	47	27	is	be	AUX
ajst-32484	47	28	not	not	PART
ajst-32484	47	29	recommended	recommend	VERB
ajst-32484	47	30	due	due	ADP
ajst-32484	47	31	to	to	ADP
ajst-32484	47	32	safety	safety	NOUN
ajst-32484	47	33	concerns	concern	NOUN
ajst-32484	47	34	[	[	X
ajst-32484	47	35	23	23	NUM
ajst-32484	47	36	]	]	PUNCT
ajst-32484	47	37	.	.	PUNCT
ajst-32484	48	1	regimens	regimen	NOUN
ajst-32484	48	2	combining	combine	VERB
ajst-32484	48	3	immunotherapy	immunotherapy	NOUN
ajst-32484	48	4	,	,	PUNCT
ajst-32484	48	5	chemotherapy	chemotherapy	NOUN
ajst-32484	48	6	,	,	PUNCT
ajst-32484	48	7	and	and	CCONJ
ajst-32484	48	8	anti	anti	ADJ
ajst-32484	48	9	-	-	ADJ
ajst-32484	48	10	angiogenesis	angiogenesis	ADJ
ajst-32484	48	11	,	,	PUNCT
ajst-32484	48	12	such	such	ADJ
ajst-32484	48	13	as	as	ADP
ajst-32484	48	14	the	the	DET
ajst-32484	48	15	abcp	abcp	NOUN
ajst-32484	48	16	regimen	regiman	NOUN
ajst-32484	48	17	in	in	ADP
ajst-32484	48	18	impower150	impower150	PROPN
ajst-32484	49	1	[	[	X
ajst-32484	49	2	24	24	NUM
ajst-32484	49	3	]	]	PUNCT
ajst-32484	49	4	and	and	CCONJ
ajst-32484	49	5	sintilimab	sintilimab	NOUN
ajst-32484	49	6	-	-	PUNCT
ajst-32484	49	7	based	base	VERB
ajst-32484	49	8	combinations	combination	NOUN
ajst-32484	49	9	in	in	ADP
ajst-32484	49	10	orient-31	orient-31	PROPN
ajst-32484	49	11	[	[	X
ajst-32484	49	12	25	25	NUM
ajst-32484	49	13	]	]	PUNCT
ajst-32484	49	14	,	,	PUNCT
ajst-32484	49	15	have	have	AUX
ajst-32484	49	16	shown	show	VERB
ajst-32484	49	17	efficacy	efficacy	NOUN
ajst-32484	49	18	in	in	ADP
ajst-32484	49	19	selected	select	VERB
ajst-32484	49	20	populations	population	NOUN
ajst-32484	49	21	.	.	PUNCT
ajst-32484	50	1	3.2	3.2	NUM
ajst-32484	50	2	treatment	treatment	NOUN
ajst-32484	50	3	after	after	ADP
ajst-32484	50	4	other	other	ADJ
ajst-32484	50	5	tki	tki	X
ajst-32484	50	6	resistance	resistance	NOUN
ajst-32484	50	7	strategies	strategy	NOUN
ajst-32484	50	8	for	for	ADP
ajst-32484	50	9	met	meet	VERB
ajst-32484	50	10	-	-	PUNCT
ajst-32484	50	11	tki	tki	X
ajst-32484	50	12	and	and	CCONJ
ajst-32484	50	13	alk	alk	PROPN
ajst-32484	50	14	-	-	PUNCT
ajst-32484	50	15	tki	tki	NOUN
ajst-32484	50	16	resistance	resistance	NOUN
ajst-32484	50	17	reference	reference	NOUN
ajst-32484	50	18	egfr	egfr	X
ajst-32484	50	19	-	-	PUNCT
ajst-32484	50	20	tki	tki	NOUN
ajst-32484	50	21	approaches	approach	NOUN
ajst-32484	50	22	,	,	PUNCT
ajst-32484	50	23	tailored	tailor	VERB
ajst-32484	50	24	to	to	ADP
ajst-32484	50	25	progression	progression	NOUN
ajst-32484	50	26	patterns	pattern	NOUN
ajst-32484	50	27	and	and	CCONJ
ajst-32484	50	28	mechanisms	mechanism	NOUN
ajst-32484	50	29	.	.	PUNCT
ajst-32484	51	1	3.2.1	3.2.1	NUM
ajst-32484	51	2	treatment	treatment	NOUN
ajst-32484	51	3	after	after	ADP
ajst-32484	51	4	met	meet	VERB
ajst-32484	51	5	-	-	PUNCT
ajst-32484	51	6	tki	tki	NOUN
ajst-32484	51	7	resistance	resistance	NOUN
ajst-32484	51	8	management	management	NOUN
ajst-32484	51	9	depends	depend	VERB
ajst-32484	51	10	on	on	ADP
ajst-32484	51	11	the	the	DET
ajst-32484	51	12	resistance	resistance	NOUN
ajst-32484	51	13	type	type	NOUN
ajst-32484	51	14	and	and	CCONJ
ajst-32484	51	15	clinical	clinical	ADJ
ajst-32484	51	16	context	context	NOUN
ajst-32484	51	17	.	.	PUNCT
ajst-32484	52	1	met	meet	VERB
ajst-32484	52	2	-	-	PUNCT
ajst-32484	52	3	dependent	dependent	ADJ
ajst-32484	52	4	resistance	resistance	NOUN
ajst-32484	52	5	(	(	PUNCT
ajst-32484	52	6	20%-35	20%-35	NUM
ajst-32484	52	7	%	%	NOUN
ajst-32484	52	8	of	of	ADP
ajst-32484	52	9	cases	case	NOUN
ajst-32484	52	10	)	)	PUNCT
ajst-32484	53	1	[	[	X
ajst-32484	53	2	12	12	NUM
ajst-32484	53	3	,	,	PUNCT
ajst-32484	53	4	13	13	NUM
ajst-32484	53	5	]	]	PUNCT
ajst-32484	53	6	may	may	AUX
ajst-32484	53	7	respond	respond	VERB
ajst-32484	53	8	to	to	ADP
ajst-32484	53	9	sequential	sequential	ADJ
ajst-32484	53	10	met	meet	VERB
ajst-32484	53	11	-	-	PUNCT
ajst-32484	53	12	tkis	tkis	NOUN
ajst-32484	53	13	,	,	PUNCT
ajst-32484	53	14	leveraging	leverage	VERB
ajst-32484	53	15	differential	differential	ADJ
ajst-32484	53	16	sensitivity	sensitivity	NOUN
ajst-32484	53	17	between	between	ADP
ajst-32484	53	18	type	type	NOUN
ajst-32484	53	19	i	i	PROPN
ajst-32484	53	20	/	/	SYM
ajst-32484	53	21	ii	ii	PROPN
ajst-32484	53	22	inhibitors	inhibitor	NOUN
ajst-32484	53	23	[	[	X
ajst-32484	53	24	29	29	NUM
ajst-32484	53	25	]	]	PUNCT
ajst-32484	53	26	.	.	PUNCT
ajst-32484	54	1	the	the	DET
ajst-32484	54	2	vision	vision	NOUN
ajst-32484	54	3	trial	trial	NOUN
ajst-32484	54	4	confirmed	confirm	VERB
ajst-32484	54	5	tepotinib	tepotinib	NOUN
ajst-32484	54	6	's	's	PART
ajst-32484	54	7	efficacy	efficacy	NOUN
ajst-32484	54	8	in	in	ADP
ajst-32484	54	9	metex14mutant	metex14mutant	ADJ
ajst-32484	54	10	nsclc	nsclc	NOUN
ajst-32484	54	11	[	[	X
ajst-32484	54	12	30	30	NUM
ajst-32484	54	13	]	]	PUNCT
ajst-32484	54	14	.	.	PUNCT
ajst-32484	55	1	met	meet	VERB
ajst-32484	55	2	-	-	PUNCT
ajst-32484	55	3	independent	independent	ADJ
ajst-32484	55	4	resistance	resistance	NOUN
ajst-32484	55	5	involves	involve	VERB
ajst-32484	55	6	alternative	alternative	ADJ
ajst-32484	55	7	pathways	pathway	NOUN
ajst-32484	55	8	(	(	PUNCT
ajst-32484	55	9	e.g.	e.g.	ADV
ajst-32484	55	10	,	,	PUNCT
ajst-32484	55	11	ras	ras	NOUN
ajst-32484	55	12	/	/	SYM
ajst-32484	55	13	mapk	mapk	NOUN
ajst-32484	55	14	,	,	PUNCT
ajst-32484	55	15	pi3k	pi3k	PROPN
ajst-32484	55	16	/	/	SYM
ajst-32484	55	17	akt	akt	PROPN
ajst-32484	55	18	)	)	PUNCT
ajst-32484	55	19	or	or	CCONJ
ajst-32484	55	20	bypass	bypass	NOUN
ajst-32484	55	21	activation	activation	NOUN
ajst-32484	55	22	(	(	PUNCT
ajst-32484	55	23	e.g.	e.g.	ADV
ajst-32484	55	24	,	,	PUNCT
ajst-32484	55	25	egfr	egfr	X
ajst-32484	55	26	/	/	SYM
ajst-32484	55	27	her2	her2	PROPN
ajst-32484	55	28	)	)	PUNCT
ajst-32484	56	1	[	[	X
ajst-32484	56	2	12	12	NUM
ajst-32484	56	3	,	,	PUNCT
ajst-32484	56	4	13	13	NUM
ajst-32484	56	5	,	,	PUNCT
ajst-32484	56	6	29	29	NUM
ajst-32484	56	7	,	,	PUNCT
ajst-32484	56	8	31	31	NUM
ajst-32484	56	9	]	]	PUNCT
ajst-32484	56	10	,	,	PUNCT
ajst-32484	56	11	potentially	potentially	ADV
ajst-32484	56	12	requiring	require	VERB
ajst-32484	56	13	combination	combination	NOUN
ajst-32484	56	14	strategies	strategy	NOUN
ajst-32484	56	15	.	.	PUNCT
ajst-32484	57	1	for	for	ADP
ajst-32484	57	2	undefined	undefined	ADJ
ajst-32484	57	3	mechanisms	mechanism	NOUN
ajst-32484	57	4	(	(	PUNCT
ajst-32484	57	5	25%-47	25%-47	NUM
ajst-32484	57	6	%	%	NOUN
ajst-32484	57	7	)	)	PUNCT
ajst-32484	57	8	,	,	PUNCT
ajst-32484	57	9	platinum	platinum	NOUN
ajst-32484	57	10	chemotherapy	chemotherapy	NOUN
ajst-32484	57	11	,	,	PUNCT
ajst-32484	57	12	immunotherapy	immunotherapy	NOUN
ajst-32484	57	13	,	,	PUNCT
ajst-32484	57	14	or	or	CCONJ
ajst-32484	57	15	anti	anti	ADJ
ajst-32484	57	16	-	-	ADJ
ajst-32484	57	17	angiogenic	angiogenic	ADJ
ajst-32484	57	18	therapy	therapy	NOUN
ajst-32484	57	19	are	be	AUX
ajst-32484	57	20	standard	standard	ADJ
ajst-32484	57	21	options	option	NOUN
ajst-32484	57	22	.	.	PUNCT
ajst-32484	58	1	114	114	NUM
ajst-32484	58	2	table	table	NOUN
ajst-32484	58	3	1	1	NUM
ajst-32484	58	4	.	.	PUNCT
ajst-32484	58	5	data	datum	NOUN
ajst-32484	58	6	summary	summary	NOUN
ajst-32484	58	7	of	of	ADP
ajst-32484	58	8	clinical	clinical	ADJ
ajst-32484	58	9	trials	trial	NOUN
ajst-32484	58	10	in	in	ADP
ajst-32484	58	11	egfr	egfr	ADJ
ajst-32484	58	12	mutant	mutant	ADJ
ajst-32484	58	13	metastatic	metastatic	ADJ
ajst-32484	58	14	nsclc	nsclc	NOUN
ajst-32484	58	15	cases	case	NOUN
ajst-32484	58	16	progressing	progress	VERB
ajst-32484	58	17	on	on	ADP
ajst-32484	58	18	egfr	egfr	ADJ
ajst-32484	58	19	inhibitors	inhibitor	NOUN
ajst-32484	58	20	generation	generation	NOUN
ajst-32484	58	21	resistance	resistance	NOUN
ajst-32484	58	22	type	type	NOUN
ajst-32484	58	23	reference	reference	NOUN
ajst-32484	58	24	study	study	NOUN
ajst-32484	58	25	name	name	NOUN
ajst-32484	58	26	phase	phase	NOUN
ajst-32484	58	27	treatment	treatment	NOUN
ajst-32484	58	28	arm	arm	NOUN
ajst-32484	58	29	efficacy	efficacy	NOUN
ajst-32484	58	30	safety	safety	NOUN
ajst-32484	58	31	first	first	ADJ
ajst-32484	58	32	/	/	SYM
ajst-32484	58	33	second	second	ADJ
ajst-32484	58	34	generation	generation	NOUN
ajst-32484	58	35	t790	t790	NUM
ajst-32484	58	36	m	m	NOUN
ajst-32484	59	1	[	[	X
ajst-32484	59	2	26	26	NUM
ajst-32484	59	3	]	]	X
ajst-32484	59	4	apollo	apollo	PROPN
ajst-32484	59	5	(	(	PUNCT
ajst-32484	59	6	nct02981108	nct02981108	PROPN
ajst-32484	59	7	)	)	PUNCT
ajst-32484	59	8	ⅱ	ⅱ	PROPN
ajst-32484	59	9	almonertinib	almonertinib	NOUN
ajst-32484	59	10	mpfs:12.4mo	mpfs:12.4mo	VERB
ajst-32484	59	11	orr:68.9	orr:68.9	X
ajst-32484	59	12	%	%	NOUN
ajst-32484	59	13	dcr:93.4	dcr:93.4	NOUN
ajst-32484	59	14	%	%	NOUN
ajst-32484	59	15	the	the	DET
ajst-32484	59	16	incidence	incidence	NOUN
ajst-32484	59	17	of	of	ADP
ajst-32484	59	18	grade	grade	NOUN
ajst-32484	59	19	3	3	NUM
ajst-32484	59	20	and	and	CCONJ
ajst-32484	59	21	above	above	ADP
ajst-32484	59	22	adverse	adverse	ADJ
ajst-32484	59	23	events	event	NOUN
ajst-32484	59	24	is	be	AUX
ajst-32484	59	25	low	low	ADJ
ajst-32484	59	26	,	,	PUNCT
ajst-32484	59	27	and	and	CCONJ
ajst-32484	59	28	the	the	DET
ajst-32484	59	29	safety	safety	NOUN
ajst-32484	59	30	is	be	AUX
ajst-32484	59	31	good	good	ADJ
ajst-32484	59	32	.	.	PUNCT
ajst-32484	60	1	third	third	ADJ
ajst-32484	60	2	generation	generation	NOUN
ajst-32484	60	3	c797s	c797s	PROPN
ajst-32484	61	1	[	[	X
ajst-32484	61	2	15	15	NUM
ajst-32484	61	3	]	]	PUNCT
ajst-32484	61	4	nct05256290	nct05256290	VERB
ajst-32484	61	5	ⅱ	ⅱ	PROPN
ajst-32484	61	6	bdtx-1535	bdtx-1535	NOUN
ajst-32484	61	7	orr:42	orr:42	NOUN
ajst-32484	61	8	%	%	NOUN
ajst-32484	61	9	most	most	ADJ
ajst-32484	61	10	aes	aes	NOUN
ajst-32484	61	11	are	be	AUX
ajst-32484	61	12	mild	mild	ADJ
ajst-32484	61	13	or	or	CCONJ
ajst-32484	61	14	moderate	moderate	ADJ
ajst-32484	61	15	,	,	PUNCT
ajst-32484	61	16	and	and	CCONJ
ajst-32484	61	17	the	the	DET
ajst-32484	61	18	researchers	researcher	NOUN
ajst-32484	61	19	did	do	AUX
ajst-32484	61	20	not	not	PART
ajst-32484	61	21	observe	observe	VERB
ajst-32484	61	22	new	new	ADJ
ajst-32484	61	23	safety	safety	NOUN
ajst-32484	61	24	signals	signal	NOUN
ajst-32484	61	25	.	.	PUNCT
ajst-32484	62	1	met	meet	VERB
ajst-32484	63	1	[	[	X
ajst-32484	63	2	16	16	NUM
ajst-32484	63	3	]	]	PUNCT
ajst-32484	63	4	orchard	orchard	NOUN
ajst-32484	63	5	ⅱ	ⅱ	PROPN
ajst-32484	63	6	osimertinib	osimertinib	NOUN
ajst-32484	63	7	+	+	CCONJ
ajst-32484	63	8	savolitinib	savolitinib	VERB
ajst-32484	63	9	orr:41	orr:41	ADJ
ajst-32484	63	10	%	%	NOUN
ajst-32484	63	11	grade	grade	NOUN
ajst-32484	63	12	≥	≥	PROPN
ajst-32484	63	13	3	3	NUM
ajst-32484	63	14	ae	ae	PROPN
ajst-32484	63	15	:	:	PUNCT
ajst-32484	63	16	30	30	NUM
ajst-32484	63	17	%	%	NOUN
ajst-32484	63	18	sae	sae	PROPN
ajst-32484	63	19	:	:	PUNCT
ajst-32484	63	20	30	30	NUM
ajst-32484	63	21	%	%	NOUN
ajst-32484	63	22	[	[	X
ajst-32484	63	23	17	17	NUM
ajst-32484	63	24	]	]	X
ajst-32484	63	25	insight2	insight2	NOUN
ajst-32484	63	26	ⅱ	ⅱ	PROPN
ajst-32484	63	27	osimertinib	osimertinib	NOUN
ajst-32484	63	28	+	+	CCONJ
ajst-32484	63	29	tepotinib	tepotinib	NOUN
ajst-32484	63	30	mpfs:5.6	mpfs:5.6	PROPN
ajst-32484	63	31	mo	mo	PROPN
ajst-32484	63	32	orr:50	orr:50	PROPN
ajst-32484	63	33	%	%	NOUN
ajst-32484	63	34	mos:17.8mo	mos:17.8mo	NOUN
ajst-32484	63	35	grade	grade	NOUN
ajst-32484	63	36	≥	≥	PROPN
ajst-32484	63	37	3	3	NUM
ajst-32484	63	38	ae	ae	PROPN
ajst-32484	63	39	:	:	PUNCT
ajst-32484	63	40	34	34	NUM
ajst-32484	63	41	%	%	NOUN
ajst-32484	63	42	sae	sae	PROPN
ajst-32484	63	43	:	:	PUNCT
ajst-32484	63	44	29	29	NUM
ajst-32484	63	45	%	%	NOUN
ajst-32484	63	46	her2	her2	VERB
ajst-32484	64	1	[	[	X
ajst-32484	64	2	18	18	NUM
ajst-32484	64	3	]	]	X
ajst-32484	64	4	destiny	destiny	NOUN
ajst-32484	64	5	-	-	PUNCT
ajst-32484	64	6	lung02	lung02	VERB
ajst-32484	64	7	(	(	PUNCT
ajst-32484	64	8	nct04644237	nct04644237	NOUN
ajst-32484	64	9	)	)	PUNCT
ajst-32484	64	10	ⅱ	ⅱ	PROPN
ajst-32484	64	11	t	t	PROPN
ajst-32484	64	12	-	-	PUNCT
ajst-32484	64	13	dxd	dxd	PROPN
ajst-32484	64	14	,	,	PUNCT
ajst-32484	64	15	ds8201	ds8201	ADJ
ajst-32484	64	16	mpfs	mpf	NOUN
ajst-32484	64	17	:	:	PUNCT
ajst-32484	64	18	5.4mg	5.4mg	NUM
ajst-32484	64	19	/	/	SYM
ajst-32484	64	20	kg	kg	NOUN
ajst-32484	64	21	group:10.0mo	group:10.0mo	VERB
ajst-32484	64	22	6.4mg	6.4mg	PROPN
ajst-32484	64	23	/	/	SYM
ajst-32484	64	24	kg	kg	PROPN
ajst-32484	64	25	group:12.9mo	group:12.9mo	PROPN
ajst-32484	64	26	orr	orr	PROPN
ajst-32484	64	27	:	:	PUNCT
ajst-32484	64	28	5.4mg	5.4mg	PROPN
ajst-32484	64	29	/	/	SYM
ajst-32484	64	30	kg	kg	NOUN
ajst-32484	64	31	group:49	group:49	PUNCT
ajst-32484	64	32	%	%	NOUN
ajst-32484	64	33	6.4mg	6.4mg	NUM
ajst-32484	64	34	/	/	SYM
ajst-32484	64	35	kg	kg	NOUN
ajst-32484	64	36	group:56	group:56	NOUN
ajst-32484	64	37	%	%	NOUN
ajst-32484	64	38	mos	mos	NOUN
ajst-32484	64	39	:	:	PUNCT
ajst-32484	64	40	5.4mg	5.4mg	NUM
ajst-32484	64	41	/	/	SYM
ajst-32484	64	42	kg	kg	PROPN
ajst-32484	64	43	group:19.0mo	group:19.0mo	VERB
ajst-32484	64	44	6.4mg	6.4mg	PROPN
ajst-32484	64	45	/	/	SYM
ajst-32484	64	46	kg	kg	PROPN
ajst-32484	64	47	group:17.3mo	group:17.3mo	ADJ
ajst-32484	64	48	grade	grade	NOUN
ajst-32484	64	49	≥	≥	PROPN
ajst-32484	64	50	3	3	NUM
ajst-32484	64	51	ae	ae	PROPN
ajst-32484	64	52	:	:	PUNCT
ajst-32484	64	53	5.4mg	5.4mg	NUM
ajst-32484	64	54	/	/	SYM
ajst-32484	64	55	kg	kg	PROPN
ajst-32484	64	56	group:39.6	group:39.6	NOUN
ajst-32484	64	57	%	%	NOUN
ajst-32484	64	58	6.4mg	6.4mg	NUM
ajst-32484	64	59	/	/	SYM
ajst-32484	64	60	kg	kg	NUM
ajst-32484	64	61	group:60.0	group:60.0	NOUN
ajst-32484	64	62	%	%	NOUN
ajst-32484	64	63	braf	braf	NOUN
ajst-32484	65	1	[	[	X
ajst-32484	65	2	19	19	NUM
ajst-32484	65	3	,	,	PUNCT
ajst-32484	65	4	20	20	NUM
ajst-32484	65	5	,	,	PUNCT
ajst-32484	65	6	27	27	NUM
ajst-32484	65	7	]	]	PUNCT
ajst-32484	65	8	brf113928	brf113928	PROPN
ajst-32484	65	9	ⅱ	ⅱ	PROPN
ajst-32484	65	10	a	a	DET
ajst-32484	65	11	:	:	PUNCT
ajst-32484	65	12	dabrafenib	dabrafenib	NOUN
ajst-32484	65	13	monotherapy	monotherapy	NOUN
ajst-32484	66	1	b	b	PROPN
ajst-32484	66	2	:	:	PUNCT
ajst-32484	66	3	dabrafenib+	dabrafenib+	X
ajst-32484	66	4	trametinib	trametinib	NOUN
ajst-32484	66	5	(	(	PUNCT
ajst-32484	66	6	treated	treat	VERB
ajst-32484	66	7	patients	patient	NOUN
ajst-32484	66	8	)	)	PUNCT
ajst-32484	67	1	c	c	X
ajst-32484	67	2	:	:	PUNCT
ajst-32484	67	3	dabrafenib+	dabrafenib+	X
ajst-32484	67	4	trametinib	trametinib	NOUN
ajst-32484	67	5	(	(	PUNCT
ajst-32484	67	6	untreated	untreated	ADJ
ajst-32484	67	7	patients	patient	NOUN
ajst-32484	67	8	)	)	PUNCT
ajst-32484	67	9	mpfs	mpf	VERB
ajst-32484	67	10	:	:	PUNCT
ajst-32484	67	11	a:5.5mo	a:5.5mo	ADJ
ajst-32484	67	12	b:9.7mo	b:9.7mo	PROPN
ajst-32484	67	13	c:10.9mo	c:10.9mo	PROPN
ajst-32484	67	14	orr	orr	PROPN
ajst-32484	67	15	:	:	PUNCT
ajst-32484	67	16	a:33	a:33	PROPN
ajst-32484	67	17	%	%	NOUN
ajst-32484	67	18	b:63.2	b:63.2	NOUN
ajst-32484	67	19	%	%	NOUN
ajst-32484	67	20	c:64	c:64	VERB
ajst-32484	67	21	%	%	NOUN
ajst-32484	67	22	a	a	DET
ajst-32484	67	23	:	:	PUNCT
ajst-32484	67	24	common	common	ADJ
ajst-32484	67	25	adverse	adverse	ADJ
ajst-32484	67	26	events	event	NOUN
ajst-32484	67	27	include	include	VERB
ajst-32484	67	28	fever	fever	NOUN
ajst-32484	67	29	,	,	PUNCT
ajst-32484	67	30	fatigue	fatigue	NOUN
ajst-32484	67	31	,	,	PUNCT
ajst-32484	67	32	nausea	nausea	NOUN
ajst-32484	67	33	,	,	PUNCT
ajst-32484	67	34	and	and	CCONJ
ajst-32484	67	35	skin	skin	NOUN
ajst-32484	67	36	-	-	PUNCT
ajst-32484	67	37	related	relate	VERB
ajst-32484	67	38	toxicities	toxicity	NOUN
ajst-32484	67	39	.	.	PUNCT
ajst-32484	68	1	b	b	X
ajst-32484	68	2	:	:	PUNCT
ajst-32484	68	3	adverse	adverse	ADJ
ajst-32484	68	4	events	event	NOUN
ajst-32484	68	5	of	of	ADP
ajst-32484	68	6	combination	combination	NOUN
ajst-32484	68	7	therapy	therapy	NOUN
ajst-32484	68	8	include	include	VERB
ajst-32484	68	9	fever	fever	NOUN
ajst-32484	68	10	,	,	PUNCT
ajst-32484	68	11	diarrhea	diarrhea	NOUN
ajst-32484	68	12	,	,	PUNCT
ajst-32484	68	13	nausea	nausea	NOUN
ajst-32484	68	14	,	,	PUNCT
ajst-32484	68	15	and	and	CCONJ
ajst-32484	68	16	rash	rash	NOUN
ajst-32484	68	17	,	,	PUNCT
ajst-32484	68	18	but	but	CCONJ
ajst-32484	68	19	they	they	PRON
ajst-32484	68	20	are	be	AUX
ajst-32484	68	21	generally	generally	ADV
ajst-32484	68	22	controllable	controllable	ADJ
ajst-32484	68	23	.	.	PUNCT
ajst-32484	69	1	c	c	X
ajst-32484	69	2	:	:	PUNCT
ajst-32484	69	3	similar	similar	ADJ
ajst-32484	69	4	to	to	ADP
ajst-32484	69	5	cohort	cohort	PROPN
ajst-32484	69	6	b.	b.	PROPN
ajst-32484	69	7	undefined	undefined	PROPN
ajst-32484	69	8	(	(	PUNCT
ajst-32484	69	9	her3	her3	PROPN
ajst-32484	69	10	)	)	PUNCT
ajst-32484	70	1	[	[	X
ajst-32484	70	2	21	21	NUM
ajst-32484	70	3	]	]	PUNCT
ajst-32484	70	4	herthenalung01	herthenalung01	X
ajst-32484	70	5	ⅱ	ⅱ	PROPN
ajst-32484	70	6	patritumab	patritumab	NOUN
ajst-32484	70	7	deruxtecan(he	deruxtecan(he	PROPN
ajst-32484	70	8	r3	r3	PROPN
ajst-32484	70	9	-	-	PUNCT
ajst-32484	70	10	dxd	dxd	NOUN
ajst-32484	70	11	:	:	PUNCT
ajst-32484	70	12	u31402	u31402	PROPN
ajst-32484	70	13	)	)	PUNCT
ajst-32484	70	14	mpfs:5.5	mpfs:5.5	NOUN
ajst-32484	70	15	mo	mo	PROPN
ajst-32484	70	16	orr:29.8	orr:29.8	PROPN
ajst-32484	70	17	%	%	PROPN
ajst-32484	70	18	mos:11.9	mos:11.9	PROPN
ajst-32484	70	19	mo	mo	PROPN
ajst-32484	70	20	grade	grade	PROPN
ajst-32484	70	21	≥	≥	PROPN
ajst-32484	70	22	3	3	NUM
ajst-32484	70	23	teae	teae	ADV
ajst-32484	70	24	:	:	PUNCT
ajst-32484	70	25	64.9	64.9	NUM
ajst-32484	70	26	%	%	NOUN
ajst-32484	70	27	sae	sae	PROPN
ajst-32484	70	28	:	:	PUNCT
ajst-32484	70	29	40	40	NUM
ajst-32484	70	30	%	%	NOUN
ajst-32484	70	31	undefined	undefined	ADJ
ajst-32484	70	32	(	(	PUNCT
ajst-32484	70	33	trop2	trop2	NOUN
ajst-32484	70	34	)	)	PUNCT
ajst-32484	71	1	[	[	X
ajst-32484	71	2	28	28	NUM
ajst-32484	71	3	]	]	PUNCT
ajst-32484	71	4	tropionlung01	tropionlung01	VERB
ajst-32484	71	5	ⅲ	ⅲ	ADJ
ajst-32484	71	6	a	a	DET
ajst-32484	71	7	:	:	PUNCT
ajst-32484	71	8	dato	dato	PROPN
ajst-32484	71	9	-	-	PUNCT
ajst-32484	71	10	dxd	dxd	PROPN
ajst-32484	71	11	b	b	PROPN
ajst-32484	71	12	:	:	PUNCT
ajst-32484	71	13	docetaxel	docetaxel	NOUN
ajst-32484	71	14	mpfs	mpf	VERB
ajst-32484	71	15	:	:	PUNCT
ajst-32484	71	16	a	a	X
ajst-32484	71	17	:	:	PUNCT
ajst-32484	71	18	4.4	4.4	NUM
ajst-32484	71	19	mo	mo	PROPN
ajst-32484	71	20	b	b	PROPN
ajst-32484	71	21	:	:	PUNCT
ajst-32484	71	22	3.7	3.7	NUM
ajst-32484	71	23	mo	mo	PROPN
ajst-32484	71	24	orr	orr	PROPN
ajst-32484	71	25	:	:	PUNCT
ajst-32484	71	26	a:26.4	a:26.4	PROPN
ajst-32484	71	27	%	%	NOUN
ajst-32484	71	28	b:12.8	b:12.8	NOUN
ajst-32484	71	29	%	%	NOUN
ajst-32484	71	30	grade	grade	NOUN
ajst-32484	71	31	≥	≥	PROPN
ajst-32484	71	32	3	3	NUM
ajst-32484	71	33	trae	trae	PROPN
ajst-32484	71	34	:	:	PUNCT
ajst-32484	71	35	a	a	DET
ajst-32484	71	36	:	:	PUNCT
ajst-32484	71	37	25	25	NUM
ajst-32484	71	38	%	%	NOUN
ajst-32484	71	39	;	;	PUNCT
ajst-32484	71	40	b	b	X
ajst-32484	71	41	:	:	PUNCT
ajst-32484	71	42	41	41	NUM
ajst-32484	71	43	%	%	NOUN
ajst-32484	71	44	serious	serious	ADJ
ajst-32484	71	45	trae	trae	PROPN
ajst-32484	71	46	:	:	PUNCT
ajst-32484	71	47	a	a	DET
ajst-32484	71	48	:	:	PUNCT
ajst-32484	71	49	10	10	NUM
ajst-32484	71	50	%	%	NOUN
ajst-32484	71	51	;	;	PUNCT
ajst-32484	71	52	b	b	X
ajst-32484	71	53	:	:	PUNCT
ajst-32484	71	54	12	12	NUM
ajst-32484	71	55	%	%	NOUN
ajst-32484	71	56	undefined	undefined	ADJ
ajst-32484	71	57	[	[	X
ajst-32484	71	58	22	22	NUM
ajst-32484	71	59	]	]	SYM
ajst-32484	71	60	chrysalis-2	chrysalis-2	NUM
ajst-32484	71	61	ib	ib	PROPN
ajst-32484	71	62	/	/	SYM
ajst-32484	71	63	ii	ii	PROPN
ajst-32484	71	64	amivantamab	amivantamab	X
ajst-32484	72	1	+	+	SYM
ajst-32484	72	2	lazertinib	lazertinib	NOUN
ajst-32484	72	3	+	+	ADV
ajst-32484	72	4	carboplatin+	carboplatin+	PROPN
ajst-32484	72	5	pemetrexed	pemetrexe	VERB
ajst-32484	72	6	the	the	DET
ajst-32484	72	7	orr	orr	PROPN
ajst-32484	72	8	reached	reach	VERB
ajst-32484	72	9	50	50	NUM
ajst-32484	72	10	%	%	NOUN
ajst-32484	72	11	.	.	PUNCT
ajst-32484	73	1	the	the	DET
ajst-32484	73	2	mpfs	mpf	NOUN
ajst-32484	73	3	of	of	ADP
ajst-32484	73	4	11	11	NUM
ajst-32484	73	5	patients	patient	NOUN
ajst-32484	73	6	was	be	AUX
ajst-32484	73	7	14.0	14.0	NUM
ajst-32484	73	8	months	month	NOUN
ajst-32484	73	9	.	.	PUNCT
ajst-32484	74	1	the	the	DET
ajst-32484	74	2	most	most	ADV
ajst-32484	74	3	common	common	ADJ
ajst-32484	74	4	grade	grade	NOUN
ajst-32484	74	5	≥	≥	NOUN
ajst-32484	74	6	3	3	NUM
ajst-32484	74	7	teaes	teaes	NOUN
ajst-32484	74	8	include	include	VERB
ajst-32484	74	9	neutropenia	neutropenia	NOUN
ajst-32484	74	10	(	(	PUNCT
ajst-32484	74	11	70	70	NUM
ajst-32484	74	12	%	%	NOUN
ajst-32484	74	13	)	)	PUNCT
ajst-32484	74	14	,	,	PUNCT
ajst-32484	74	15	thrombocytopenia	thrombocytopenia	PROPN
ajst-32484	74	16	(	(	PUNCT
ajst-32484	74	17	25	25	NUM
ajst-32484	74	18	%	%	NOUN
ajst-32484	74	19	)	)	PUNCT
ajst-32484	74	20	,	,	PUNCT
ajst-32484	74	21	and	and	CCONJ
ajst-32484	74	22	fatigue	fatigue	NOUN
ajst-32484	74	23	(	(	PUNCT
ajst-32484	74	24	25	25	NUM
ajst-32484	74	25	%	%	NOUN
ajst-32484	74	26	)	)	PUNCT
ajst-32484	74	27	.	.	PUNCT
ajst-32484	75	1	undefined	undefined	ADJ
ajst-32484	75	2	[	[	X
ajst-32484	75	3	24	24	NUM
ajst-32484	75	4	]	]	PUNCT
ajst-32484	75	5	impower150	impower150	PROPN
ajst-32484	76	1	ⅲ	ⅲ	ADJ
ajst-32484	76	2	atezolizumab	atezolizumab	NOUN
ajst-32484	76	3	+	+	NOUN
ajst-32484	76	4	bevacizumab	bevacizumab	NOUN
ajst-32484	76	5	+	+	CCONJ
ajst-32484	76	6	carboplatin+p	carboplatin+p	X
ajst-32484	76	7	aclitaxel	aclitaxel	NOUN
ajst-32484	76	8	(	(	PUNCT
ajst-32484	76	9	abcp	abcp	NOUN
ajst-32484	76	10	)	)	PUNCT
ajst-32484	76	11	atezolizumab	atezolizumab	NOUN
ajst-32484	76	12	+	+	CCONJ
ajst-32484	76	13	carboplatin+p	carboplatin+p	PROPN
ajst-32484	76	14	aclitaxel	aclitaxel	NOUN
ajst-32484	76	15	(	(	PUNCT
ajst-32484	76	16	acp	acp	PROPN
ajst-32484	76	17	)	)	PUNCT
ajst-32484	76	18	compared	compare	VERB
ajst-32484	76	19	with	with	ADP
ajst-32484	76	20	the	the	DET
ajst-32484	76	21	standard	standard	ADJ
ajst-32484	76	22	treatment	treatment	NOUN
ajst-32484	76	23	bevacizumab+	bevacizumab+	NOUN
ajst-32484	76	24	carboplatin+p	carboplatin+p	PROPN
ajst-32484	76	25	aclitaxel	aclitaxel	NOUN
ajst-32484	76	26	(	(	PUNCT
ajst-32484	76	27	bcp	bcp	PROPN
ajst-32484	76	28	)	)	PUNCT
ajst-32484	76	29	mpfs	mpf	VERB
ajst-32484	76	30	:	:	PUNCT
ajst-32484	76	31	acp:6.9mo	acp:6.9mo	PROPN
ajst-32484	76	32	bcp:6.9mo	bcp:6.9mo	PROPN
ajst-32484	76	33	abcp:10.2mo	abcp:10.2mo	PROPN
ajst-32484	76	34	mos	mos	PROPN
ajst-32484	76	35	:	:	PUNCT
ajst-32484	76	36	acp:19.0mo	acp:19.0mo	NOUN
ajst-32484	76	37	bcp:18.1mo	bcp:18.1mo	NOUN
ajst-32484	76	38	abcp:29.4mo	abcp:29.4mo	VERB
ajst-32484	76	39	the	the	DET
ajst-32484	76	40	incidences	incidence	NOUN
ajst-32484	76	41	of	of	ADP
ajst-32484	76	42	grade	grade	NOUN
ajst-32484	76	43	3	3	NUM
ajst-32484	76	44	-	-	SYM
ajst-32484	76	45	4	4	NUM
ajst-32484	76	46	treatment	treatment	NOUN
ajst-32484	76	47	-	-	PUNCT
ajst-32484	76	48	related	relate	VERB
ajst-32484	76	49	adverse	adverse	ADJ
ajst-32484	76	50	reactions	reaction	NOUN
ajst-32484	76	51	were	be	AUX
ajst-32484	76	52	56.8	56.8	NUM
ajst-32484	76	53	%	%	NOUN
ajst-32484	76	54	,	,	PUNCT
ajst-32484	76	55	55.8	55.8	NUM
ajst-32484	76	56	%	%	NOUN
ajst-32484	76	57	,	,	PUNCT
ajst-32484	76	58	and	and	CCONJ
ajst-32484	76	59	66.7	66.7	NUM
ajst-32484	76	60	%	%	NOUN
ajst-32484	76	61	respectively	respectively	ADV
ajst-32484	76	62	.	.	PUNCT
ajst-32484	77	1	undefined	undefined	ADJ
ajst-32484	77	2	[	[	X
ajst-32484	77	3	25	25	NUM
ajst-32484	77	4	]	]	X
ajst-32484	77	5	orient-31	orient-31	NOUN
ajst-32484	77	6	ⅲ	ⅲ	PROPN
ajst-32484	77	7	a	a	DET
ajst-32484	77	8	:	:	PUNCT
ajst-32484	77	9	sintilimab+i	sintilimab+i	ADP
ajst-32484	77	10	bi305+chemo	bi305+chemo	PROPN
ajst-32484	77	11	b	b	X
ajst-32484	77	12	:	:	PUNCT
ajst-32484	77	13	sintilimab+	sintilimab+	X
ajst-32484	77	14	chemo	chemo	NOUN
ajst-32484	77	15	c	c	NOUN
ajst-32484	77	16	:	:	PUNCT
ajst-32484	77	17	chemo	chemo	NOUN
ajst-32484	77	18	mpfs	mpf	VERB
ajst-32484	77	19	:	:	PUNCT
ajst-32484	77	20	a	a	X
ajst-32484	77	21	:	:	PUNCT
ajst-32484	77	22	7.2	7.2	NUM
ajst-32484	77	23	mo	mo	PROPN
ajst-32484	77	24	b	b	PROPN
ajst-32484	77	25	:	:	PUNCT
ajst-32484	77	26	5.5	5.5	NUM
ajst-32484	77	27	mo	mo	NOUN
ajst-32484	77	28	c	c	PROPN
ajst-32484	77	29	:	:	PUNCT
ajst-32484	77	30	4.3	4.3	NUM
ajst-32484	77	31	mo	mo	PROPN
ajst-32484	77	32	grade	grade	PROPN
ajst-32484	77	33	≥	≥	PROPN
ajst-32484	77	34	3	3	NUM
ajst-32484	77	35	trae	trae	PROPN
ajst-32484	77	36	:	:	PUNCT
ajst-32484	77	37	a	a	PRON
ajst-32484	77	38	:	:	PUNCT
ajst-32484	77	39	56	56	NUM
ajst-32484	77	40	%	%	NOUN
ajst-32484	77	41	b	b	NOUN
ajst-32484	77	42	:	:	PUNCT
ajst-32484	77	43	41	41	NUM
ajst-32484	77	44	%	%	NOUN
ajst-32484	77	45	c	c	NOUN
ajst-32484	77	46	:	:	PUNCT
ajst-32484	77	47	49	49	NUM
ajst-32484	77	48	%	%	NOUN
ajst-32484	77	49	115	115	NUM
ajst-32484	77	50	3.2.2	3.2.2	NUM
ajst-32484	77	51	treatment	treatment	NOUN
ajst-32484	77	52	after	after	ADP
ajst-32484	77	53	alk	alk	NOUN
ajst-32484	77	54	-	-	PUNCT
ajst-32484	77	55	tki	tki	NOUN
ajst-32484	77	56	resistance	resistance	NOUN
ajst-32484	77	57	therapeutic	therapeutic	ADJ
ajst-32484	77	58	strategies	strategy	NOUN
ajst-32484	77	59	include	include	VERB
ajst-32484	77	60	sequential	sequential	ADJ
ajst-32484	77	61	alk	alk	NOUN
ajst-32484	77	62	-	-	PUNCT
ajst-32484	77	63	tkis	tkis	NOUN
ajst-32484	77	64	,	,	PUNCT
ajst-32484	77	65	combination	combination	NOUN
ajst-32484	77	66	therapies	therapy	NOUN
ajst-32484	77	67	,	,	PUNCT
ajst-32484	77	68	or	or	CCONJ
ajst-32484	77	69	local	local	ADJ
ajst-32484	77	70	intervention	intervention	NOUN
ajst-32484	77	71	for	for	ADP
ajst-32484	77	72	oligoprogression	oligoprogression	NOUN
ajst-32484	77	73	.	.	PUNCT
ajst-32484	78	1	alk	alk	VERB
ajst-32484	78	2	-	-	PUNCT
ajst-32484	78	3	dependent	dependent	ADJ
ajst-32484	78	4	resistance	resistance	NOUN
ajst-32484	78	5	,	,	PUNCT
ajst-32484	78	6	particularly	particularly	ADV
ajst-32484	78	7	compound	compound	NOUN
ajst-32484	78	8	mutations	mutation	NOUN
ajst-32484	78	9	involving	involve	VERB
ajst-32484	78	10	g1202r	g1202r	NOUN
ajst-32484	78	11	,	,	PUNCT
ajst-32484	78	12	often	often	ADV
ajst-32484	78	13	retains	retain	VERB
ajst-32484	78	14	sensitivity	sensitivity	NOUN
ajst-32484	78	15	to	to	ADP
ajst-32484	78	16	next	next	ADJ
ajst-32484	78	17	-	-	PUNCT
ajst-32484	78	18	generation	generation	NOUN
ajst-32484	78	19	agents	agent	NOUN
ajst-32484	78	20	like	like	ADP
ajst-32484	78	21	lorlatinib	lorlatinib	NOUN
ajst-32484	78	22	[	[	X
ajst-32484	78	23	32	32	NUM
ajst-32484	78	24	-	-	SYM
ajst-32484	78	25	36	36	NUM
ajst-32484	78	26	]	]	PUNCT
ajst-32484	78	27	.	.	PUNCT
ajst-32484	79	1	alk	alk	VERB
ajst-32484	79	2	-	-	PUNCT
ajst-32484	79	3	independent	independent	ADJ
ajst-32484	79	4	resistance	resistance	NOUN
ajst-32484	79	5	,	,	PUNCT
ajst-32484	79	6	frequently	frequently	ADV
ajst-32484	79	7	involving	involve	VERB
ajst-32484	79	8	bypass	bypass	NOUN
ajst-32484	79	9	activation	activation	NOUN
ajst-32484	79	10	of	of	ADP
ajst-32484	79	11	mapk	mapk	NOUN
ajst-32484	79	12	,	,	PUNCT
ajst-32484	79	13	pi3k	pi3k	PROPN
ajst-32484	79	14	,	,	PUNCT
ajst-32484	79	15	or	or	CCONJ
ajst-32484	79	16	rtk	rtk	PROPN
ajst-32484	79	17	pathways	pathway	NOUN
ajst-32484	79	18	as	as	SCONJ
ajst-32484	79	19	reported	report	VERB
ajst-32484	79	20	in	in	ADP
ajst-32484	79	21	the	the	DET
ajst-32484	79	22	2024	2024	NUM
ajst-32484	79	23	asco	asco	ADJ
ajst-32484	79	24	crown	crown	NOUN
ajst-32484	79	25	study	study	NOUN
ajst-32484	79	26	[	[	X
ajst-32484	79	27	14	14	NUM
ajst-32484	79	28	]	]	PUNCT
ajst-32484	79	29	,	,	PUNCT
ajst-32484	79	30	may	may	AUX
ajst-32484	79	31	benefit	benefit	VERB
ajst-32484	79	32	from	from	ADP
ajst-32484	79	33	combination	combination	NOUN
ajst-32484	79	34	approaches	approach	NOUN
ajst-32484	79	35	such	such	ADJ
ajst-32484	79	36	as	as	ADP
ajst-32484	79	37	alk	alk	NOUN
ajst-32484	79	38	-	-	PUNCT
ajst-32484	79	39	tkis	tkis	NOUN
ajst-32484	79	40	with	with	ADP
ajst-32484	79	41	mek	mek	PROPN
ajst-32484	79	42	inhibitors	inhibitor	NOUN
ajst-32484	79	43	[	[	X
ajst-32484	79	44	37	37	NUM
ajst-32484	79	45	,	,	PUNCT
ajst-32484	79	46	38	38	NUM
ajst-32484	79	47	]	]	PUNCT
ajst-32484	79	48	.	.	PUNCT
ajst-32484	80	1	lorlatinib	lorlatinib	NOUN
ajst-32484	80	2	demonstrates	demonstrate	VERB
ajst-32484	80	3	notable	notable	ADJ
ajst-32484	80	4	intracranial	intracranial	ADJ
ajst-32484	80	5	activity	activity	NOUN
ajst-32484	80	6	[	[	X
ajst-32484	80	7	39	39	NUM
ajst-32484	80	8	]	]	PUNCT
ajst-32484	80	9	,	,	PUNCT
ajst-32484	80	10	while	while	SCONJ
ajst-32484	80	11	brigatinib	brigatinib	NOUN
ajst-32484	80	12	offers	offer	VERB
ajst-32484	80	13	efficacy	efficacy	NOUN
ajst-32484	80	14	against	against	ADP
ajst-32484	80	15	specific	specific	ADJ
ajst-32484	80	16	mutations	mutation	NOUN
ajst-32484	80	17	and	and	CCONJ
ajst-32484	80	18	bypass	bypass	NOUN
ajst-32484	80	19	mechanisms	mechanism	NOUN
ajst-32484	80	20	[	[	X
ajst-32484	80	21	40	40	NUM
ajst-32484	80	22	]	]	PUNCT
ajst-32484	80	23	.	.	PUNCT
ajst-32484	81	1	table	table	NOUN
ajst-32484	81	2	2	2	NUM
ajst-32484	81	3	.	.	PUNCT
ajst-32484	81	4	data	datum	NOUN
ajst-32484	81	5	summary	summary	NOUN
ajst-32484	81	6	of	of	ADP
ajst-32484	81	7	clinical	clinical	ADJ
ajst-32484	81	8	trials	trial	NOUN
ajst-32484	81	9	in	in	ADP
ajst-32484	81	10	met	meet	VERB
ajst-32484	81	11	and	and	CCONJ
ajst-32484	81	12	alk	alk	VERB
ajst-32484	81	13	mutant	mutant	ADJ
ajst-32484	81	14	metastatic	metastatic	ADJ
ajst-32484	81	15	nsclc	nsclc	NOUN
ajst-32484	81	16	cases	case	NOUN
ajst-32484	81	17	progressing	progress	VERB
ajst-32484	81	18	on	on	ADP
ajst-32484	81	19	met	meet	VERB
ajst-32484	81	20	and	and	CCONJ
ajst-32484	81	21	alk	alk	VERB
ajst-32484	81	22	inhibitors	inhibitor	NOUN
ajst-32484	81	23	generation	generation	NOUN
ajst-32484	81	24	resistance	resistance	NOUN
ajst-32484	81	25	type	type	NOUN
ajst-32484	81	26	reference	reference	NOUN
ajst-32484	81	27	study	study	NOUN
ajst-32484	81	28	name	name	NOUN
ajst-32484	81	29	phase	phase	NOUN
ajst-32484	81	30	treatment	treatment	NOUN
ajst-32484	81	31	arm	arm	NOUN
ajst-32484	81	32	efficacy	efficacy	NOUN
ajst-32484	81	33	safety	safety	NOUN
ajst-32484	81	34	first	first	ADJ
ajst-32484	81	35	generation	generation	NOUN
ajst-32484	81	36	mettkis	mettki	NOUN
ajst-32484	82	1	[	[	X
ajst-32484	82	2	41	41	NUM
ajst-32484	82	3	]	]	X
ajst-32484	82	4	nct02414139	nct02414139	ADJ
ajst-32484	82	5	ⅱ	ⅱ	PROPN
ajst-32484	82	6	capmatinib	capmatinib	NOUN
ajst-32484	82	7	mpfs	mpf	VERB
ajst-32484	82	8	:	:	PUNCT
ajst-32484	82	9	untreated	untreated	ADJ
ajst-32484	82	10	patients	patient	NOUN
ajst-32484	82	11	:	:	PUNCT
ajst-32484	82	12	9.69	9.69	NUM
ajst-32484	82	13	mo	mo	NOUN
ajst-32484	82	14	treated	treat	VERB
ajst-32484	82	15	patients	patient	NOUN
ajst-32484	82	16	:	:	PUNCT
ajst-32484	82	17	5.42	5.42	NUM
ajst-32484	82	18	mo	mo	PROPN
ajst-32484	82	19	orr	orr	PROPN
ajst-32484	82	20	:	:	PUNCT
ajst-32484	82	21	untreated	untreated	ADJ
ajst-32484	82	22	patients	patient	NOUN
ajst-32484	82	23	:	:	PUNCT
ajst-32484	82	24	67.9	67.9	NUM
ajst-32484	82	25	%	%	NOUN
ajst-32484	82	26	treated	treat	VERB
ajst-32484	82	27	patients	patient	NOUN
ajst-32484	82	28	:	:	PUNCT
ajst-32484	82	29	40.6	40.6	NUM
ajst-32484	82	30	%	%	NOUN
ajst-32484	82	31	mos	mos	ADJ
ajst-32484	82	32	:	:	PUNCT
ajst-32484	82	33	untreated	untreated	ADJ
ajst-32484	82	34	patients	patient	NOUN
ajst-32484	82	35	:	:	PUNCT
ajst-32484	82	36	20.82	20.82	NUM
ajst-32484	82	37	mo	mo	PROPN
ajst-32484	82	38	treated	treat	VERB
ajst-32484	82	39	patients	patient	NOUN
ajst-32484	82	40	:	:	PUNCT
ajst-32484	82	41	13.56	13.56	NUM
ajst-32484	82	42	mo	mo	NOUN
ajst-32484	82	43	the	the	DET
ajst-32484	82	44	safety	safety	NOUN
ajst-32484	82	45	is	be	AUX
ajst-32484	82	46	good	good	ADJ
ajst-32484	82	47	,	,	PUNCT
ajst-32484	82	48	and	and	CCONJ
ajst-32484	82	49	most	most	ADJ
ajst-32484	82	50	adverse	adverse	ADJ
ajst-32484	82	51	events	event	NOUN
ajst-32484	82	52	are	be	AUX
ajst-32484	82	53	mild	mild	ADJ
ajst-32484	82	54	to	to	PART
ajst-32484	82	55	moderate	moderate	VERB
ajst-32484	82	56	.	.	PUNCT
ajst-32484	83	1	[	[	X
ajst-32484	83	2	30	30	NUM
ajst-32484	83	3	]	]	PUNCT
ajst-32484	83	4	nct02864992	nct02864992	NOUN
ajst-32484	83	5	ⅱ	ⅱ	PROPN
ajst-32484	83	6	tepotinib	tepotinib	NOUN
ajst-32484	83	7	in	in	ADP
ajst-32484	83	8	the	the	DET
ajst-32484	83	9	overall	overall	ADJ
ajst-32484	83	10	patient	patient	ADJ
ajst-32484	83	11	population	population	NOUN
ajst-32484	83	12	,	,	PUNCT
ajst-32484	83	13	the	the	DET
ajst-32484	83	14	orr	orr	PROPN
ajst-32484	83	15	of	of	ADP
ajst-32484	83	16	tepotinib	tepotinib	NOUN
ajst-32484	83	17	was	be	AUX
ajst-32484	83	18	51.4	51.4	NUM
ajst-32484	83	19	%	%	NOUN
ajst-32484	83	20	,	,	PUNCT
ajst-32484	83	21	the	the	DET
ajst-32484	83	22	mdor	mdor	NOUN
ajst-32484	83	23	was	be	AUX
ajst-32484	83	24	18.0	18.0	NUM
ajst-32484	83	25	months	month	NOUN
ajst-32484	83	26	,	,	PUNCT
ajst-32484	83	27	the	the	DET
ajst-32484	83	28	mpfs	mpf	NOUN
ajst-32484	83	29	was	be	AUX
ajst-32484	83	30	11.2	11.2	NUM
ajst-32484	83	31	months	month	NOUN
ajst-32484	83	32	,	,	PUNCT
ajst-32484	83	33	and	and	CCONJ
ajst-32484	83	34	the	the	DET
ajst-32484	83	35	mos	mos	NOUN
ajst-32484	83	36	was	be	AUX
ajst-32484	83	37	19.6	19.6	NUM
ajst-32484	83	38	months	month	NOUN
ajst-32484	83	39	.	.	PUNCT
ajst-32484	84	1	most	most	ADJ
ajst-32484	84	2	adverse	adverse	ADJ
ajst-32484	84	3	events	event	NOUN
ajst-32484	84	4	are	be	AUX
ajst-32484	84	5	mild	mild	ADJ
ajst-32484	84	6	to	to	PART
ajst-32484	84	7	moderate	moderate	ADJ
ajst-32484	84	8	,	,	PUNCT
ajst-32484	84	9	and	and	CCONJ
ajst-32484	84	10	the	the	DET
ajst-32484	84	11	incidence	incidence	NOUN
ajst-32484	84	12	of	of	ADP
ajst-32484	84	13	grade	grade	NOUN
ajst-32484	84	14	3	3	NUM
ajst-32484	84	15	and	and	CCONJ
ajst-32484	84	16	above	above	ADP
ajst-32484	84	17	adverse	adverse	ADJ
ajst-32484	84	18	events	event	NOUN
ajst-32484	84	19	is	be	AUX
ajst-32484	84	20	28.2	28.2	NUM
ajst-32484	84	21	%	%	NOUN
ajst-32484	84	22	.	.	PUNCT
ajst-32484	85	1	second	second	ADJ
ajst-32484	85	2	generation	generation	NOUN
ajst-32484	85	3	alktkis	alktki	NOUN
ajst-32484	86	1	[	[	X
ajst-32484	86	2	39	39	NUM
ajst-32484	86	3	]	]	PUNCT
ajst-32484	86	4	nct01970865	nct01970865	ADJ
ajst-32484	86	5	ⅱ	ⅱ	PROPN
ajst-32484	86	6	lorlatinib	lorlatinib	NOUN
ajst-32484	86	7	among	among	ADP
ajst-32484	86	8	patients	patient	NOUN
ajst-32484	86	9	who	who	PRON
ajst-32484	86	10	had	have	AUX
ajst-32484	86	11	received	receive	VERB
ajst-32484	86	12	≥	≥	NOUN
ajst-32484	86	13	1	1	NUM
ajst-32484	86	14	secondgeneration	secondgeneration	NOUN
ajst-32484	86	15	alk	alk	PROPN
ajst-32484	86	16	-	-	PUNCT
ajst-32484	86	17	tki	tki	PROPN
ajst-32484	86	18	,	,	PUNCT
ajst-32484	86	19	the	the	DET
ajst-32484	86	20	orr	orr	NOUN
ajst-32484	86	21	reached	reach	VERB
ajst-32484	86	22	39.6	39.6	NUM
ajst-32484	86	23	%	%	NOUN
ajst-32484	86	24	,	,	PUNCT
ajst-32484	86	25	the	the	DET
ajst-32484	86	26	mdor	mdor	NOUN
ajst-32484	86	27	was	be	AUX
ajst-32484	86	28	9.6	9.6	NUM
ajst-32484	86	29	months	month	NOUN
ajst-32484	86	30	,	,	PUNCT
ajst-32484	86	31	the	the	DET
ajst-32484	86	32	mpfs	mpf	NOUN
ajst-32484	86	33	was	be	AUX
ajst-32484	86	34	6.6	6.6	NUM
ajst-32484	86	35	months	month	NOUN
ajst-32484	86	36	,	,	PUNCT
ajst-32484	86	37	and	and	CCONJ
ajst-32484	86	38	the	the	DET
ajst-32484	86	39	mos	mos	NOUN
ajst-32484	86	40	was	be	AUX
ajst-32484	86	41	20.7	20.7	NUM
ajst-32484	86	42	months	month	NOUN
ajst-32484	86	43	.	.	PUNCT
ajst-32484	87	1	common	common	ADJ
ajst-32484	87	2	adverse	adverse	ADJ
ajst-32484	87	3	events	event	NOUN
ajst-32484	87	4	include	include	VERB
ajst-32484	87	5	hypercholesterolemia	hypercholesterolemia	NOUN
ajst-32484	87	6	,	,	PUNCT
ajst-32484	87	7	hypertriglyceridemia	hypertriglyceridemia	NOUN
ajst-32484	87	8	,	,	PUNCT
ajst-32484	87	9	and	and	CCONJ
ajst-32484	87	10	peripheral	peripheral	ADJ
ajst-32484	87	11	neuropathy	neuropathy	ADJ
ajst-32484	87	12	,	,	PUNCT
ajst-32484	87	13	and	and	CCONJ
ajst-32484	87	14	most	most	ADJ
ajst-32484	87	15	of	of	ADP
ajst-32484	87	16	them	they	PRON
ajst-32484	87	17	are	be	AUX
ajst-32484	87	18	grade	grade	NOUN
ajst-32484	87	19	1	1	NUM
ajst-32484	87	20	-	-	SYM
ajst-32484	87	21	2	2	NUM
ajst-32484	87	22	.	.	PUNCT
ajst-32484	88	1	[	[	X
ajst-32484	88	2	40	40	NUM
ajst-32484	88	3	]	]	PUNCT
ajst-32484	88	4	nct02737501	nct02737501	VERB
ajst-32484	88	5	ⅱ	ⅱ	PROPN
ajst-32484	88	6	brigatinib	brigatinib	NOUN
ajst-32484	88	7	among	among	ADP
ajst-32484	88	8	patients	patient	NOUN
ajst-32484	88	9	who	who	PRON
ajst-32484	88	10	had	have	AUX
ajst-32484	88	11	received	receive	VERB
ajst-32484	88	12	crizotinib	crizotinib	NOUN
ajst-32484	88	13	treatment	treatment	NOUN
ajst-32484	88	14	,	,	PUNCT
ajst-32484	88	15	the	the	DET
ajst-32484	88	16	orr	orr	PROPN
ajst-32484	88	17	was	be	AUX
ajst-32484	88	18	53	53	NUM
ajst-32484	88	19	%	%	NOUN
ajst-32484	88	20	,	,	PUNCT
ajst-32484	88	21	and	and	CCONJ
ajst-32484	88	22	the	the	DET
ajst-32484	88	23	mpfs	mpf	NOUN
ajst-32484	88	24	was	be	AUX
ajst-32484	88	25	16.7	16.7	NUM
ajst-32484	88	26	months	month	NOUN
ajst-32484	88	27	.	.	PUNCT
ajst-32484	89	1	common	common	ADJ
ajst-32484	89	2	adverse	adverse	ADJ
ajst-32484	89	3	events	event	NOUN
ajst-32484	89	4	include	include	VERB
ajst-32484	89	5	nausea	nausea	NOUN
ajst-32484	89	6	,	,	PUNCT
ajst-32484	89	7	diarrhea	diarrhea	PROPN
ajst-32484	89	8	,	,	PUNCT
ajst-32484	89	9	headache	headache	NOUN
ajst-32484	89	10	,	,	PUNCT
ajst-32484	89	11	and	and	CCONJ
ajst-32484	89	12	cough	cough	NOUN
ajst-32484	89	13	,	,	PUNCT
ajst-32484	89	14	and	and	CCONJ
ajst-32484	89	15	most	most	ADJ
ajst-32484	89	16	of	of	ADP
ajst-32484	89	17	them	they	PRON
ajst-32484	89	18	are	be	AUX
ajst-32484	89	19	grade	grade	NOUN
ajst-32484	89	20	1	1	NUM
ajst-32484	89	21	-	-	SYM
ajst-32484	89	22	2	2	NUM
ajst-32484	89	23	.	.	NOUN
ajst-32484	89	24	4	4	NUM
ajst-32484	89	25	.	.	X
ajst-32484	90	1	discussions	discussion	NOUN
ajst-32484	90	2	targeted	target	VERB
ajst-32484	90	3	therapy	therapy	NOUN
ajst-32484	90	4	significantly	significantly	ADV
ajst-32484	90	5	improves	improve	VERB
ajst-32484	90	6	nsclc	nsclc	NOUN
ajst-32484	90	7	management	management	NOUN
ajst-32484	90	8	,	,	PUNCT
ajst-32484	90	9	yet	yet	CCONJ
ajst-32484	90	10	acquired	acquire	VERB
ajst-32484	90	11	resistance	resistance	NOUN
ajst-32484	90	12	remains	remain	VERB
ajst-32484	90	13	a	a	DET
ajst-32484	90	14	critical	critical	ADJ
ajst-32484	90	15	barrier	barrier	NOUN
ajst-32484	90	16	.	.	PUNCT
ajst-32484	91	1	this	this	DET
ajst-32484	91	2	review	review	NOUN
ajst-32484	91	3	synthesizes	synthesize	VERB
ajst-32484	91	4	key	key	ADJ
ajst-32484	91	5	resistance	resistance	NOUN
ajst-32484	91	6	mechanisms	mechanism	NOUN
ajst-32484	91	7	and	and	CCONJ
ajst-32484	91	8	evolving	evolve	VERB
ajst-32484	91	9	strategies	strategy	NOUN
ajst-32484	91	10	,	,	PUNCT
ajst-32484	91	11	emphasizing	emphasize	VERB
ajst-32484	91	12	that	that	SCONJ
ajst-32484	91	13	effective	effective	ADJ
ajst-32484	91	14	post	post	ADJ
ajst-32484	91	15	-	-	ADJ
ajst-32484	91	16	resistance	resistance	NOUN
ajst-32484	91	17	treatment	treatment	NOUN
ajst-32484	91	18	requires	require	VERB
ajst-32484	91	19	personalized	personalized	ADJ
ajst-32484	91	20	approaches	approach	NOUN
ajst-32484	91	21	based	base	VERB
ajst-32484	91	22	on	on	ADP
ajst-32484	91	23	molecular	molecular	ADJ
ajst-32484	91	24	profiling	profiling	NOUN
ajst-32484	91	25	and	and	CCONJ
ajst-32484	91	26	clinical	clinical	ADJ
ajst-32484	91	27	context	context	NOUN
ajst-32484	91	28	.	.	PUNCT
ajst-32484	92	1	while	while	SCONJ
ajst-32484	92	2	next	next	ADJ
ajst-32484	92	3	-	-	PUNCT
ajst-32484	92	4	generation	generation	NOUN
ajst-32484	92	5	tkis	tkis	NOUN
ajst-32484	92	6	,	,	PUNCT
ajst-32484	92	7	adcs	adcs	ADJ
ajst-32484	92	8	,	,	PUNCT
ajst-32484	92	9	and	and	CCONJ
ajst-32484	92	10	combination	combination	NOUN
ajst-32484	92	11	therapies	therapy	NOUN
ajst-32484	92	12	show	show	VERB
ajst-32484	92	13	promise	promise	NOUN
ajst-32484	92	14	in	in	ADP
ajst-32484	92	15	extending	extend	VERB
ajst-32484	92	16	survival	survival	NOUN
ajst-32484	92	17	,	,	PUNCT
ajst-32484	92	18	tki	tki	ADJ
ajst-32484	92	19	-	-	ADJ
ajst-32484	92	20	immunotherapy	immunotherapy	NOUN
ajst-32484	92	21	combinations	combination	NOUN
ajst-32484	92	22	remain	remain	VERB
ajst-32484	92	23	limited	limited	ADJ
ajst-32484	92	24	by	by	ADP
ajst-32484	92	25	safety	safety	NOUN
ajst-32484	92	26	concerns	concern	NOUN
ajst-32484	92	27	and	and	CCONJ
ajst-32484	92	28	insufficient	insufficient	ADJ
ajst-32484	92	29	evidence	evidence	NOUN
ajst-32484	92	30	.	.	PUNCT
ajst-32484	93	1	beyond	beyond	ADP
ajst-32484	93	2	genetic	genetic	ADJ
ajst-32484	93	3	alterations	alteration	NOUN
ajst-32484	93	4	,	,	PUNCT
ajst-32484	93	5	emerging	emerge	VERB
ajst-32484	93	6	research	research	NOUN
ajst-32484	93	7	highlights	highlight	NOUN
ajst-32484	93	8	non	non	ADJ
ajst-32484	93	9	-	-	ADJ
ajst-32484	93	10	genetic	genetic	ADJ
ajst-32484	93	11	mechanisms	mechanism	NOUN
ajst-32484	93	12	driving	drive	VERB
ajst-32484	93	13	resistance	resistance	NOUN
ajst-32484	93	14	.	.	PUNCT
ajst-32484	94	1	drug	drug	NOUN
ajst-32484	94	2	-	-	PUNCT
ajst-32484	94	3	tolerant	tolerant	ADJ
ajst-32484	94	4	persister	persister	NOUN
ajst-32484	94	5	(	(	PUNCT
ajst-32484	94	6	dtp	dtp	PROPN
ajst-32484	94	7	)	)	PUNCT
ajst-32484	94	8	cells	cell	NOUN
ajst-32484	94	9	evade	evade	VERB
ajst-32484	94	10	therapy	therapy	NOUN
ajst-32484	94	11	through	through	ADP
ajst-32484	94	12	epigenetic	epigenetic	ADJ
ajst-32484	94	13	and	and	CCONJ
ajst-32484	94	14	signaling	signal	VERB
ajst-32484	94	15	adaptations	adaptation	NOUN
ajst-32484	94	16	[	[	X
ajst-32484	94	17	42	42	NUM
ajst-32484	94	18	]	]	PUNCT
ajst-32484	94	19	,	,	PUNCT
ajst-32484	94	20	while	while	SCONJ
ajst-32484	94	21	dysregulated	dysregulated	ADJ
ajst-32484	94	22	ferroptosis	ferroptosis	NOUN
ajst-32484	94	23	,	,	PUNCT
ajst-32484	94	24	controlled	control	VERB
ajst-32484	94	25	by	by	ADP
ajst-32484	94	26	gpx4	gpx4	PROPN
ajst-32484	94	27	,	,	PUNCT
ajst-32484	94	28	slc7a11	slc7a11	NOUN
ajst-32484	94	29	,	,	PUNCT
ajst-32484	94	30	and	and	CCONJ
ajst-32484	94	31	nrf2	nrf2	NOUN
ajst-32484	94	32	,	,	PUNCT
ajst-32484	94	33	represents	represent	VERB
ajst-32484	94	34	another	another	DET
ajst-32484	94	35	key	key	ADJ
ajst-32484	94	36	resistance	resistance	NOUN
ajst-32484	94	37	pathway	pathway	NOUN
ajst-32484	94	38	.	.	PUNCT
ajst-32484	95	1	targeting	target	VERB
ajst-32484	95	2	dtp	dtp	NOUN
ajst-32484	95	3	populations	population	NOUN
ajst-32484	95	4	and	and	CCONJ
ajst-32484	95	5	modulating	modulate	VERB
ajst-32484	95	6	ferroptosis	ferroptosis	NOUN
ajst-32484	95	7	offer	offer	VERB
ajst-32484	95	8	novel	novel	ADJ
ajst-32484	95	9	therapeutic	therapeutic	ADJ
ajst-32484	95	10	opportunities	opportunity	NOUN
ajst-32484	95	11	to	to	PART
ajst-32484	95	12	re	re	VERB
ajst-32484	95	13	-	-	VERB
ajst-32484	95	14	sensitise	sensitise	ADJ
ajst-32484	95	15	tumors	tumor	NOUN
ajst-32484	95	16	to	to	ADP
ajst-32484	95	17	treatment	treatment	VERB
ajst-32484	95	18	.	.	PUNCT
ajst-32484	96	1	future	future	ADJ
ajst-32484	96	2	advances	advance	NOUN
ajst-32484	96	3	will	will	AUX
ajst-32484	96	4	depend	depend	VERB
ajst-32484	96	5	on	on	ADP
ajst-32484	96	6	elucidating	elucidate	VERB
ajst-32484	96	7	these	these	DET
ajst-32484	96	8	mechanisms	mechanism	NOUN
ajst-32484	96	9	and	and	CCONJ
ajst-32484	96	10	integrating	integrate	VERB
ajst-32484	96	11	multidisciplinary	multidisciplinary	ADJ
ajst-32484	96	12	strategies	strategy	NOUN
ajst-32484	96	13	to	to	PART
ajst-32484	96	14	overcome	overcome	VERB
ajst-32484	96	15	resistance	resistance	NOUN
ajst-32484	96	16	and	and	CCONJ
ajst-32484	96	17	improve	improve	VERB
ajst-32484	96	18	long	long	ADJ
ajst-32484	96	19	-	-	PUNCT
ajst-32484	96	20	term	term	NOUN
ajst-32484	96	21	outcomes	outcome	NOUN
ajst-32484	96	22	.	.	PUNCT
ajst-32484	97	1	116	116	NUM
ajst-32484	97	2	5	5	NUM
ajst-32484	97	3	.	.	PUNCT
ajst-32484	97	4	conclusion	conclusion	NOUN
ajst-32484	97	5	targeted	target	VERB
ajst-32484	97	6	therapy	therapy	NOUN
ajst-32484	97	7	has	have	AUX
ajst-32484	97	8	transformed	transform	VERB
ajst-32484	97	9	nsclc	nsclc	NOUN
ajst-32484	97	10	treatment	treatment	NOUN
ajst-32484	97	11	by	by	ADP
ajst-32484	97	12	improving	improve	VERB
ajst-32484	97	13	precision	precision	NOUN
ajst-32484	97	14	and	and	CCONJ
ajst-32484	97	15	patient	patient	ADJ
ajst-32484	97	16	outcomes	outcome	NOUN
ajst-32484	97	17	,	,	PUNCT
ajst-32484	97	18	yet	yet	ADV
ajst-32484	97	19	acquired	acquire	VERB
ajst-32484	97	20	resistance	resistance	NOUN
ajst-32484	97	21	continues	continue	VERB
ajst-32484	97	22	to	to	PART
ajst-32484	97	23	limit	limit	VERB
ajst-32484	97	24	long	long	ADJ
ajst-32484	97	25	-	-	PUNCT
ajst-32484	97	26	term	term	NOUN
ajst-32484	97	27	efficacy	efficacy	NOUN
ajst-32484	97	28	.	.	PUNCT
ajst-32484	98	1	this	this	DET
ajst-32484	98	2	review	review	NOUN
ajst-32484	98	3	summarizes	summarize	VERB
ajst-32484	98	4	the	the	DET
ajst-32484	98	5	principal	principal	ADJ
ajst-32484	98	6	resistance	resistance	NOUN
ajst-32484	98	7	mechanisms	mechanism	NOUN
ajst-32484	98	8	and	and	CCONJ
ajst-32484	98	9	corresponding	corresponding	ADJ
ajst-32484	98	10	strategies	strategy	NOUN
ajst-32484	98	11	,	,	PUNCT
ajst-32484	98	12	underscoring	underscore	VERB
ajst-32484	98	13	the	the	DET
ajst-32484	98	14	necessity	necessity	NOUN
ajst-32484	98	15	of	of	ADP
ajst-32484	98	16	mechanismguided	mechanismguide	VERB
ajst-32484	98	17	therapy	therapy	NOUN
ajst-32484	98	18	.	.	PUNCT
ajst-32484	99	1	the	the	DET
ajst-32484	99	2	integration	integration	NOUN
ajst-32484	99	3	of	of	ADP
ajst-32484	99	4	next	next	ADJ
ajst-32484	99	5	-	-	PUNCT
ajst-32484	99	6	generation	generation	NOUN
ajst-32484	99	7	tkis	tkis	NOUN
ajst-32484	99	8	,	,	PUNCT
ajst-32484	99	9	adcs	adcs	ADJ
ajst-32484	99	10	,	,	PUNCT
ajst-32484	99	11	and	and	CCONJ
ajst-32484	99	12	rational	rational	ADJ
ajst-32484	99	13	combinations	combination	NOUN
ajst-32484	99	14	provides	provide	VERB
ajst-32484	99	15	promising	promising	ADJ
ajst-32484	99	16	paths	path	NOUN
ajst-32484	99	17	to	to	PART
ajst-32484	99	18	extend	extend	VERB
ajst-32484	99	19	survival	survival	NOUN
ajst-32484	99	20	after	after	ADP
ajst-32484	99	21	resistance	resistance	NOUN
ajst-32484	99	22	development	development	NOUN
ajst-32484	99	23	.	.	PUNCT
ajst-32484	100	1	future	future	ADJ
ajst-32484	100	2	success	success	NOUN
ajst-32484	100	3	will	will	AUX
ajst-32484	100	4	rely	rely	VERB
ajst-32484	100	5	on	on	ADP
ajst-32484	100	6	targeting	target	VERB
ajst-32484	100	7	non	non	ADJ
ajst-32484	100	8	-	-	ADJ
ajst-32484	100	9	genetic	genetic	ADJ
ajst-32484	100	10	mechanisms	mechanism	NOUN
ajst-32484	100	11	such	such	ADJ
ajst-32484	100	12	as	as	ADP
ajst-32484	100	13	dtp	dtp	PROPN
ajst-32484	100	14	cells	cell	NOUN
ajst-32484	100	15	and	and	CCONJ
ajst-32484	100	16	ferroptosis	ferroptosis	NOUN
ajst-32484	100	17	,	,	PUNCT
ajst-32484	100	18	advancing	advance	VERB
ajst-32484	100	19	personalized	personalized	ADJ
ajst-32484	100	20	multimodal	multimodal	NOUN
ajst-32484	100	21	strategies	strategy	NOUN
ajst-32484	100	22	to	to	PART
ajst-32484	100	23	overcome	overcome	VERB
ajst-32484	100	24	resistance	resistance	NOUN
ajst-32484	100	25	and	and	CCONJ
ajst-32484	100	26	improve	improve	VERB
ajst-32484	100	27	prognosis	prognosis	NOUN
ajst-32484	100	28	in	in	ADP
ajst-32484	100	29	nsclc	nsclc	NOUN
ajst-32484	100	30	ultimately	ultimately	ADV
ajst-32484	100	31	.	.	PUNCT
ajst-32484	101	1	declarations	declaration	NOUN
ajst-32484	101	2	ethics	ethic	NOUN
ajst-32484	101	3	approval	approval	NOUN
ajst-32484	101	4	and	and	CCONJ
ajst-32484	101	5	consent	consent	NOUN
ajst-32484	101	6	to	to	PART
ajst-32484	101	7	participate	participate	VERB
ajst-32484	101	8	:	:	PUNCT
ajst-32484	101	9	not	not	PART
ajst-32484	101	10	applicable	applicable	ADJ
ajst-32484	101	11	.	.	PUNCT
ajst-32484	102	1	consent	consent	NOUN
ajst-32484	102	2	for	for	ADP
ajst-32484	102	3	publication	publication	NOUN
ajst-32484	102	4	:	:	PUNCT
ajst-32484	102	5	not	not	PART
ajst-32484	102	6	applicable	applicable	ADJ
ajst-32484	102	7	.	.	PUNCT
ajst-32484	103	1	author	author	NOUN
ajst-32484	103	2	contributions	contribution	VERB
ajst-32484	103	3	yuzhu	yuzhu	PROPN
ajst-32484	103	4	chen	chen	PROPN
ajst-32484	103	5	:	:	PUNCT
ajst-32484	103	6	data	datum	NOUN
ajst-32484	103	7	curation	curation	NOUN
ajst-32484	103	8	;	;	PUNCT
ajst-32484	103	9	resources	resource	NOUN
ajst-32484	103	10	;	;	PUNCT
ajst-32484	103	11	writing	writing	NOUN
ajst-32484	103	12	,	,	PUNCT
ajst-32484	103	13	review	review	NOUN
ajst-32484	103	14	&	&	CCONJ
ajst-32484	103	15	editing	editing	PROPN
ajst-32484	103	16	.	.	PUNCT
ajst-32484	104	1	ziyuan	ziyuan	PROPN
ajst-32484	104	2	gao	gao	PROPN
ajst-32484	104	3	:	:	PUNCT
ajst-32484	104	4	writing	write	VERB
ajst-32484	104	5	–	–	PUNCT
ajst-32484	104	6	review	review	NOUN
ajst-32484	104	7	&	&	CCONJ
ajst-32484	104	8	editing	editing	NOUN
ajst-32484	104	9	.	.	PUNCT
ajst-32484	105	1	competing	compete	VERB
ajst-32484	105	2	interests	interest	NOUN
ajst-32484	105	3	the	the	DET
ajst-32484	105	4	authors	author	NOUN
ajst-32484	105	5	declare	declare	VERB
ajst-32484	105	6	that	that	SCONJ
ajst-32484	105	7	there	there	PRON
ajst-32484	105	8	is	be	VERB
ajst-32484	105	9	no	no	DET
ajst-32484	105	10	conflict	conflict	NOUN
ajst-32484	105	11	of	of	ADP
ajst-32484	105	12	interest	interest	NOUN
ajst-32484	105	13	.	.	PUNCT
ajst-32484	106	1	availability	availability	NOUN
ajst-32484	106	2	of	of	ADP
ajst-32484	106	3	data	datum	NOUN
ajst-32484	106	4	and	and	CCONJ
ajst-32484	106	5	materials	material	NOUN
ajst-32484	106	6	not	not	PART
ajst-32484	106	7	applicable	applicable	ADJ
ajst-32484	106	8	.	.	PUNCT
ajst-32484	107	1	references	reference	NOUN
ajst-32484	107	2	[	[	X
ajst-32484	107	3	1	1	NUM
ajst-32484	107	4	]	]	X
ajst-32484	107	5	bray	bray	NOUN
ajst-32484	107	6	,	,	PUNCT
ajst-32484	107	7	f.	f.	PROPN
ajst-32484	107	8	,	,	PUNCT
ajst-32484	107	9	et	et	PROPN
ajst-32484	107	10	al	al	PROPN
ajst-32484	107	11	.	.	PROPN
ajst-32484	107	12	,	,	PUNCT
ajst-32484	107	13	global	global	ADJ
ajst-32484	107	14	cancer	cancer	NOUN
ajst-32484	107	15	statistics	statistic	NOUN
ajst-32484	107	16	2018	2018	NUM
ajst-32484	107	17	:	:	PUNCT
ajst-32484	107	18	globocan	globocan	PROPN
ajst-32484	107	19	estimates	estimate	NOUN
ajst-32484	107	20	of	of	ADP
ajst-32484	107	21	incidence	incidence	NOUN
ajst-32484	107	22	and	and	CCONJ
ajst-32484	107	23	mortality	mortality	NOUN
ajst-32484	107	24	worldwide	worldwide	ADV
ajst-32484	107	25	for	for	ADP
ajst-32484	107	26	36	36	NUM
ajst-32484	107	27	cancers	cancer	NOUN
ajst-32484	107	28	in	in	ADP
ajst-32484	107	29	185	185	NUM
ajst-32484	107	30	countries	country	NOUN
ajst-32484	107	31	.	.	PUNCT
ajst-32484	108	1	ca	can	AUX
ajst-32484	108	2	cancer	cancer	PROPN
ajst-32484	108	3	j	j	PROPN
ajst-32484	108	4	clin	clin	PROPN
ajst-32484	108	5	,	,	PUNCT
ajst-32484	108	6	2018	2018	NUM
ajst-32484	108	7	.	.	PUNCT
ajst-32484	109	1	68(6	68(6	NOUN
ajst-32484	109	2	):	):	PUNCT
ajst-32484	109	3	p.	p.	NOUN
ajst-32484	109	4	394	394	NUM
ajst-32484	109	5	-	-	SYM
ajst-32484	109	6	424	424	NUM
ajst-32484	109	7	.	.	PUNCT
ajst-32484	110	1	[	[	X
ajst-32484	110	2	2	2	NUM
ajst-32484	110	3	]	]	PUNCT
ajst-32484	110	4	alduais	alduais	NOUN
ajst-32484	110	5	,	,	PUNCT
ajst-32484	110	6	y.	y.	PROPN
ajst-32484	110	7	,	,	PUNCT
ajst-32484	110	8	et	et	PROPN
ajst-32484	110	9	al	al	PROPN
ajst-32484	110	10	.	.	PROPN
ajst-32484	110	11	,	,	PUNCT
ajst-32484	110	12	non	non	ADJ
ajst-32484	110	13	-	-	ADJ
ajst-32484	110	14	small	small	ADJ
ajst-32484	110	15	cell	cell	NOUN
ajst-32484	110	16	lung	lung	NOUN
ajst-32484	110	17	cancer	cancer	NOUN
ajst-32484	110	18	(	(	PUNCT
ajst-32484	110	19	nsclc	nsclc	NOUN
ajst-32484	110	20	):	):	PUNCT
ajst-32484	110	21	a	a	DET
ajst-32484	110	22	review	review	NOUN
ajst-32484	110	23	of	of	ADP
ajst-32484	110	24	risk	risk	NOUN
ajst-32484	110	25	factors	factor	NOUN
ajst-32484	110	26	,	,	PUNCT
ajst-32484	110	27	diagnosis	diagnosis	NOUN
ajst-32484	110	28	,	,	PUNCT
ajst-32484	110	29	and	and	CCONJ
ajst-32484	110	30	treatment	treatment	NOUN
ajst-32484	110	31	.	.	PUNCT
ajst-32484	111	1	medicine	medicine	NOUN
ajst-32484	111	2	(	(	PUNCT
ajst-32484	111	3	baltimore	baltimore	PROPN
ajst-32484	111	4	)	)	PUNCT
ajst-32484	111	5	,	,	PUNCT
ajst-32484	111	6	2023	2023	NUM
ajst-32484	111	7	.	.	PUNCT
ajst-32484	112	1	102(8	102(8	NUM
ajst-32484	112	2	):	):	PUNCT
ajst-32484	112	3	p.	p.	PROPN
ajst-32484	112	4	e32899	e32899	PROPN
ajst-32484	112	5	.	.	PUNCT
ajst-32484	113	1	[	[	X
ajst-32484	113	2	3	3	NUM
ajst-32484	113	3	]	]	SYM
ajst-32484	113	4	wu	wu	PROPN
ajst-32484	113	5	,	,	PUNCT
ajst-32484	113	6	l.	l.	PROPN
ajst-32484	113	7	,	,	PUNCT
ajst-32484	113	8	et	et	PROPN
ajst-32484	113	9	al	al	PROPN
ajst-32484	113	10	.	.	PROPN
ajst-32484	113	11	,	,	PUNCT
ajst-32484	113	12	development	development	NOUN
ajst-32484	113	13	of	of	ADP
ajst-32484	113	14	egfr	egfr	ADJ
ajst-32484	113	15	tkis	tkis	NOUN
ajst-32484	113	16	and	and	CCONJ
ajst-32484	113	17	options	option	NOUN
ajst-32484	113	18	to	to	PART
ajst-32484	113	19	manage	manage	VERB
ajst-32484	113	20	resistance	resistance	NOUN
ajst-32484	113	21	of	of	ADP
ajst-32484	113	22	third	third	ADJ
ajst-32484	113	23	-	-	PUNCT
ajst-32484	113	24	generation	generation	NOUN
ajst-32484	113	25	egfr	egfr	NOUN
ajst-32484	113	26	tki	tki	PROPN
ajst-32484	113	27	osimertinib	osimertinib	NOUN
ajst-32484	113	28	:	:	PUNCT
ajst-32484	113	29	conventional	conventional	ADJ
ajst-32484	113	30	ways	way	NOUN
ajst-32484	113	31	and	and	CCONJ
ajst-32484	113	32	immune	immune	ADJ
ajst-32484	113	33	checkpoint	checkpoint	NOUN
ajst-32484	113	34	inhibitors	inhibitor	NOUN
ajst-32484	113	35	.	.	PUNCT
ajst-32484	114	1	front	front	ADJ
ajst-32484	114	2	oncol	oncol	ADJ
ajst-32484	114	3	,	,	PUNCT
ajst-32484	114	4	2020	2020	NUM
ajst-32484	114	5	.	.	PUNCT
ajst-32484	115	1	10	10	NUM
ajst-32484	115	2	:	:	PUNCT
ajst-32484	115	3	p.	p.	NOUN
ajst-32484	115	4	602762	602762	NUM
ajst-32484	115	5	.	.	PUNCT
ajst-32484	116	1	[	[	X
ajst-32484	116	2	4	4	NUM
ajst-32484	116	3	]	]	PUNCT
ajst-32484	116	4	michaels	michaels	PROPN
ajst-32484	116	5	,	,	PUNCT
ajst-32484	116	6	e.	e.	PROPN
ajst-32484	116	7	and	and	CCONJ
ajst-32484	116	8	c.m	c.m	PROPN
ajst-32484	116	9	.	.	PROPN
ajst-32484	116	10	bestvina	bestvina	PROPN
ajst-32484	116	11	,	,	PUNCT
ajst-32484	116	12	meeting	meet	VERB
ajst-32484	116	13	an	an	DET
ajst-32484	116	14	un	un	PROPN
ajst-32484	116	15	-	-	ADJ
ajst-32484	116	16	met	meet	VERB
ajst-32484	116	17	need	need	NOUN
ajst-32484	116	18	:	:	PUNCT
ajst-32484	116	19	targeting	targeting	NOUN
ajst-32484	116	20	met	meet	VERB
ajst-32484	116	21	in	in	ADP
ajst-32484	116	22	non	non	ADJ
ajst-32484	116	23	-	-	ADJ
ajst-32484	116	24	small	small	ADJ
ajst-32484	116	25	cell	cell	NOUN
ajst-32484	116	26	lung	lung	NOUN
ajst-32484	116	27	cancer	cancer	NOUN
ajst-32484	116	28	.	.	PUNCT
ajst-32484	117	1	front	front	ADJ
ajst-32484	117	2	oncol	oncol	ADJ
ajst-32484	117	3	,	,	PUNCT
ajst-32484	117	4	2022	2022	NUM
ajst-32484	117	5	.	.	PUNCT
ajst-32484	118	1	12	12	NUM
ajst-32484	118	2	:	:	PUNCT
ajst-32484	118	3	p.	p.	NOUN
ajst-32484	118	4	1004198	1004198	NUM
ajst-32484	118	5	.	.	PUNCT
ajst-32484	119	1	[	[	X
ajst-32484	119	2	5	5	NUM
ajst-32484	119	3	]	]	PUNCT
ajst-32484	119	4	herbst	herbst	PROPN
ajst-32484	119	5	,	,	PUNCT
ajst-32484	119	6	r.s	r.s	PROPN
ajst-32484	119	7	.	.	PROPN
ajst-32484	119	8	,	,	PUNCT
ajst-32484	119	9	d.	d.	PROPN
ajst-32484	119	10	morgensztern	morgensztern	PROPN
ajst-32484	119	11	,	,	PUNCT
ajst-32484	119	12	and	and	CCONJ
ajst-32484	119	13	c.	c.	PROPN
ajst-32484	119	14	boshoff	boshoff	PROPN
ajst-32484	119	15	,	,	PUNCT
ajst-32484	119	16	the	the	DET
ajst-32484	119	17	biology	biology	NOUN
ajst-32484	119	18	and	and	CCONJ
ajst-32484	119	19	management	management	NOUN
ajst-32484	119	20	of	of	ADP
ajst-32484	119	21	non	non	ADJ
ajst-32484	119	22	-	-	ADJ
ajst-32484	119	23	small	small	ADJ
ajst-32484	119	24	cell	cell	NOUN
ajst-32484	119	25	lung	lung	NOUN
ajst-32484	119	26	cancer	cancer	NOUN
ajst-32484	119	27	.	.	PUNCT
ajst-32484	120	1	nature	nature	NOUN
ajst-32484	120	2	,	,	PUNCT
ajst-32484	120	3	2018	2018	NUM
ajst-32484	120	4	.	.	PUNCT
ajst-32484	121	1	553(7689	553(7689	NUM
ajst-32484	121	2	):	):	PUNCT
ajst-32484	122	1	p.	p.	NOUN
ajst-32484	122	2	446	446	NUM
ajst-32484	122	3	-	-	SYM
ajst-32484	122	4	454	454	NUM
ajst-32484	122	5	.	.	PUNCT
ajst-32484	123	1	[	[	X
ajst-32484	123	2	6	6	NUM
ajst-32484	123	3	]	]	SYM
ajst-32484	123	4	yun	yun	PROPN
ajst-32484	123	5	,	,	PUNCT
ajst-32484	123	6	c.h	c.h	PROPN
ajst-32484	123	7	.	.	PROPN
ajst-32484	123	8	,	,	PUNCT
ajst-32484	123	9	et	et	PROPN
ajst-32484	123	10	al	al	PROPN
ajst-32484	123	11	.	.	PROPN
ajst-32484	123	12	,	,	PUNCT
ajst-32484	123	13	the	the	DET
ajst-32484	123	14	t790	t790	NUM
ajst-32484	123	15	m	m	NOUN
ajst-32484	123	16	mutation	mutation	NOUN
ajst-32484	123	17	in	in	ADP
ajst-32484	123	18	egfr	egfr	PROPN
ajst-32484	123	19	kinase	kinase	PROPN
ajst-32484	123	20	causes	cause	VERB
ajst-32484	123	21	drug	drug	NOUN
ajst-32484	123	22	resistance	resistance	NOUN
ajst-32484	123	23	by	by	ADP
ajst-32484	123	24	increasing	increase	VERB
ajst-32484	123	25	the	the	DET
ajst-32484	123	26	affinity	affinity	NOUN
ajst-32484	123	27	for	for	ADP
ajst-32484	123	28	atp	atp	PROPN
ajst-32484	123	29	.	.	PROPN
ajst-32484	124	1	proc	proc	PROPN
ajst-32484	124	2	natl	natl	PROPN
ajst-32484	124	3	acad	acad	PROPN
ajst-32484	124	4	sci	sci	PROPN
ajst-32484	124	5	u	u	PROPN
ajst-32484	124	6	s	s	PROPN
ajst-32484	124	7	a	a	PRON
ajst-32484	124	8	,	,	PUNCT
ajst-32484	124	9	2008	2008	NUM
ajst-32484	124	10	.	.	PUNCT
ajst-32484	125	1	105(6	105(6	NUM
ajst-32484	125	2	):	):	PUNCT
ajst-32484	125	3	p.	p.	NOUN
ajst-32484	125	4	2070	2070	NUM
ajst-32484	125	5	-	-	SYM
ajst-32484	125	6	5	5	NUM
ajst-32484	125	7	.	.	PUNCT
ajst-32484	126	1	[	[	X
ajst-32484	126	2	7	7	NUM
ajst-32484	126	3	]	]	X
ajst-32484	126	4	patel	patel	PROPN
ajst-32484	126	5	,	,	PUNCT
ajst-32484	126	6	h.	h.	PROPN
ajst-32484	126	7	,	,	PUNCT
ajst-32484	126	8	et	et	PROPN
ajst-32484	126	9	al	al	PROPN
ajst-32484	126	10	.	.	PROPN
ajst-32484	126	11	,	,	PUNCT
ajst-32484	126	12	recent	recent	ADJ
ajst-32484	126	13	updates	update	NOUN
ajst-32484	126	14	on	on	ADP
ajst-32484	126	15	third	third	ADJ
ajst-32484	126	16	generation	generation	NOUN
ajst-32484	126	17	egfr	egfr	VERB
ajst-32484	126	18	inhibitors	inhibitor	NOUN
ajst-32484	126	19	and	and	CCONJ
ajst-32484	126	20	emergence	emergence	NOUN
ajst-32484	126	21	of	of	ADP
ajst-32484	126	22	fourth	fourth	ADJ
ajst-32484	126	23	generation	generation	NOUN
ajst-32484	126	24	egfr	egfr	VERB
ajst-32484	126	25	inhibitors	inhibitor	NOUN
ajst-32484	126	26	to	to	PART
ajst-32484	126	27	combat	combat	VERB
ajst-32484	126	28	c797s	c797s	ADJ
ajst-32484	126	29	resistance	resistance	NOUN
ajst-32484	126	30	.	.	PUNCT
ajst-32484	127	1	eur	eur	PROPN
ajst-32484	127	2	j	j	PROPN
ajst-32484	127	3	med	med	PROPN
ajst-32484	127	4	chem	chem	NOUN
ajst-32484	127	5	,	,	PUNCT
ajst-32484	127	6	2017	2017	NUM
ajst-32484	127	7	.	.	PUNCT
ajst-32484	128	1	142	142	NUM
ajst-32484	128	2	:	:	PUNCT
ajst-32484	129	1	p.	p.	NOUN
ajst-32484	129	2	32	32	NUM
ajst-32484	129	3	-	-	SYM
ajst-32484	129	4	47	47	NUM
ajst-32484	129	5	.	.	PUNCT
ajst-32484	130	1	[	[	X
ajst-32484	130	2	8	8	NUM
ajst-32484	130	3	]	]	SYM
ajst-32484	130	4	yu	yu	PROPN
ajst-32484	130	5	,	,	PUNCT
ajst-32484	130	6	h.a	h.a	PROPN
ajst-32484	130	7	.	.	PROPN
ajst-32484	130	8	,	,	PUNCT
ajst-32484	130	9	et	et	PROPN
ajst-32484	130	10	al	al	PROPN
ajst-32484	130	11	.	.	PROPN
ajst-32484	130	12	,	,	PUNCT
ajst-32484	130	13	analysis	analysis	NOUN
ajst-32484	130	14	of	of	ADP
ajst-32484	130	15	tumor	tumor	NOUN
ajst-32484	130	16	specimens	specimen	NOUN
ajst-32484	130	17	at	at	ADP
ajst-32484	130	18	the	the	DET
ajst-32484	130	19	time	time	NOUN
ajst-32484	130	20	of	of	ADP
ajst-32484	130	21	acquired	acquire	VERB
ajst-32484	130	22	resistance	resistance	NOUN
ajst-32484	130	23	to	to	ADP
ajst-32484	130	24	egfr	egfr	ADJ
ajst-32484	130	25	-	-	PUNCT
ajst-32484	130	26	tki	tki	NOUN
ajst-32484	130	27	therapy	therapy	NOUN
ajst-32484	130	28	in	in	ADP
ajst-32484	130	29	155	155	NUM
ajst-32484	130	30	patients	patient	NOUN
ajst-32484	130	31	with	with	ADP
ajst-32484	130	32	egfr	egfr	ADJ
ajst-32484	130	33	-	-	PUNCT
ajst-32484	130	34	mutant	mutant	ADJ
ajst-32484	130	35	lung	lung	NOUN
ajst-32484	130	36	cancers	cancer	NOUN
ajst-32484	130	37	.	.	PUNCT
ajst-32484	131	1	clin	clin	PROPN
ajst-32484	131	2	cancer	cancer	NOUN
ajst-32484	131	3	res	re	NOUN
ajst-32484	131	4	,	,	PUNCT
ajst-32484	131	5	2013	2013	NUM
ajst-32484	131	6	.	.	PUNCT
ajst-32484	132	1	19(8	19(8	NUM
ajst-32484	132	2	):	):	PUNCT
ajst-32484	132	3	p.	p.	NOUN
ajst-32484	132	4	2240	2240	NUM
ajst-32484	132	5	-	-	SYM
ajst-32484	132	6	7	7	NUM
ajst-32484	132	7	.	.	PUNCT
ajst-32484	133	1	[	[	X
ajst-32484	133	2	9	9	NUM
ajst-32484	133	3	]	]	PUNCT
ajst-32484	133	4	engelman	engelman	NOUN
ajst-32484	133	5	,	,	PUNCT
ajst-32484	133	6	j.a	j.a	PROPN
ajst-32484	133	7	.	.	PROPN
ajst-32484	133	8	,	,	PUNCT
ajst-32484	133	9	et	et	PROPN
ajst-32484	133	10	al	al	PROPN
ajst-32484	133	11	.	.	PROPN
ajst-32484	133	12	,	,	PUNCT
ajst-32484	133	13	met	meet	VERB
ajst-32484	133	14	amplification	amplification	NOUN
ajst-32484	133	15	leads	lead	VERB
ajst-32484	133	16	to	to	ADP
ajst-32484	133	17	gefitinib	gefitinib	NOUN
ajst-32484	133	18	resistance	resistance	NOUN
ajst-32484	133	19	in	in	ADP
ajst-32484	133	20	lung	lung	NOUN
ajst-32484	133	21	cancer	cancer	NOUN
ajst-32484	133	22	by	by	ADP
ajst-32484	133	23	activating	activate	VERB
ajst-32484	133	24	erbb3	erbb3	NOUN
ajst-32484	133	25	signaling	signal	VERB
ajst-32484	133	26	.	.	PUNCT
ajst-32484	134	1	science	science	NOUN
ajst-32484	134	2	,	,	PUNCT
ajst-32484	134	3	2007	2007	NUM
ajst-32484	134	4	.	.	PUNCT
ajst-32484	135	1	316(5827	316(5827	NUM
ajst-32484	135	2	):	):	PUNCT
ajst-32484	135	3	p.	p.	NOUN
ajst-32484	135	4	1039	1039	NUM
ajst-32484	135	5	-	-	SYM
ajst-32484	135	6	43	43	NUM
ajst-32484	135	7	.	.	PUNCT
ajst-32484	136	1	[	[	X
ajst-32484	136	2	10	10	NUM
ajst-32484	136	3	]	]	X
ajst-32484	136	4	bean	bean	NOUN
ajst-32484	136	5	,	,	PUNCT
ajst-32484	136	6	j.	j.	PROPN
ajst-32484	136	7	,	,	PUNCT
ajst-32484	136	8	et	et	PROPN
ajst-32484	136	9	al	al	PROPN
ajst-32484	136	10	.	.	PROPN
ajst-32484	136	11	,	,	PUNCT
ajst-32484	136	12	met	meet	VERB
ajst-32484	136	13	amplification	amplification	NOUN
ajst-32484	136	14	occurs	occur	VERB
ajst-32484	136	15	with	with	ADP
ajst-32484	136	16	or	or	CCONJ
ajst-32484	136	17	without	without	ADP
ajst-32484	136	18	t790	t790	NUM
ajst-32484	136	19	m	m	NOUN
ajst-32484	136	20	mutations	mutation	NOUN
ajst-32484	136	21	in	in	ADP
ajst-32484	136	22	egfr	egfr	ADJ
ajst-32484	136	23	mutant	mutant	ADJ
ajst-32484	136	24	lung	lung	NOUN
ajst-32484	136	25	tumors	tumor	NOUN
ajst-32484	136	26	with	with	ADP
ajst-32484	136	27	acquired	acquire	VERB
ajst-32484	136	28	resistance	resistance	NOUN
ajst-32484	136	29	to	to	ADP
ajst-32484	136	30	gefitinib	gefitinib	NOUN
ajst-32484	136	31	or	or	CCONJ
ajst-32484	136	32	erlotinib	erlotinib	NOUN
ajst-32484	136	33	.	.	PUNCT
ajst-32484	137	1	proc	proc	PROPN
ajst-32484	137	2	natl	natl	PROPN
ajst-32484	137	3	acad	acad	PROPN
ajst-32484	137	4	sci	sci	PROPN
ajst-32484	137	5	u	u	PROPN
ajst-32484	137	6	s	s	PROPN
ajst-32484	137	7	a	a	PRON
ajst-32484	137	8	,	,	PUNCT
ajst-32484	137	9	2007	2007	NUM
ajst-32484	137	10	.	.	PUNCT
ajst-32484	138	1	104(52	104(52	NUM
ajst-32484	138	2	):	):	PUNCT
ajst-32484	138	3	p.	p.	NOUN
ajst-32484	138	4	20932	20932	NUM
ajst-32484	138	5	-	-	SYM
ajst-32484	138	6	7	7	NUM
ajst-32484	138	7	.	.	NOUN
ajst-32484	138	8	117	117	NUM
ajst-32484	138	9	[	[	SYM
ajst-32484	138	10	11	11	NUM
ajst-32484	138	11	]	]	X
ajst-32484	138	12	lee	lee	PROPN
ajst-32484	138	13	,	,	PUNCT
ajst-32484	138	14	j.k	j.k	PROPN
ajst-32484	138	15	.	.	PROPN
ajst-32484	138	16	,	,	PUNCT
ajst-32484	138	17	et	et	PROPN
ajst-32484	138	18	al	al	PROPN
ajst-32484	138	19	.	.	PROPN
ajst-32484	138	20	,	,	PUNCT
ajst-32484	138	21	clonal	clonal	ADJ
ajst-32484	138	22	history	history	NOUN
ajst-32484	138	23	and	and	CCONJ
ajst-32484	138	24	genetic	genetic	ADJ
ajst-32484	138	25	predictors	predictor	NOUN
ajst-32484	138	26	of	of	ADP
ajst-32484	138	27	transformation	transformation	NOUN
ajst-32484	138	28	into	into	ADP
ajst-32484	138	29	small	small	ADJ
ajst-32484	138	30	-	-	PUNCT
ajst-32484	138	31	cell	cell	NOUN
ajst-32484	138	32	carcinomas	carcinoma	NOUN
ajst-32484	138	33	from	from	ADP
ajst-32484	138	34	lung	lung	NOUN
ajst-32484	138	35	adenocarcinomas	adenocarcinoma	NOUN
ajst-32484	138	36	.	.	PUNCT
ajst-32484	139	1	j	j	PROPN
ajst-32484	139	2	clin	clin	PROPN
ajst-32484	139	3	oncol	oncol	PROPN
ajst-32484	139	4	,	,	PUNCT
ajst-32484	139	5	2017	2017	NUM
ajst-32484	139	6	.	.	PUNCT
ajst-32484	140	1	35(26	35(26	NUM
ajst-32484	140	2	):	):	PUNCT
ajst-32484	140	3	p.	p.	NOUN
ajst-32484	140	4	3065	3065	NUM
ajst-32484	140	5	-	-	SYM
ajst-32484	140	6	3074	3074	NUM
ajst-32484	140	7	.	.	PUNCT
ajst-32484	141	1	[	[	X
ajst-32484	141	2	12	12	NUM
ajst-32484	141	3	]	]	X
ajst-32484	141	4	recondo	recondo	NOUN
ajst-32484	141	5	,	,	PUNCT
ajst-32484	141	6	g.	g.	PROPN
ajst-32484	141	7	,	,	PUNCT
ajst-32484	141	8	et	et	PROPN
ajst-32484	141	9	al	al	PROPN
ajst-32484	141	10	.	.	PROPN
ajst-32484	141	11	,	,	PUNCT
ajst-32484	141	12	molecular	molecular	ADJ
ajst-32484	141	13	mechanisms	mechanism	NOUN
ajst-32484	141	14	of	of	ADP
ajst-32484	141	15	acquired	acquire	VERB
ajst-32484	141	16	resistance	resistance	NOUN
ajst-32484	141	17	to	to	PART
ajst-32484	141	18	met	met	VERB
ajst-32484	141	19	tyrosine	tyrosine	PROPN
ajst-32484	141	20	kinase	kinase	PROPN
ajst-32484	141	21	inhibitors	inhibitor	NOUN
ajst-32484	141	22	in	in	ADP
ajst-32484	141	23	patients	patient	NOUN
ajst-32484	141	24	with	with	ADP
ajst-32484	141	25	met	meet	VERB
ajst-32484	141	26	exon	exon	PROPN
ajst-32484	141	27	14	14	NUM
ajst-32484	141	28	-	-	PUNCT
ajst-32484	141	29	mutant	mutant	NOUN
ajst-32484	141	30	nsclc	nsclc	NOUN
ajst-32484	141	31	.	.	PUNCT
ajst-32484	142	1	clin	clin	PROPN
ajst-32484	142	2	cancer	cancer	NOUN
ajst-32484	142	3	res	re	NOUN
ajst-32484	142	4	,	,	PUNCT
ajst-32484	142	5	2020	2020	NUM
ajst-32484	142	6	.	.	PUNCT
ajst-32484	143	1	26(11	26(11	NUM
ajst-32484	143	2	):	):	PUNCT
ajst-32484	143	3	p.	p.	NOUN
ajst-32484	143	4	2615	2615	NUM
ajst-32484	143	5	-	-	SYM
ajst-32484	143	6	2625	2625	NUM
ajst-32484	143	7	.	.	PUNCT
ajst-32484	144	1	[	[	X
ajst-32484	144	2	13	13	NUM
ajst-32484	144	3	]	]	X
ajst-32484	144	4	guo	guo	PROPN
ajst-32484	144	5	,	,	PUNCT
ajst-32484	144	6	r.	r.	PROPN
ajst-32484	144	7	,	,	PUNCT
ajst-32484	144	8	et	et	PROPN
ajst-32484	144	9	al	al	PROPN
ajst-32484	144	10	.	.	PROPN
ajst-32484	144	11	,	,	PUNCT
ajst-32484	144	12	met	meet	VERB
ajst-32484	144	13	exon	exon	PROPN
ajst-32484	144	14	14	14	NUM
ajst-32484	144	15	-	-	PUNCT
ajst-32484	144	16	altered	alter	VERB
ajst-32484	144	17	lung	lung	NOUN
ajst-32484	144	18	cancers	cancer	NOUN
ajst-32484	144	19	and	and	CCONJ
ajst-32484	144	20	met	meet	VERB
ajst-32484	144	21	inhibitor	inhibitor	NOUN
ajst-32484	144	22	resistance	resistance	NOUN
ajst-32484	144	23	.	.	PUNCT
ajst-32484	145	1	clin	clin	PROPN
ajst-32484	145	2	cancer	cancer	NOUN
ajst-32484	145	3	res	re	NOUN
ajst-32484	145	4	,	,	PUNCT
ajst-32484	145	5	2021	2021	NUM
ajst-32484	145	6	.	.	PUNCT
ajst-32484	146	1	27(3	27(3	NUM
ajst-32484	146	2	):	):	PUNCT
ajst-32484	146	3	p.	p.	NOUN
ajst-32484	146	4	799	799	NUM
ajst-32484	146	5	-	-	SYM
ajst-32484	146	6	806	806	NUM
ajst-32484	146	7	.	.	PUNCT
ajst-32484	147	1	[	[	X
ajst-32484	147	2	14	14	NUM
ajst-32484	147	3	]	]	X
ajst-32484	147	4	solomon	solomon	PROPN
ajst-32484	147	5	,	,	PUNCT
ajst-32484	147	6	b.j	b.j	PROPN
ajst-32484	147	7	.	.	PROPN
ajst-32484	147	8	,	,	PUNCT
ajst-32484	147	9	et	et	PROPN
ajst-32484	147	10	al	al	PROPN
ajst-32484	147	11	.	.	PROPN
ajst-32484	147	12	,	,	PUNCT
ajst-32484	147	13	lorlatinib	lorlatinib	NOUN
ajst-32484	147	14	versus	versus	ADP
ajst-32484	147	15	crizotinib	crizotinib	NOUN
ajst-32484	147	16	in	in	ADP
ajst-32484	147	17	patients	patient	NOUN
ajst-32484	147	18	with	with	ADP
ajst-32484	147	19	advanced	advanced	ADJ
ajst-32484	147	20	alk	alk	VERB
ajst-32484	147	21	-	-	PUNCT
ajst-32484	147	22	positive	positive	ADJ
ajst-32484	147	23	non	non	ADJ
ajst-32484	147	24	-	-	ADJ
ajst-32484	147	25	small	small	ADJ
ajst-32484	147	26	cell	cell	NOUN
ajst-32484	147	27	lung	lung	NOUN
ajst-32484	147	28	cancer	cancer	NOUN
ajst-32484	147	29	:	:	PUNCT
ajst-32484	147	30	5	5	NUM
ajst-32484	147	31	-	-	PUNCT
ajst-32484	147	32	year	year	NOUN
ajst-32484	147	33	outcomes	outcome	NOUN
ajst-32484	147	34	from	from	ADP
ajst-32484	147	35	the	the	DET
ajst-32484	147	36	phase	phase	NOUN
ajst-32484	147	37	iii	iii	NUM
ajst-32484	147	38	crown	crown	NOUN
ajst-32484	147	39	study	study	NOUN
ajst-32484	147	40	.	.	PUNCT
ajst-32484	148	1	j	j	PROPN
ajst-32484	148	2	clin	clin	PROPN
ajst-32484	148	3	oncol	oncol	PROPN
ajst-32484	148	4	,	,	PUNCT
ajst-32484	148	5	2024	2024	NUM
ajst-32484	148	6	.	.	PUNCT
ajst-32484	149	1	42(29	42(29	NUM
ajst-32484	149	2	):	):	PUNCT
ajst-32484	149	3	p.	p.	NOUN
ajst-32484	149	4	3400	3400	NUM
ajst-32484	149	5	-	-	SYM
ajst-32484	149	6	3409	3409	NUM
ajst-32484	149	7	.	.	PUNCT
ajst-32484	150	1	[	[	X
ajst-32484	150	2	15	15	NUM
ajst-32484	150	3	]	]	X
ajst-32484	150	4	clinicaltrials.gov	clinicaltrials.gov	X
ajst-32484	150	5	.	.	PUNCT
ajst-32484	150	6	a	a	DET
ajst-32484	150	7	study	study	NOUN
ajst-32484	150	8	of	of	ADP
ajst-32484	150	9	bdtx-1535	bdtx-1535	NOUN
ajst-32484	150	10	in	in	ADP
ajst-32484	150	11	patients	patient	NOUN
ajst-32484	150	12	with	with	ADP
ajst-32484	150	13	glioblastoma	glioblastoma	NOUN
ajst-32484	150	14	or	or	CCONJ
ajst-32484	150	15	non	non	ADJ
ajst-32484	150	16	-	-	ADJ
ajst-32484	150	17	small	small	ADJ
ajst-32484	150	18	cell	cell	NOUN
ajst-32484	150	19	lung	lung	NOUN
ajst-32484	150	20	cancer	cancer	NOUN
ajst-32484	150	21	.	.	PUNCT
ajst-32484	151	1	2022	2022	NUM
ajst-32484	151	2	2025	2025	NUM
ajst-32484	151	3	-	-	SYM
ajst-32484	151	4	3	3	NUM
ajst-32484	151	5	-	-	SYM
ajst-32484	151	6	25	25	NUM
ajst-32484	151	7	]	]	PUNCT
ajst-32484	151	8	;	;	PUNCT
ajst-32484	151	9	available	available	ADJ
ajst-32484	151	10	from	from	ADP
ajst-32484	151	11	:	:	PUNCT
ajst-32484	151	12	https://clinicaltrials.gov/study/nct05256290	https://clinicaltrials.gov/study/nct05256290	PROPN
ajst-32484	151	13	.	.	PUNCT
ajst-32484	152	1	[	[	X
ajst-32484	152	2	16	16	NUM
ajst-32484	152	3	]	]	X
ajst-32484	152	4	yu	yu	PROPN
ajst-32484	152	5	,	,	PUNCT
ajst-32484	152	6	h.a	h.a	PROPN
ajst-32484	152	7	.	.	PROPN
ajst-32484	152	8	,	,	PUNCT
ajst-32484	152	9	et	et	PROPN
ajst-32484	152	10	al	al	PROPN
ajst-32484	152	11	.	.	PROPN
ajst-32484	152	12	,	,	PUNCT
ajst-32484	152	13	biomarker	biomarker	NOUN
ajst-32484	152	14	-	-	PUNCT
ajst-32484	152	15	directed	direct	VERB
ajst-32484	152	16	phase	phase	NOUN
ajst-32484	152	17	ii	ii	NOUN
ajst-32484	152	18	platform	platform	NOUN
ajst-32484	152	19	study	study	NOUN
ajst-32484	152	20	in	in	ADP
ajst-32484	152	21	patients	patient	NOUN
ajst-32484	152	22	with	with	ADP
ajst-32484	152	23	egfr	egfr	NOUN
ajst-32484	152	24	sensitizing	sensitize	VERB
ajst-32484	152	25	mutation	mutation	NOUN
ajst-32484	152	26	-	-	PUNCT
ajst-32484	152	27	positive	positive	ADJ
ajst-32484	152	28	advanced	advanced	ADJ
ajst-32484	152	29	/	/	SYM
ajst-32484	152	30	metastatic	metastatic	ADJ
ajst-32484	152	31	non	non	ADJ
ajst-32484	152	32	-	-	ADJ
ajst-32484	152	33	small	small	ADJ
ajst-32484	152	34	cell	cell	NOUN
ajst-32484	152	35	lung	lung	NOUN
ajst-32484	152	36	cancer	cancer	NOUN
ajst-32484	152	37	whose	whose	DET
ajst-32484	152	38	disease	disease	NOUN
ajst-32484	152	39	has	have	AUX
ajst-32484	152	40	progressed	progress	VERB
ajst-32484	152	41	on	on	ADP
ajst-32484	152	42	first	first	ADJ
ajst-32484	152	43	-	-	PUNCT
ajst-32484	152	44	line	line	NOUN
ajst-32484	152	45	osimertinib	osimertinib	NOUN
ajst-32484	152	46	therapy	therapy	NOUN
ajst-32484	152	47	(	(	PUNCT
ajst-32484	152	48	orchard	orchard	NOUN
ajst-32484	152	49	)	)	PUNCT
ajst-32484	152	50	.	.	PUNCT
ajst-32484	153	1	clin	clin	PROPN
ajst-32484	153	2	lung	lung	PROPN
ajst-32484	153	3	cancer	cancer	NOUN
ajst-32484	153	4	,	,	PUNCT
ajst-32484	153	5	2021	2021	NUM
ajst-32484	153	6	.	.	PUNCT
ajst-32484	154	1	22(6	22(6	NUM
ajst-32484	154	2	):	):	PUNCT
ajst-32484	155	1	p.	p.	NOUN
ajst-32484	155	2	601	601	NUM
ajst-32484	155	3	-	-	SYM
ajst-32484	155	4	606	606	NUM
ajst-32484	155	5	.	.	PUNCT
ajst-32484	156	1	[	[	X
ajst-32484	156	2	17	17	NUM
ajst-32484	156	3	]	]	SYM
ajst-32484	156	4	wu	wu	PROPN
ajst-32484	156	5	,	,	PUNCT
ajst-32484	156	6	y.l	y.l	PROPN
ajst-32484	156	7	.	.	PROPN
ajst-32484	156	8	,	,	PUNCT
ajst-32484	156	9	et	et	PROPN
ajst-32484	156	10	al	al	PROPN
ajst-32484	156	11	.	.	PROPN
ajst-32484	156	12	,	,	PUNCT
ajst-32484	156	13	tepotinib	tepotinib	NOUN
ajst-32484	156	14	plus	plus	CCONJ
ajst-32484	156	15	osimertinib	osimertinib	NOUN
ajst-32484	156	16	in	in	ADP
ajst-32484	156	17	patients	patient	NOUN
ajst-32484	156	18	with	with	ADP
ajst-32484	156	19	egfr	egfr	NOUN
ajst-32484	156	20	-	-	PUNCT
ajst-32484	156	21	mutated	mutate	VERB
ajst-32484	156	22	non	non	ADJ
ajst-32484	156	23	-	-	ADJ
ajst-32484	156	24	small	small	ADJ
ajst-32484	156	25	-	-	PUNCT
ajst-32484	156	26	cell	cell	NOUN
ajst-32484	156	27	lung	lung	NOUN
ajst-32484	156	28	cancer	cancer	NOUN
ajst-32484	156	29	with	with	ADP
ajst-32484	156	30	met	meet	VERB
ajst-32484	156	31	amplification	amplification	NOUN
ajst-32484	156	32	following	follow	VERB
ajst-32484	156	33	progression	progression	NOUN
ajst-32484	156	34	on	on	ADP
ajst-32484	156	35	first	first	ADJ
ajst-32484	156	36	-	-	PUNCT
ajst-32484	156	37	line	line	NOUN
ajst-32484	156	38	osimertinib	osimertinib	NOUN
ajst-32484	156	39	(	(	PUNCT
ajst-32484	156	40	insight	insight	NOUN
ajst-32484	156	41	2	2	NUM
ajst-32484	156	42	):	):	PUNCT
ajst-32484	156	43	a	a	DET
ajst-32484	156	44	multicentre	multicentre	NOUN
ajst-32484	156	45	,	,	PUNCT
ajst-32484	156	46	open	open	ADJ
ajst-32484	156	47	-	-	PUNCT
ajst-32484	156	48	label	label	NOUN
ajst-32484	156	49	,	,	PUNCT
ajst-32484	156	50	phase	phase	NOUN
ajst-32484	156	51	2	2	NUM
ajst-32484	156	52	trial	trial	NOUN
ajst-32484	156	53	.	.	PUNCT
ajst-32484	157	1	lancet	lancet	PROPN
ajst-32484	157	2	oncol	oncol	PROPN
ajst-32484	157	3	,	,	PUNCT
ajst-32484	157	4	2024	2024	NUM
ajst-32484	157	5	.	.	PUNCT
ajst-32484	158	1	25(8	25(8	NUM
ajst-32484	158	2	):	):	PUNCT
ajst-32484	158	3	p.	p.	NOUN
ajst-32484	158	4	989	989	NUM
ajst-32484	158	5	-	-	PUNCT
ajst-32484	158	6	1002	1002	NUM
ajst-32484	158	7	.	.	PUNCT
ajst-32484	159	1	[	[	X
ajst-32484	159	2	18	18	NUM
ajst-32484	159	3	]	]	X
ajst-32484	159	4	goto	goto	NOUN
ajst-32484	159	5	,	,	PUNCT
ajst-32484	159	6	k.	k.	PROPN
ajst-32484	159	7	,	,	PUNCT
ajst-32484	159	8	et	et	PROPN
ajst-32484	159	9	al	al	PROPN
ajst-32484	159	10	.	.	PROPN
ajst-32484	159	11	,	,	PUNCT
ajst-32484	159	12	trastuzumab	trastuzumab	NOUN
ajst-32484	159	13	deruxtecan	deruxtecan	NOUN
ajst-32484	159	14	in	in	ADP
ajst-32484	159	15	patients	patient	NOUN
ajst-32484	159	16	with	with	ADP
ajst-32484	159	17	her2	her2	NOUN
ajst-32484	159	18	-	-	PUNCT
ajst-32484	159	19	mutant	mutant	ADJ
ajst-32484	159	20	metastatic	metastatic	ADJ
ajst-32484	159	21	non	non	ADJ
ajst-32484	159	22	-	-	ADJ
ajst-32484	159	23	small	small	ADJ
ajst-32484	159	24	-	-	PUNCT
ajst-32484	159	25	cell	cell	NOUN
ajst-32484	159	26	lung	lung	NOUN
ajst-32484	159	27	cancer	cancer	NOUN
ajst-32484	159	28	:	:	PUNCT
ajst-32484	159	29	primary	primary	ADJ
ajst-32484	159	30	results	result	NOUN
ajst-32484	159	31	from	from	ADP
ajst-32484	159	32	the	the	DET
ajst-32484	159	33	randomized	randomized	ADJ
ajst-32484	159	34	,	,	PUNCT
ajst-32484	159	35	phase	phase	NOUN
ajst-32484	159	36	ii	ii	NUM
ajst-32484	159	37	destiny	destiny	NOUN
ajst-32484	159	38	-	-	PUNCT
ajst-32484	159	39	lung02	lung02	VERB
ajst-32484	159	40	trial	trial	NOUN
ajst-32484	159	41	.	.	PUNCT
ajst-32484	160	1	j	j	PROPN
ajst-32484	160	2	clin	clin	PROPN
ajst-32484	160	3	oncol	oncol	PROPN
ajst-32484	160	4	,	,	PUNCT
ajst-32484	160	5	2023	2023	NUM
ajst-32484	160	6	.	.	PUNCT
ajst-32484	161	1	41(31	41(31	NOUN
ajst-32484	161	2	):	):	PUNCT
ajst-32484	161	3	p.	p.	NOUN
ajst-32484	161	4	4852	4852	NUM
ajst-32484	161	5	-	-	SYM
ajst-32484	161	6	4863	4863	NUM
ajst-32484	161	7	.	.	PUNCT
ajst-32484	162	1	[	[	X
ajst-32484	162	2	19	19	NUM
ajst-32484	162	3	]	]	X
ajst-32484	162	4	planchard	planchard	NOUN
ajst-32484	162	5	,	,	PUNCT
ajst-32484	162	6	d.	d.	PROPN
ajst-32484	162	7	,	,	PUNCT
ajst-32484	162	8	et	et	PROPN
ajst-32484	162	9	al	al	PROPN
ajst-32484	162	10	.	.	PROPN
ajst-32484	162	11	,	,	PUNCT
ajst-32484	162	12	dabrafenib	dabrafenib	NOUN
ajst-32484	162	13	in	in	ADP
ajst-32484	162	14	patients	patient	NOUN
ajst-32484	162	15	with	with	ADP
ajst-32484	162	16	braf(v600e)-positive	braf(v600e)-positive	NUM
ajst-32484	162	17	advanced	advanced	ADJ
ajst-32484	162	18	non	non	ADJ
ajst-32484	162	19	-	-	ADJ
ajst-32484	162	20	small	small	ADJ
ajst-32484	162	21	-	-	PUNCT
ajst-32484	162	22	cell	cell	NOUN
ajst-32484	162	23	lung	lung	NOUN
ajst-32484	162	24	cancer	cancer	NOUN
ajst-32484	162	25	:	:	PUNCT
ajst-32484	162	26	a	a	DET
ajst-32484	162	27	single	single	ADJ
ajst-32484	162	28	-	-	PUNCT
ajst-32484	162	29	arm	arm	NOUN
ajst-32484	162	30	,	,	PUNCT
ajst-32484	162	31	multicentre	multicentre	NOUN
ajst-32484	162	32	,	,	PUNCT
ajst-32484	162	33	open	open	ADJ
ajst-32484	162	34	-	-	PUNCT
ajst-32484	162	35	label	label	NOUN
ajst-32484	162	36	,	,	PUNCT
ajst-32484	162	37	phase	phase	NOUN
ajst-32484	162	38	2	2	NUM
ajst-32484	162	39	trial	trial	NOUN
ajst-32484	162	40	.	.	PUNCT
ajst-32484	163	1	lancet	lancet	PROPN
ajst-32484	163	2	oncol	oncol	PROPN
ajst-32484	163	3	,	,	PUNCT
ajst-32484	163	4	2016	2016	NUM
ajst-32484	163	5	.	.	PUNCT
ajst-32484	164	1	17(5	17(5	NUM
ajst-32484	164	2	):	):	PUNCT
ajst-32484	165	1	p.	p.	NOUN
ajst-32484	165	2	642	642	NUM
ajst-32484	165	3	-	-	SYM
ajst-32484	165	4	50	50	NUM
ajst-32484	165	5	.	.	PUNCT
ajst-32484	166	1	[	[	X
ajst-32484	166	2	20	20	NUM
ajst-32484	166	3	]	]	X
ajst-32484	166	4	planchard	planchard	NOUN
ajst-32484	166	5	,	,	PUNCT
ajst-32484	166	6	d.	d.	PROPN
ajst-32484	166	7	,	,	PUNCT
ajst-32484	166	8	et	et	PROPN
ajst-32484	166	9	al	al	PROPN
ajst-32484	166	10	.	.	PROPN
ajst-32484	166	11	,	,	PUNCT
ajst-32484	166	12	dabrafenib	dabrafenib	NOUN
ajst-32484	166	13	plus	plus	CCONJ
ajst-32484	166	14	trametinib	trametinib	NOUN
ajst-32484	166	15	in	in	ADP
ajst-32484	166	16	patients	patient	NOUN
ajst-32484	166	17	with	with	ADP
ajst-32484	166	18	previously	previously	ADV
ajst-32484	166	19	untreated	untreated	ADJ
ajst-32484	166	20	braf(v600e)mutant	braf(v600e)mutant	NOUN
ajst-32484	166	21	metastatic	metastatic	ADJ
ajst-32484	166	22	non	non	ADJ
ajst-32484	166	23	-	-	ADJ
ajst-32484	166	24	small	small	ADJ
ajst-32484	166	25	-	-	PUNCT
ajst-32484	166	26	cell	cell	NOUN
ajst-32484	166	27	lung	lung	NOUN
ajst-32484	166	28	cancer	cancer	NOUN
ajst-32484	166	29	:	:	PUNCT
ajst-32484	166	30	an	an	DET
ajst-32484	166	31	open	open	ADJ
ajst-32484	166	32	-	-	PUNCT
ajst-32484	166	33	label	label	NOUN
ajst-32484	166	34	,	,	PUNCT
ajst-32484	166	35	phase	phase	NOUN
ajst-32484	166	36	2	2	NUM
ajst-32484	166	37	trial	trial	NOUN
ajst-32484	166	38	.	.	PUNCT
ajst-32484	167	1	lancet	lancet	PROPN
ajst-32484	167	2	oncol	oncol	PROPN
ajst-32484	167	3	,	,	PUNCT
ajst-32484	167	4	2017	2017	NUM
ajst-32484	167	5	.	.	PUNCT
ajst-32484	168	1	18(10	18(10	NUM
ajst-32484	168	2	):	):	PUNCT
ajst-32484	169	1	p.	p.	NOUN
ajst-32484	169	2	1307	1307	NUM
ajst-32484	169	3	-	-	SYM
ajst-32484	169	4	1316	1316	NUM
ajst-32484	169	5	.	.	PUNCT
ajst-32484	170	1	[	[	X
ajst-32484	170	2	21	21	NUM
ajst-32484	170	3	]	]	X
ajst-32484	170	4	yu	yu	PROPN
ajst-32484	170	5	,	,	PUNCT
ajst-32484	170	6	h.a	h.a	PROPN
ajst-32484	170	7	.	.	PROPN
ajst-32484	170	8	,	,	PUNCT
ajst-32484	170	9	et	et	PROPN
ajst-32484	170	10	al	al	PROPN
ajst-32484	170	11	.	.	PROPN
ajst-32484	170	12	,	,	PUNCT
ajst-32484	170	13	herthena	herthena	PROPN
ajst-32484	170	14	-	-	PUNCT
ajst-32484	170	15	lung01	lung01	PROPN
ajst-32484	170	16	,	,	PUNCT
ajst-32484	170	17	a	a	DET
ajst-32484	170	18	phase	phase	NOUN
ajst-32484	170	19	ii	ii	NOUN
ajst-32484	170	20	trial	trial	NOUN
ajst-32484	170	21	of	of	ADP
ajst-32484	170	22	patritumab	patritumab	NOUN
ajst-32484	170	23	deruxtecan	deruxtecan	ADJ
ajst-32484	170	24	(	(	PUNCT
ajst-32484	170	25	her3	her3	PROPN
ajst-32484	170	26	-	-	PUNCT
ajst-32484	170	27	dxd	dxd	PROPN
ajst-32484	170	28	)	)	PUNCT
ajst-32484	170	29	in	in	ADP
ajst-32484	170	30	epidermal	epidermal	ADJ
ajst-32484	170	31	growth	growth	NOUN
ajst-32484	170	32	factor	factor	NOUN
ajst-32484	170	33	receptor	receptor	NOUN
ajst-32484	170	34	-	-	PUNCT
ajst-32484	170	35	mutated	mutate	VERB
ajst-32484	170	36	non	non	ADJ
ajst-32484	170	37	-	-	ADJ
ajst-32484	170	38	small	small	ADJ
ajst-32484	170	39	-	-	PUNCT
ajst-32484	170	40	cell	cell	NOUN
ajst-32484	170	41	lung	lung	NOUN
ajst-32484	170	42	cancer	cancer	NOUN
ajst-32484	170	43	after	after	ADP
ajst-32484	170	44	epidermal	epidermal	ADJ
ajst-32484	170	45	growth	growth	NOUN
ajst-32484	170	46	factor	factor	NOUN
ajst-32484	170	47	receptor	receptor	NOUN
ajst-32484	170	48	tyrosine	tyrosine	PROPN
ajst-32484	170	49	kinase	kinase	PROPN
ajst-32484	170	50	inhibitor	inhibitor	NOUN
ajst-32484	170	51	therapy	therapy	NOUN
ajst-32484	170	52	and	and	CCONJ
ajst-32484	170	53	platinum	platinum	NOUN
ajst-32484	170	54	-	-	PUNCT
ajst-32484	170	55	based	base	VERB
ajst-32484	170	56	chemotherapy	chemotherapy	NOUN
ajst-32484	170	57	.	.	PUNCT
ajst-32484	171	1	j	j	PROPN
ajst-32484	171	2	clin	clin	PROPN
ajst-32484	171	3	oncol	oncol	PROPN
ajst-32484	171	4	,	,	PUNCT
ajst-32484	171	5	2023	2023	NUM
ajst-32484	171	6	.	.	PUNCT
ajst-32484	172	1	41(35	41(35	NUM
ajst-32484	172	2	):	):	PUNCT
ajst-32484	172	3	p.	p.	NOUN
ajst-32484	172	4	5363	5363	NUM
ajst-32484	172	5	-	-	SYM
ajst-32484	172	6	5375	5375	NUM
ajst-32484	172	7	.	.	PUNCT
ajst-32484	173	1	[	[	X
ajst-32484	173	2	22	22	NUM
ajst-32484	173	3	]	]	X
ajst-32484	173	4	lee	lee	PROPN
ajst-32484	173	5	,	,	PUNCT
ajst-32484	173	6	s.h	s.h	PROPN
ajst-32484	173	7	.	.	PROPN
ajst-32484	173	8	,	,	PUNCT
ajst-32484	173	9	et	et	PROPN
ajst-32484	173	10	al	al	PROPN
ajst-32484	173	11	.	.	PROPN
ajst-32484	173	12	,	,	PUNCT
ajst-32484	173	13	ma13.06	ma13.06	PROPN
ajst-32484	173	14	amivantamab	amivantamab	NOUN
ajst-32484	173	15	,	,	PUNCT
ajst-32484	173	16	lazertinib	lazertinib	NOUN
ajst-32484	173	17	plus	plus	CCONJ
ajst-32484	173	18	platinum	platinum	NOUN
ajst-32484	173	19	-	-	PUNCT
ajst-32484	173	20	based	base	VERB
ajst-32484	173	21	chemotherapy	chemotherapy	NOUN
ajst-32484	173	22	in	in	ADP
ajst-32484	173	23	egfrmutated	egfrmutate	VERB
ajst-32484	173	24	advanced	advanced	ADJ
ajst-32484	173	25	nsclc	nsclc	NOUN
ajst-32484	173	26	:	:	PUNCT
ajst-32484	173	27	updated	update	VERB
ajst-32484	173	28	results	result	NOUN
ajst-32484	173	29	from	from	ADP
ajst-32484	173	30	chrysalis-2	chrysalis-2	NUM
ajst-32484	173	31	.	.	PUNCT
ajst-32484	174	1	journal	journal	PROPN
ajst-32484	174	2	of	of	ADP
ajst-32484	174	3	thoracic	thoracic	NOUN
ajst-32484	174	4	oncology	oncology	NOUN
ajst-32484	174	5	,	,	PUNCT
ajst-32484	174	6	2023	2023	NUM
ajst-32484	174	7	.	.	PUNCT
ajst-32484	175	1	18(11	18(11	NUM
ajst-32484	175	2	):	):	PUNCT
ajst-32484	176	1	p.	p.	NOUN
ajst-32484	176	2	s146	s146	PROPN
ajst-32484	176	3	-	-	PROPN
ajst-32484	176	4	s147	s147	PROPN
ajst-32484	176	5	.	.	PUNCT
ajst-32484	177	1	[	[	X
ajst-32484	177	2	23	23	NUM
ajst-32484	177	3	]	]	X
ajst-32484	177	4	hartmaier	hartmaier	NOUN
ajst-32484	177	5	,	,	PUNCT
ajst-32484	177	6	r.j	r.j	PROPN
ajst-32484	177	7	.	.	PROPN
ajst-32484	177	8	,	,	PUNCT
ajst-32484	177	9	et	et	PROPN
ajst-32484	177	10	al	al	PROPN
ajst-32484	177	11	.	.	PROPN
ajst-32484	177	12	,	,	PUNCT
ajst-32484	177	13	osimertinib	osimertinib	NOUN
ajst-32484	177	14	+	+	CCONJ
ajst-32484	177	15	savolitinib	savolitinib	NOUN
ajst-32484	177	16	to	to	PART
ajst-32484	177	17	overcome	overcome	VERB
ajst-32484	177	18	acquired	acquire	VERB
ajst-32484	177	19	met	meet	VERB
ajst-32484	177	20	-	-	PUNCT
ajst-32484	177	21	mediated	mediate	VERB
ajst-32484	177	22	resistance	resistance	NOUN
ajst-32484	177	23	in	in	ADP
ajst-32484	177	24	epidermal	epidermal	ADJ
ajst-32484	177	25	growth	growth	NOUN
ajst-32484	177	26	factor	factor	NOUN
ajst-32484	177	27	receptor	receptor	NOUN
ajst-32484	177	28	-	-	PUNCT
ajst-32484	177	29	mutated	mutate	VERB
ajst-32484	177	30	,	,	PUNCT
ajst-32484	177	31	met	met	AUX
ajst-32484	177	32	-	-	PUNCT
ajst-32484	177	33	amplified	amplify	VERB
ajst-32484	177	34	non	non	ADJ
ajst-32484	177	35	-	-	ADJ
ajst-32484	177	36	small	small	ADJ
ajst-32484	177	37	cell	cell	NOUN
ajst-32484	177	38	lung	lung	NOUN
ajst-32484	177	39	cancer	cancer	NOUN
ajst-32484	177	40	:	:	PUNCT
ajst-32484	177	41	tatton	tatton	PROPN
ajst-32484	177	42	.	.	PUNCT
ajst-32484	178	1	cancer	cancer	NOUN
ajst-32484	178	2	discov	discov	NOUN
ajst-32484	178	3	,	,	PUNCT
ajst-32484	178	4	2023	2023	NUM
ajst-32484	178	5	.	.	PUNCT
ajst-32484	179	1	13(1	13(1	X
ajst-32484	179	2	):	):	PUNCT
ajst-32484	180	1	p.	p.	NOUN
ajst-32484	180	2	98	98	NUM
ajst-32484	180	3	-	-	SYM
ajst-32484	180	4	113	113	NUM
ajst-32484	180	5	.	.	PUNCT
ajst-32484	181	1	[	[	X
ajst-32484	181	2	24	24	NUM
ajst-32484	181	3	]	]	SYM
ajst-32484	181	4	nogami	nogami	NOUN
ajst-32484	181	5	,	,	PUNCT
ajst-32484	181	6	n.	n.	NOUN
ajst-32484	181	7	,	,	PUNCT
ajst-32484	181	8	et	et	PROPN
ajst-32484	181	9	al	al	PROPN
ajst-32484	181	10	.	.	PROPN
ajst-32484	181	11	,	,	PUNCT
ajst-32484	181	12	impower150	impower150	PROPN
ajst-32484	181	13	final	final	ADJ
ajst-32484	181	14	exploratory	exploratory	ADJ
ajst-32484	181	15	analyses	analysis	NOUN
ajst-32484	181	16	for	for	ADP
ajst-32484	181	17	atezolizumab	atezolizumab	NOUN
ajst-32484	181	18	plus	plus	CCONJ
ajst-32484	181	19	bevacizumab	bevacizumab	NOUN
ajst-32484	181	20	and	and	CCONJ
ajst-32484	181	21	chemotherapy	chemotherapy	NOUN
ajst-32484	181	22	in	in	ADP
ajst-32484	181	23	key	key	ADJ
ajst-32484	181	24	nsclc	nsclc	NOUN
ajst-32484	181	25	patient	patient	NOUN
ajst-32484	181	26	subgroups	subgroup	NOUN
ajst-32484	181	27	with	with	ADP
ajst-32484	181	28	egfr	egfr	ADJ
ajst-32484	181	29	mutations	mutation	NOUN
ajst-32484	181	30	or	or	CCONJ
ajst-32484	181	31	metastases	metastasis	NOUN
ajst-32484	181	32	in	in	ADP
ajst-32484	181	33	the	the	DET
ajst-32484	181	34	liver	liver	NOUN
ajst-32484	181	35	or	or	CCONJ
ajst-32484	181	36	brain	brain	NOUN
ajst-32484	181	37	.	.	PUNCT
ajst-32484	182	1	j	j	PROPN
ajst-32484	182	2	thorac	thorac	PROPN
ajst-32484	182	3	oncol	oncol	ADJ
ajst-32484	182	4	,	,	PUNCT
ajst-32484	182	5	2022	2022	NUM
ajst-32484	182	6	.	.	PUNCT
ajst-32484	183	1	17(2	17(2	NUM
ajst-32484	183	2	):	):	PUNCT
ajst-32484	183	3	p.	p.	NOUN
ajst-32484	183	4	309	309	NUM
ajst-32484	183	5	-	-	SYM
ajst-32484	183	6	323	323	NUM
ajst-32484	183	7	.	.	PUNCT
ajst-32484	184	1	[	[	X
ajst-32484	184	2	25	25	NUM
ajst-32484	184	3	]	]	X
ajst-32484	184	4	lu	lu	PROPN
ajst-32484	184	5	,	,	PUNCT
ajst-32484	184	6	s.	s.	PROPN
ajst-32484	184	7	,	,	PUNCT
ajst-32484	184	8	et	et	PROPN
ajst-32484	184	9	al	al	PROPN
ajst-32484	184	10	.	.	PROPN
ajst-32484	184	11	,	,	PUNCT
ajst-32484	184	12	sintilimab	sintilimab	NOUN
ajst-32484	184	13	plus	plus	CCONJ
ajst-32484	184	14	chemotherapy	chemotherapy	NOUN
ajst-32484	184	15	for	for	ADP
ajst-32484	184	16	patients	patient	NOUN
ajst-32484	184	17	with	with	ADP
ajst-32484	184	18	egfr	egfr	NOUN
ajst-32484	184	19	-	-	PUNCT
ajst-32484	184	20	mutated	mutate	VERB
ajst-32484	184	21	non	non	ADJ
ajst-32484	184	22	-	-	ADJ
ajst-32484	184	23	squamous	squamous	ADJ
ajst-32484	184	24	non	non	ADJ
ajst-32484	184	25	-	-	ADJ
ajst-32484	184	26	smallcell	smallcell	ADJ
ajst-32484	184	27	lung	lung	NOUN
ajst-32484	184	28	cancer	cancer	NOUN
ajst-32484	184	29	with	with	ADP
ajst-32484	184	30	disease	disease	NOUN
ajst-32484	184	31	progression	progression	NOUN
ajst-32484	184	32	after	after	ADP
ajst-32484	184	33	egfr	egfr	ADJ
ajst-32484	184	34	tyrosine	tyrosine	PROPN
ajst-32484	184	35	-	-	PUNCT
ajst-32484	184	36	kinase	kinase	NOUN
ajst-32484	184	37	inhibitor	inhibitor	NOUN
ajst-32484	184	38	therapy	therapy	NOUN
ajst-32484	184	39	(	(	PUNCT
ajst-32484	184	40	orient-31	orient-31	ADJ
ajst-32484	184	41	):	):	PUNCT
ajst-32484	184	42	second	second	ADJ
ajst-32484	184	43	interim	interim	ADJ
ajst-32484	184	44	analysis	analysis	NOUN
ajst-32484	184	45	from	from	ADP
ajst-32484	184	46	a	a	DET
ajst-32484	184	47	double	double	ADJ
ajst-32484	184	48	-	-	PUNCT
ajst-32484	184	49	blind	blind	ADJ
ajst-32484	184	50	,	,	PUNCT
ajst-32484	184	51	randomised	randomise	VERB
ajst-32484	184	52	,	,	PUNCT
ajst-32484	184	53	placebo	placebo	NOUN
ajst-32484	184	54	-	-	PUNCT
ajst-32484	184	55	controlled	control	VERB
ajst-32484	184	56	,	,	PUNCT
ajst-32484	184	57	phase	phase	NOUN
ajst-32484	184	58	3	3	NUM
ajst-32484	184	59	trial	trial	NOUN
ajst-32484	184	60	.	.	PUNCT
ajst-32484	185	1	lancet	lancet	PROPN
ajst-32484	185	2	respir	respir	VERB
ajst-32484	185	3	med	me	VERB
ajst-32484	185	4	,	,	PUNCT
ajst-32484	185	5	2023	2023	NUM
ajst-32484	185	6	.	.	PUNCT
ajst-32484	186	1	11(7	11(7	NUM
ajst-32484	186	2	):	):	PUNCT
ajst-32484	186	3	p.	p.	NOUN
ajst-32484	186	4	624	624	NUM
ajst-32484	186	5	-	-	SYM
ajst-32484	186	6	636	636	NUM
ajst-32484	186	7	.	.	PUNCT
ajst-32484	187	1	[	[	X
ajst-32484	187	2	26	26	NUM
ajst-32484	187	3	]	]	X
ajst-32484	187	4	soria	soria	PROPN
ajst-32484	187	5	,	,	PUNCT
ajst-32484	187	6	j.c	j.c	PROPN
ajst-32484	187	7	.	.	PROPN
ajst-32484	187	8	,	,	PUNCT
ajst-32484	187	9	et	et	PROPN
ajst-32484	187	10	al	al	PROPN
ajst-32484	187	11	.	.	PROPN
ajst-32484	187	12	,	,	PUNCT
ajst-32484	187	13	osimertinib	osimertinib	NOUN
ajst-32484	187	14	in	in	ADP
ajst-32484	187	15	untreated	untreated	ADJ
ajst-32484	187	16	egfr	egfr	ADV
ajst-32484	187	17	-	-	PUNCT
ajst-32484	187	18	mutated	mutate	VERB
ajst-32484	187	19	advanced	advanced	ADJ
ajst-32484	187	20	non	non	ADJ
ajst-32484	187	21	-	-	ADJ
ajst-32484	187	22	small	small	ADJ
ajst-32484	187	23	-	-	PUNCT
ajst-32484	187	24	cell	cell	NOUN
ajst-32484	187	25	lung	lung	NOUN
ajst-32484	187	26	cancer	cancer	NOUN
ajst-32484	187	27	.	.	PUNCT
ajst-32484	188	1	n	n	PROPN
ajst-32484	188	2	engl	engl	PROPN
ajst-32484	188	3	j	j	PROPN
ajst-32484	188	4	med	med	PROPN
ajst-32484	188	5	,	,	PUNCT
ajst-32484	188	6	2018	2018	NUM
ajst-32484	188	7	.	.	PUNCT
ajst-32484	189	1	378(2	378(2	NUM
ajst-32484	189	2	):	):	PUNCT
ajst-32484	189	3	p.	p.	NOUN
ajst-32484	189	4	113	113	NUM
ajst-32484	189	5	-	-	SYM
ajst-32484	189	6	125	125	NUM
ajst-32484	189	7	.	.	PUNCT
ajst-32484	190	1	[	[	X
ajst-32484	190	2	27	27	NUM
ajst-32484	190	3	]	]	X
ajst-32484	190	4	odogwu	odogwu	PROPN
ajst-32484	190	5	,	,	PUNCT
ajst-32484	190	6	l.	l.	PROPN
ajst-32484	190	7	,	,	PUNCT
ajst-32484	190	8	et	et	PROPN
ajst-32484	190	9	al	al	PROPN
ajst-32484	190	10	.	.	PROPN
ajst-32484	190	11	,	,	PUNCT
ajst-32484	190	12	fda	fda	PROPN
ajst-32484	190	13	approval	approval	PROPN
ajst-32484	190	14	summary	summary	NOUN
ajst-32484	190	15	:	:	PUNCT
ajst-32484	190	16	dabrafenib	dabrafenib	NOUN
ajst-32484	190	17	and	and	CCONJ
ajst-32484	190	18	trametinib	trametinib	NOUN
ajst-32484	190	19	for	for	ADP
ajst-32484	190	20	the	the	DET
ajst-32484	190	21	treatment	treatment	NOUN
ajst-32484	190	22	of	of	ADP
ajst-32484	190	23	metastatic	metastatic	ADJ
ajst-32484	190	24	non	non	ADJ
ajst-32484	190	25	-	-	ADJ
ajst-32484	190	26	small	small	ADJ
ajst-32484	190	27	cell	cell	NOUN
ajst-32484	190	28	lung	lung	NOUN
ajst-32484	190	29	cancers	cancer	NOUN
ajst-32484	190	30	harboring	harbor	VERB
ajst-32484	190	31	braf	braf	NOUN
ajst-32484	190	32	v600e	v600e	VERB
ajst-32484	190	33	mutations	mutation	NOUN
ajst-32484	190	34	.	.	PUNCT
ajst-32484	191	1	oncologist	oncologist	NOUN
ajst-32484	191	2	,	,	PUNCT
ajst-32484	191	3	2018	2018	NUM
ajst-32484	191	4	.	.	PUNCT
ajst-32484	192	1	23(6	23(6	NUM
ajst-32484	192	2	):	):	PUNCT
ajst-32484	193	1	p.	p.	NOUN
ajst-32484	193	2	740	740	NUM
ajst-32484	193	3	-	-	SYM
ajst-32484	193	4	745	745	NUM
ajst-32484	193	5	.	.	PUNCT
ajst-32484	194	1	[	[	X
ajst-32484	194	2	28	28	NUM
ajst-32484	194	3	]	]	X
ajst-32484	194	4	ahn	ahn	PROPN
ajst-32484	194	5	,	,	PUNCT
ajst-32484	194	6	m.j	m.j	PROPN
ajst-32484	194	7	.	.	PROPN
ajst-32484	194	8	,	,	PUNCT
ajst-32484	194	9	et	et	PROPN
ajst-32484	194	10	al	al	PROPN
ajst-32484	194	11	.	.	PROPN
ajst-32484	194	12	,	,	PUNCT
ajst-32484	194	13	datopotamab	datopotamab	X
ajst-32484	194	14	deruxtecan	deruxtecan	PROPN
ajst-32484	194	15	versus	versus	ADP
ajst-32484	194	16	docetaxel	docetaxel	NOUN
ajst-32484	194	17	for	for	ADP
ajst-32484	194	18	previously	previously	ADV
ajst-32484	194	19	treated	treat	VERB
ajst-32484	194	20	advanced	advanced	ADJ
ajst-32484	194	21	or	or	CCONJ
ajst-32484	194	22	metastatic	metastatic	ADJ
ajst-32484	194	23	non	non	ADJ
ajst-32484	194	24	-	-	ADJ
ajst-32484	194	25	small	small	ADJ
ajst-32484	194	26	cell	cell	NOUN
ajst-32484	194	27	lung	lung	NOUN
ajst-32484	194	28	cancer	cancer	NOUN
ajst-32484	194	29	:	:	PUNCT
ajst-32484	194	30	the	the	DET
ajst-32484	194	31	randomized	randomized	ADJ
ajst-32484	194	32	,	,	PUNCT
ajst-32484	194	33	open	open	ADJ
ajst-32484	194	34	-	-	PUNCT
ajst-32484	194	35	label	label	NOUN
ajst-32484	194	36	phase	phase	NOUN
ajst-32484	194	37	iii	iii	NUM
ajst-32484	194	38	tropion	tropion	NOUN
ajst-32484	194	39	-	-	PUNCT
ajst-32484	194	40	lung01	lung01	NOUN
ajst-32484	194	41	study	study	NOUN
ajst-32484	194	42	.	.	PUNCT
ajst-32484	195	1	j	j	PROPN
ajst-32484	195	2	clin	clin	PROPN
ajst-32484	195	3	oncol	oncol	PROPN
ajst-32484	195	4	,	,	PUNCT
ajst-32484	195	5	2025	2025	NUM
ajst-32484	195	6	.	.	PUNCT
ajst-32484	196	1	43(3	43(3	NUM
ajst-32484	196	2	):	):	PUNCT
ajst-32484	196	3	p.	p.	NOUN
ajst-32484	196	4	260	260	NUM
ajst-32484	196	5	-	-	SYM
ajst-32484	196	6	272	272	NUM
ajst-32484	196	7	.	.	PUNCT
ajst-32484	197	1	[	[	X
ajst-32484	197	2	29	29	NUM
ajst-32484	197	3	]	]	X
ajst-32484	197	4	fujino	fujino	PROPN
ajst-32484	197	5	,	,	PUNCT
ajst-32484	197	6	t.	t.	PROPN
ajst-32484	197	7	,	,	PUNCT
ajst-32484	197	8	et	et	PROPN
ajst-32484	197	9	al	al	PROPN
ajst-32484	197	10	.	.	PROPN
ajst-32484	197	11	,	,	PUNCT
ajst-32484	197	12	foretinib	foretinib	PROPN
ajst-32484	197	13	can	can	AUX
ajst-32484	197	14	overcome	overcome	VERB
ajst-32484	197	15	common	common	ADJ
ajst-32484	197	16	on	on	ADP
ajst-32484	197	17	-	-	PUNCT
ajst-32484	197	18	target	target	NOUN
ajst-32484	197	19	resistance	resistance	NOUN
ajst-32484	197	20	mutations	mutation	NOUN
ajst-32484	197	21	after	after	ADP
ajst-32484	197	22	capmatinib/	capmatinib/	NUM
ajst-32484	197	23	tepotinib	tepotinib	VERB
ajst-32484	197	24	treatment	treatment	NOUN
ajst-32484	197	25	in	in	ADP
ajst-32484	197	26	nsclcs	nsclcs	NOUN
ajst-32484	197	27	with	with	ADP
ajst-32484	197	28	met	meet	VERB
ajst-32484	197	29	exon	exon	NOUN
ajst-32484	197	30	14	14	NUM
ajst-32484	197	31	skipping	skip	VERB
ajst-32484	197	32	mutation	mutation	NOUN
ajst-32484	197	33	.	.	PUNCT
ajst-32484	198	1	j	j	PROPN
ajst-32484	198	2	hematol	hematol	PROPN
ajst-32484	198	3	oncol	oncol	PROPN
ajst-32484	198	4	,	,	PUNCT
ajst-32484	198	5	2022	2022	NUM
ajst-32484	198	6	.	.	PUNCT
ajst-32484	199	1	15(1	15(1	NUM
ajst-32484	199	2	):	):	PUNCT
ajst-32484	199	3	p.	p.	NOUN
ajst-32484	199	4	79	79	NUM
ajst-32484	199	5	.	.	PUNCT
ajst-32484	200	1	118	118	NUM
ajst-32484	201	1	[	[	SYM
ajst-32484	201	2	30	30	NUM
ajst-32484	201	3	]	]	X
ajst-32484	201	4	kato	kato	PROPN
ajst-32484	201	5	,	,	PUNCT
ajst-32484	201	6	t.	t.	PROPN
ajst-32484	201	7	,	,	PUNCT
ajst-32484	201	8	et	et	PROPN
ajst-32484	201	9	al	al	PROPN
ajst-32484	201	10	.	.	PROPN
ajst-32484	201	11	,	,	PUNCT
ajst-32484	201	12	efficacy	efficacy	NOUN
ajst-32484	201	13	and	and	CCONJ
ajst-32484	201	14	safety	safety	NOUN
ajst-32484	201	15	of	of	ADP
ajst-32484	201	16	tepotinib	tepotinib	NOUN
ajst-32484	201	17	in	in	ADP
ajst-32484	201	18	asian	asian	ADJ
ajst-32484	201	19	patients	patient	NOUN
ajst-32484	201	20	with	with	ADP
ajst-32484	201	21	advanced	advanced	ADJ
ajst-32484	201	22	nsclc	nsclc	NOUN
ajst-32484	201	23	with	with	ADP
ajst-32484	201	24	met	meet	VERB
ajst-32484	201	25	exon	exon	NOUN
ajst-32484	201	26	14	14	NUM
ajst-32484	201	27	skipping	skip	VERB
ajst-32484	201	28	enrolled	enrol	VERB
ajst-32484	201	29	in	in	ADP
ajst-32484	201	30	vision	vision	NOUN
ajst-32484	201	31	.	.	PUNCT
ajst-32484	202	1	br	br	PROPN
ajst-32484	202	2	j	j	PROPN
ajst-32484	202	3	cancer	cancer	NOUN
ajst-32484	202	4	,	,	PUNCT
ajst-32484	202	5	2024	2024	NUM
ajst-32484	202	6	.	.	PUNCT
ajst-32484	203	1	130(10	130(10	NUM
ajst-32484	203	2	):	):	PUNCT
ajst-32484	203	3	p.	p.	NOUN
ajst-32484	203	4	1679	1679	NUM
ajst-32484	203	5	-	-	SYM
ajst-32484	203	6	1686	1686	NUM
ajst-32484	203	7	.	.	PUNCT
ajst-32484	204	1	[	[	X
ajst-32484	204	2	31	31	NUM
ajst-32484	204	3	]	]	SYM
ajst-32484	204	4	jamme	jamme	NOUN
ajst-32484	204	5	,	,	PUNCT
ajst-32484	204	6	p.	p.	PROPN
ajst-32484	204	7	,	,	PUNCT
ajst-32484	204	8	et	et	PROPN
ajst-32484	204	9	al	al	PROPN
ajst-32484	204	10	.	.	PROPN
ajst-32484	204	11	,	,	PUNCT
ajst-32484	204	12	alterations	alteration	NOUN
ajst-32484	204	13	in	in	ADP
ajst-32484	204	14	the	the	DET
ajst-32484	204	15	pi3k	pi3k	PROPN
ajst-32484	204	16	pathway	pathway	NOUN
ajst-32484	204	17	drive	drive	VERB
ajst-32484	204	18	resistance	resistance	NOUN
ajst-32484	204	19	to	to	PART
ajst-32484	204	20	met	meet	VERB
ajst-32484	204	21	inhibitors	inhibitor	NOUN
ajst-32484	204	22	in	in	ADP
ajst-32484	204	23	nsclc	nsclc	NOUN
ajst-32484	204	24	harboring	harboring	NOUN
ajst-32484	204	25	met	meet	VERB
ajst-32484	204	26	exon	exon	NOUN
ajst-32484	204	27	14	14	NUM
ajst-32484	204	28	skipping	skip	VERB
ajst-32484	204	29	mutations	mutation	NOUN
ajst-32484	204	30	.	.	PUNCT
ajst-32484	205	1	j	j	PROPN
ajst-32484	205	2	thorac	thorac	PROPN
ajst-32484	205	3	oncol	oncol	ADJ
ajst-32484	205	4	,	,	PUNCT
ajst-32484	205	5	2020	2020	NUM
ajst-32484	205	6	.	.	PUNCT
ajst-32484	206	1	15(5	15(5	NUM
ajst-32484	206	2	):	):	PUNCT
ajst-32484	207	1	p.	p.	NOUN
ajst-32484	207	2	741	741	NUM
ajst-32484	207	3	-	-	SYM
ajst-32484	207	4	751	751	NUM
ajst-32484	207	5	.	.	PUNCT
ajst-32484	208	1	[	[	X
ajst-32484	208	2	32	32	NUM
ajst-32484	208	3	]	]	X
ajst-32484	208	4	shiba	shiba	PROPN
ajst-32484	208	5	-	-	PUNCT
ajst-32484	208	6	ishii	ishii	PROPN
ajst-32484	208	7	,	,	PUNCT
ajst-32484	208	8	a.	a.	NOUN
ajst-32484	208	9	,	,	PUNCT
ajst-32484	208	10	et	et	PROPN
ajst-32484	208	11	al	al	PROPN
ajst-32484	208	12	.	.	PROPN
ajst-32484	208	13	,	,	PUNCT
ajst-32484	208	14	analysis	analysis	NOUN
ajst-32484	208	15	of	of	ADP
ajst-32484	208	16	lorlatinib	lorlatinib	NOUN
ajst-32484	208	17	analogs	analog	NOUN
ajst-32484	208	18	reveals	reveal	VERB
ajst-32484	208	19	a	a	DET
ajst-32484	208	20	roadmap	roadmap	NOUN
ajst-32484	208	21	for	for	ADP
ajst-32484	208	22	targeting	target	VERB
ajst-32484	208	23	diverse	diverse	ADJ
ajst-32484	208	24	compound	compound	NOUN
ajst-32484	208	25	resistance	resistance	NOUN
ajst-32484	208	26	mutations	mutation	NOUN
ajst-32484	208	27	in	in	ADP
ajst-32484	208	28	alk	alk	ADJ
ajst-32484	208	29	-	-	PUNCT
ajst-32484	208	30	positive	positive	ADJ
ajst-32484	208	31	lung	lung	NOUN
ajst-32484	208	32	cancer	cancer	NOUN
ajst-32484	208	33	.	.	PUNCT
ajst-32484	209	1	nat	nat	NOUN
ajst-32484	209	2	cancer	cancer	NOUN
ajst-32484	209	3	,	,	PUNCT
ajst-32484	209	4	2022	2022	NUM
ajst-32484	209	5	.	.	PUNCT
ajst-32484	209	6	3(6	3(6	PROPN
ajst-32484	209	7	):	):	PUNCT
ajst-32484	209	8	p.	p.	NOUN
ajst-32484	209	9	710	710	NUM
ajst-32484	209	10	-	-	SYM
ajst-32484	209	11	722	722	NUM
ajst-32484	209	12	.	.	PUNCT
ajst-32484	210	1	[	[	X
ajst-32484	210	2	33	33	NUM
ajst-32484	210	3	]	]	X
ajst-32484	210	4	shaw	shaw	PROPN
ajst-32484	210	5	,	,	PUNCT
ajst-32484	210	6	a.t	a.t	PROPN
ajst-32484	210	7	.	.	PROPN
ajst-32484	210	8	,	,	PUNCT
ajst-32484	210	9	et	et	PROPN
ajst-32484	210	10	al	al	PROPN
ajst-32484	210	11	.	.	PROPN
ajst-32484	210	12	,	,	PUNCT
ajst-32484	210	13	alk	alk	VERB
ajst-32484	210	14	resistance	resistance	NOUN
ajst-32484	210	15	mutations	mutation	NOUN
ajst-32484	210	16	and	and	CCONJ
ajst-32484	210	17	efficacy	efficacy	NOUN
ajst-32484	210	18	of	of	ADP
ajst-32484	210	19	lorlatinib	lorlatinib	NOUN
ajst-32484	210	20	in	in	ADP
ajst-32484	210	21	advanced	advanced	ADJ
ajst-32484	210	22	anaplastic	anaplastic	ADJ
ajst-32484	210	23	lymphoma	lymphoma	NOUN
ajst-32484	210	24	kinase	kinase	NOUN
ajst-32484	210	25	-	-	PUNCT
ajst-32484	210	26	positive	positive	ADJ
ajst-32484	210	27	non	non	ADJ
ajst-32484	210	28	-	-	ADJ
ajst-32484	210	29	small	small	ADJ
ajst-32484	210	30	-	-	PUNCT
ajst-32484	210	31	cell	cell	NOUN
ajst-32484	210	32	lung	lung	NOUN
ajst-32484	210	33	cancer	cancer	NOUN
ajst-32484	210	34	.	.	PUNCT
ajst-32484	211	1	j	j	PROPN
ajst-32484	211	2	clin	clin	PROPN
ajst-32484	211	3	oncol	oncol	PROPN
ajst-32484	211	4	,	,	PUNCT
ajst-32484	211	5	2019	2019	NUM
ajst-32484	211	6	.	.	PUNCT
ajst-32484	212	1	37(16	37(16	NUM
ajst-32484	212	2	):	):	PUNCT
ajst-32484	212	3	p.	p.	NOUN
ajst-32484	212	4	1370	1370	NUM
ajst-32484	212	5	-	-	SYM
ajst-32484	212	6	1379	1379	NUM
ajst-32484	212	7	.	.	PUNCT
ajst-32484	213	1	[	[	X
ajst-32484	213	2	34	34	NUM
ajst-32484	213	3	]	]	X
ajst-32484	213	4	gainor	gainor	NOUN
ajst-32484	213	5	,	,	PUNCT
ajst-32484	213	6	j.f	j.f	PROPN
ajst-32484	213	7	.	.	PROPN
ajst-32484	213	8	,	,	PUNCT
ajst-32484	213	9	et	et	PROPN
ajst-32484	213	10	al	al	PROPN
ajst-32484	213	11	.	.	PROPN
ajst-32484	213	12	,	,	PUNCT
ajst-32484	213	13	molecular	molecular	ADJ
ajst-32484	213	14	mechanisms	mechanism	NOUN
ajst-32484	213	15	of	of	ADP
ajst-32484	213	16	resistance	resistance	NOUN
ajst-32484	213	17	to	to	ADP
ajst-32484	213	18	firstand	firstand	NOUN
ajst-32484	213	19	second	second	ADJ
ajst-32484	213	20	-	-	PUNCT
ajst-32484	213	21	generation	generation	NOUN
ajst-32484	213	22	alk	alk	NOUN
ajst-32484	213	23	inhibitors	inhibitor	NOUN
ajst-32484	213	24	in	in	ADP
ajst-32484	213	25	alk	alk	NOUN
ajst-32484	213	26	-	-	PUNCT
ajst-32484	213	27	rearranged	rearrange	VERB
ajst-32484	213	28	lung	lung	NOUN
ajst-32484	213	29	cancer	cancer	NOUN
ajst-32484	213	30	.	.	PUNCT
ajst-32484	214	1	cancer	cancer	NOUN
ajst-32484	214	2	discov	discov	NOUN
ajst-32484	214	3	,	,	PUNCT
ajst-32484	214	4	2016	2016	NUM
ajst-32484	214	5	.	.	PUNCT
ajst-32484	215	1	6(10	6(10	NUM
ajst-32484	215	2	):	):	PUNCT
ajst-32484	216	1	p.	p.	NOUN
ajst-32484	216	2	1118	1118	NUM
ajst-32484	216	3	-	-	SYM
ajst-32484	216	4	1133	1133	NUM
ajst-32484	216	5	.	.	PUNCT
ajst-32484	217	1	[	[	X
ajst-32484	217	2	35	35	NUM
ajst-32484	217	3	]	]	X
ajst-32484	217	4	dagogo	dagogo	NOUN
ajst-32484	217	5	-	-	PUNCT
ajst-32484	217	6	jack	jack	PROPN
ajst-32484	217	7	,	,	PUNCT
ajst-32484	217	8	i.	i.	PROPN
ajst-32484	217	9	,	,	PUNCT
ajst-32484	217	10	et	et	PROPN
ajst-32484	217	11	al	al	PROPN
ajst-32484	217	12	.	.	PROPN
ajst-32484	217	13	,	,	PUNCT
ajst-32484	217	14	treatment	treatment	NOUN
ajst-32484	217	15	with	with	ADP
ajst-32484	217	16	next	next	ADJ
ajst-32484	217	17	-	-	PUNCT
ajst-32484	217	18	generation	generation	NOUN
ajst-32484	217	19	alk	alk	NOUN
ajst-32484	217	20	inhibitors	inhibitor	NOUN
ajst-32484	217	21	fuels	fuel	VERB
ajst-32484	217	22	plasma	plasma	NOUN
ajst-32484	217	23	alk	alk	PROPN
ajst-32484	217	24	mutation	mutation	NOUN
ajst-32484	217	25	diversity	diversity	NOUN
ajst-32484	217	26	.	.	PUNCT
ajst-32484	218	1	clin	clin	PROPN
ajst-32484	218	2	cancer	cancer	NOUN
ajst-32484	218	3	res	re	NOUN
ajst-32484	218	4	,	,	PUNCT
ajst-32484	218	5	2019	2019	NUM
ajst-32484	218	6	.	.	PUNCT
ajst-32484	219	1	25(22	25(22	NOUN
ajst-32484	219	2	):	):	PUNCT
ajst-32484	219	3	p.	p.	NOUN
ajst-32484	219	4	6662	6662	NUM
ajst-32484	219	5	-	-	SYM
ajst-32484	219	6	6670	6670	NUM
ajst-32484	219	7	.	.	PUNCT
ajst-32484	220	1	[	[	X
ajst-32484	220	2	36	36	NUM
ajst-32484	220	3	]	]	SYM
ajst-32484	220	4	yoda	yoda	PROPN
ajst-32484	220	5	,	,	PUNCT
ajst-32484	220	6	s.	s.	PROPN
ajst-32484	220	7	,	,	PUNCT
ajst-32484	220	8	et	et	PROPN
ajst-32484	220	9	al	al	PROPN
ajst-32484	220	10	.	.	PROPN
ajst-32484	220	11	,	,	PUNCT
ajst-32484	220	12	sequential	sequential	ADJ
ajst-32484	220	13	alk	alk	NOUN
ajst-32484	220	14	inhibitors	inhibitor	NOUN
ajst-32484	220	15	can	can	AUX
ajst-32484	220	16	select	select	VERB
ajst-32484	220	17	for	for	ADP
ajst-32484	220	18	lorlatinib	lorlatinib	NOUN
ajst-32484	220	19	-	-	PUNCT
ajst-32484	220	20	resistant	resistant	ADJ
ajst-32484	220	21	compound	compound	NOUN
ajst-32484	220	22	alk	alk	NOUN
ajst-32484	220	23	mutations	mutation	NOUN
ajst-32484	220	24	in	in	ADP
ajst-32484	220	25	alk	alk	ADJ
ajst-32484	220	26	-	-	PUNCT
ajst-32484	220	27	positive	positive	ADJ
ajst-32484	220	28	lung	lung	NOUN
ajst-32484	220	29	cancer	cancer	NOUN
ajst-32484	220	30	.	.	PUNCT
ajst-32484	221	1	cancer	cancer	NOUN
ajst-32484	221	2	discov	discov	NOUN
ajst-32484	221	3	,	,	PUNCT
ajst-32484	221	4	2018	2018	NUM
ajst-32484	221	5	.	.	X
ajst-32484	221	6	8(6	8(6	NUM
ajst-32484	221	7	):	):	PUNCT
ajst-32484	221	8	p.	p.	NOUN
ajst-32484	221	9	714	714	NUM
ajst-32484	221	10	-	-	SYM
ajst-32484	221	11	729	729	NUM
ajst-32484	221	12	.	.	PUNCT
ajst-32484	222	1	[	[	X
ajst-32484	222	2	37	37	NUM
ajst-32484	222	3	]	]	X
ajst-32484	222	4	crystal	crystal	NOUN
ajst-32484	222	5	,	,	PUNCT
ajst-32484	222	6	a.s	a.s	PROPN
ajst-32484	222	7	.	.	PROPN
ajst-32484	222	8	,	,	PUNCT
ajst-32484	222	9	et	et	PROPN
ajst-32484	222	10	al	al	PROPN
ajst-32484	222	11	.	.	PROPN
ajst-32484	222	12	,	,	PUNCT
ajst-32484	222	13	patient	patient	NOUN
ajst-32484	222	14	-	-	PUNCT
ajst-32484	222	15	derived	derive	VERB
ajst-32484	222	16	models	model	NOUN
ajst-32484	222	17	of	of	ADP
ajst-32484	222	18	acquired	acquire	VERB
ajst-32484	222	19	resistance	resistance	NOUN
ajst-32484	222	20	can	can	AUX
ajst-32484	222	21	identify	identify	VERB
ajst-32484	222	22	effective	effective	ADJ
ajst-32484	222	23	drug	drug	NOUN
ajst-32484	222	24	combinations	combination	NOUN
ajst-32484	222	25	for	for	ADP
ajst-32484	222	26	cancer	cancer	NOUN
ajst-32484	222	27	.	.	PUNCT
ajst-32484	223	1	science	science	NOUN
ajst-32484	223	2	,	,	PUNCT
ajst-32484	223	3	2014	2014	NUM
ajst-32484	223	4	.	.	PUNCT
ajst-32484	224	1	346(6216	346(6216	NUM
ajst-32484	224	2	):	):	PUNCT
ajst-32484	224	3	p.	p.	NOUN
ajst-32484	224	4	1480	1480	NUM
ajst-32484	224	5	-	-	SYM
ajst-32484	224	6	6	6	NUM
ajst-32484	224	7	.	.	PUNCT
ajst-32484	225	1	[	[	X
ajst-32484	225	2	38	38	NUM
ajst-32484	225	3	]	]	X
ajst-32484	225	4	hrustanovic	hrustanovic	PROPN
ajst-32484	225	5	,	,	PUNCT
ajst-32484	225	6	g.	g.	PROPN
ajst-32484	225	7	,	,	PUNCT
ajst-32484	225	8	et	et	PROPN
ajst-32484	225	9	al	al	PROPN
ajst-32484	225	10	.	.	PROPN
ajst-32484	225	11	,	,	PUNCT
ajst-32484	225	12	ras	ras	ADJ
ajst-32484	225	13	-	-	ADJ
ajst-32484	225	14	mapk	mapk	NOUN
ajst-32484	225	15	dependence	dependence	NOUN
ajst-32484	225	16	underlies	underlie	VERB
ajst-32484	225	17	a	a	DET
ajst-32484	225	18	rational	rational	ADJ
ajst-32484	225	19	polytherapy	polytherapy	NOUN
ajst-32484	225	20	strategy	strategy	NOUN
ajst-32484	225	21	in	in	ADP
ajst-32484	225	22	eml4	eml4	PROPN
ajst-32484	225	23	-	-	PUNCT
ajst-32484	225	24	alkpositive	alkpositive	ADJ
ajst-32484	225	25	lung	lung	NOUN
ajst-32484	225	26	cancer	cancer	NOUN
ajst-32484	225	27	.	.	PUNCT
ajst-32484	226	1	nat	nat	PROPN
ajst-32484	226	2	med	med	PROPN
ajst-32484	226	3	,	,	PUNCT
ajst-32484	226	4	2015	2015	NUM
ajst-32484	226	5	.	.	PUNCT
ajst-32484	227	1	21(9	21(9	NOUN
ajst-32484	227	2	):	):	PUNCT
ajst-32484	227	3	p.	p.	NOUN
ajst-32484	227	4	1038	1038	NUM
ajst-32484	227	5	-	-	SYM
ajst-32484	227	6	47	47	NUM
ajst-32484	227	7	.	.	PUNCT
ajst-32484	228	1	[	[	X
ajst-32484	228	2	39	39	NUM
ajst-32484	228	3	]	]	X
ajst-32484	228	4	kim	kim	PROPN
ajst-32484	228	5	,	,	PUNCT
ajst-32484	228	6	d.w	d.w	PROPN
ajst-32484	228	7	.	.	PROPN
ajst-32484	228	8	,	,	PUNCT
ajst-32484	228	9	et	et	PROPN
ajst-32484	228	10	al	al	PROPN
ajst-32484	228	11	.	.	PROPN
ajst-32484	228	12	,	,	PUNCT
ajst-32484	228	13	brigatinib	brigatinib	NOUN
ajst-32484	228	14	in	in	ADP
ajst-32484	228	15	patients	patient	NOUN
ajst-32484	228	16	with	with	ADP
ajst-32484	228	17	crizotinib	crizotinib	ADJ
ajst-32484	228	18	-	-	ADJ
ajst-32484	228	19	refractory	refractory	ADJ
ajst-32484	228	20	anaplastic	anaplastic	ADJ
ajst-32484	228	21	lymphoma	lymphoma	NOUN
ajst-32484	228	22	kinasepositive	kinasepositive	ADJ
ajst-32484	228	23	non	non	ADJ
ajst-32484	228	24	-	-	ADJ
ajst-32484	228	25	small	small	ADJ
ajst-32484	228	26	-	-	PUNCT
ajst-32484	228	27	cell	cell	NOUN
ajst-32484	228	28	lung	lung	NOUN
ajst-32484	228	29	cancer	cancer	NOUN
ajst-32484	228	30	:	:	PUNCT
ajst-32484	228	31	a	a	DET
ajst-32484	228	32	randomized	randomized	ADJ
ajst-32484	228	33	,	,	PUNCT
ajst-32484	228	34	multicenter	multicenter	NOUN
ajst-32484	228	35	phase	phase	NOUN
ajst-32484	228	36	ii	ii	NOUN
ajst-32484	228	37	trial	trial	NOUN
ajst-32484	228	38	.	.	PUNCT
ajst-32484	229	1	j	j	PROPN
ajst-32484	229	2	clin	clin	PROPN
ajst-32484	229	3	oncol	oncol	PROPN
ajst-32484	229	4	,	,	PUNCT
ajst-32484	229	5	2017	2017	NUM
ajst-32484	229	6	.	.	PUNCT
ajst-32484	230	1	35	35	NUM
ajst-32484	230	2	(	(	PUNCT
ajst-32484	230	3	22	22	NUM
ajst-32484	230	4	):	):	PUNCT
ajst-32484	230	5	p.	p.	NOUN
ajst-32484	230	6	2490	2490	NUM
ajst-32484	230	7	-	-	SYM
ajst-32484	230	8	2498	2498	NUM
ajst-32484	230	9	.	.	PUNCT
ajst-32484	231	1	[	[	X
ajst-32484	231	2	40	40	NUM
ajst-32484	231	3	]	]	PUNCT
ajst-32484	231	4	felip	felip	PROPN
ajst-32484	231	5	,	,	PUNCT
ajst-32484	231	6	e.	e.	PROPN
ajst-32484	231	7	,	,	PUNCT
ajst-32484	231	8	et	et	PROPN
ajst-32484	231	9	al	al	PROPN
ajst-32484	231	10	.	.	PROPN
ajst-32484	231	11	,	,	PUNCT
ajst-32484	231	12	intracranial	intracranial	ADJ
ajst-32484	231	13	and	and	CCONJ
ajst-32484	231	14	extracranial	extracranial	ADJ
ajst-32484	231	15	efficacy	efficacy	NOUN
ajst-32484	231	16	of	of	ADP
ajst-32484	231	17	lorlatinib	lorlatinib	NOUN
ajst-32484	231	18	in	in	ADP
ajst-32484	231	19	patients	patient	NOUN
ajst-32484	231	20	with	with	ADP
ajst-32484	231	21	alk	alk	NOUN
ajst-32484	231	22	-	-	PUNCT
ajst-32484	231	23	positive	positive	ADJ
ajst-32484	231	24	nonsmall	nonsmall	ADJ
ajst-32484	231	25	-	-	PUNCT
ajst-32484	231	26	cell	cell	NOUN
ajst-32484	231	27	lung	lung	NOUN
ajst-32484	231	28	cancer	cancer	NOUN
ajst-32484	231	29	previously	previously	ADV
ajst-32484	231	30	treated	treat	VERB
ajst-32484	231	31	with	with	ADP
ajst-32484	231	32	second	second	ADJ
ajst-32484	231	33	-	-	PUNCT
ajst-32484	231	34	generation	generation	NOUN
ajst-32484	231	35	alk	alk	NOUN
ajst-32484	231	36	tkis	tkis	PROPN
ajst-32484	231	37	.	.	PUNCT
ajst-32484	232	1	ann	ann	PROPN
ajst-32484	232	2	oncol	oncol	PROPN
ajst-32484	232	3	,	,	PUNCT
ajst-32484	232	4	2021	2021	NUM
ajst-32484	232	5	.	.	PUNCT
ajst-32484	233	1	32(5	32(5	NOUN
ajst-32484	233	2	):	):	PUNCT
ajst-32484	233	3	p.	p.	NOUN
ajst-32484	233	4	620	620	NUM
ajst-32484	233	5	-	-	SYM
ajst-32484	233	6	630	630	NUM
ajst-32484	233	7	.	.	PUNCT
ajst-32484	234	1	[	[	X
ajst-32484	234	2	41	41	NUM
ajst-32484	234	3	]	]	X
ajst-32484	234	4	wolf	wolf	PROPN
ajst-32484	234	5	,	,	PUNCT
ajst-32484	234	6	j.	j.	PROPN
ajst-32484	234	7	,	,	PUNCT
ajst-32484	234	8	et	et	PROPN
ajst-32484	234	9	al	al	PROPN
ajst-32484	234	10	.	.	PROPN
ajst-32484	234	11	,	,	PUNCT
ajst-32484	234	12	capmatinib	capmatinib	NOUN
ajst-32484	234	13	in	in	ADP
ajst-32484	234	14	met	meet	VERB
ajst-32484	234	15	exon	exon	PROPN
ajst-32484	234	16	14	14	NUM
ajst-32484	234	17	-	-	PUNCT
ajst-32484	234	18	mutated	mutate	VERB
ajst-32484	234	19	non	non	ADJ
ajst-32484	234	20	-	-	ADJ
ajst-32484	234	21	small	small	ADJ
ajst-32484	234	22	-	-	PUNCT
ajst-32484	234	23	cell	cell	NOUN
ajst-32484	234	24	lung	lung	NOUN
ajst-32484	234	25	cancer	cancer	NOUN
ajst-32484	234	26	:	:	PUNCT
ajst-32484	234	27	final	final	ADJ
ajst-32484	234	28	results	result	NOUN
ajst-32484	234	29	from	from	ADP
ajst-32484	234	30	the	the	DET
ajst-32484	234	31	open	open	ADJ
ajst-32484	234	32	-	-	PUNCT
ajst-32484	234	33	label	label	NOUN
ajst-32484	234	34	,	,	PUNCT
ajst-32484	234	35	phase	phase	NOUN
ajst-32484	234	36	2	2	NUM
ajst-32484	234	37	geometry	geometry	NOUN
ajst-32484	234	38	mono-1	mono-1	NOUN
ajst-32484	234	39	trial	trial	NOUN
ajst-32484	234	40	.	.	PUNCT
ajst-32484	235	1	lancet	lancet	PROPN
ajst-32484	235	2	oncol	oncol	PROPN
ajst-32484	235	3	,	,	PUNCT
ajst-32484	235	4	2024	2024	NUM
ajst-32484	235	5	.	.	PUNCT
ajst-32484	236	1	25(10	25(10	NUM
ajst-32484	236	2	):	):	PUNCT
ajst-32484	236	3	p.	p.	NOUN
ajst-32484	236	4	1357	1357	NUM
ajst-32484	236	5	-	-	SYM
ajst-32484	236	6	1370	1370	NUM
ajst-32484	236	7	.	.	PUNCT
ajst-32484	237	1	[	[	X
ajst-32484	237	2	42	42	NUM
ajst-32484	237	3	]	]	X
ajst-32484	237	4	sadida	sadida	PROPN
ajst-32484	237	5	,	,	PUNCT
ajst-32484	237	6	h.q	h.q	PROPN
ajst-32484	237	7	.	.	PROPN
ajst-32484	237	8	,	,	PUNCT
ajst-32484	237	9	et	et	PROPN
ajst-32484	237	10	al	al	PROPN
ajst-32484	237	11	.	.	PROPN
ajst-32484	237	12	,	,	PUNCT
ajst-32484	237	13	epigenetic	epigenetic	ADJ
ajst-32484	237	14	modifications	modification	NOUN
ajst-32484	237	15	:	:	PUNCT
ajst-32484	237	16	key	key	ADJ
ajst-32484	237	17	players	player	NOUN
ajst-32484	237	18	in	in	ADP
ajst-32484	237	19	cancer	cancer	NOUN
ajst-32484	237	20	heterogeneity	heterogeneity	NOUN
ajst-32484	237	21	and	and	CCONJ
ajst-32484	237	22	drug	drug	NOUN
ajst-32484	237	23	resistance	resistance	NOUN
ajst-32484	237	24	.	.	PUNCT
ajst-32484	238	1	transl	transl	PROPN
ajst-32484	238	2	oncol	oncol	PROPN
ajst-32484	238	3	,	,	PUNCT
ajst-32484	238	4	2024	2024	NUM
ajst-32484	238	5	.	.	PUNCT
ajst-32484	239	1	39	39	NUM
ajst-32484	239	2	:	:	PUNCT
ajst-32484	240	1	p.	p.	NOUN
ajst-32484	240	2	101821	101821	NUM
ajst-32484	240	3	.	.	PUNCT